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Preface to ”Immunophenotyping in Autoimmune
Diseases and Cancer”
The mammalian immune system is a Janus-faced network of well-coordinated, highly
specialized cells and biomolecules. The sensitive balance of reactive and suppressive signals
maintains homeostasis in the physiological state. Under pathological conditions, however,
responsiveness can escalate in autoimmune diseases or remain suppressed in cancer. In severe
autoimmunity, the overwhelming immune response leads to devastating diseases such as
rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and sclerosis multiplex.
Conversely, immune cells, e.g., professional antigen-presenting cells and cytotoxic T cells, are
not able to execute their physiological function in cancer. Recent progress in fluorescence flow
cytometry and mass cytometry has contributed to a high-dimensional resolution of the complex
immunophenotype both in autoimmune diseases and in cancer. We called authors to publish
their latest achievements associated with the perturbance of the regulation of immune activation
and the discovery of rare subpopulations of both innate and adaptive immune players in
autoimmune diseases and cancer. The online version of the Special Issue can be found at
https://www.mdpi.com/journal/ijms/special issues/Immunophenotyping.
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Abstract: Despite advances in cancer therapy, several persistent issues remain. These include cancer
recurrence, effective targeting of aggressive or therapy-resistant cancers, and selective treatments for
transformed cells. This review evaluates the current findings and highlights the potential of targeting
the unfolded protein response to treat cancer. The unfolded protein response, an evolutionarily
conserved pathway in all eukaryotes, is initiated in response to misfolded proteins accumulating
within the lumen of the endoplasmic reticulum. This pathway is initially cytoprotective, allowing
cells to survive stressful events; however, prolonged activation of the unfolded protein response
also activates apoptotic responses. This balance is key in successful mammalian immune response
and inducing cell death in malignant cells. We discuss how the unfolded protein response affects
cancer progression, survival, and immune response to cancer cells. The literature shows that
targeting the unfolded protein response as a monotherapy or in combination with chemotherapy
or immunotherapies increases the efficacy of these drugs; however, systemic unfolded protein
response targeting may yield deleterious effects on immune cell function and should be taken into
consideration. The material in this review shows the promise of both approaches, each of which
merits further research.
Keywords: unfolded protein response; Inositol-requiring enzyme 1 (IRE1); PKR-like endoplasmic
reticulum kinase (PERK); Glucose-regulated protein 78 (GRP78); Activating transcription factor 6
(ATF6); immune cells; T cell; macrophage; tumor microenvironment
1. Introduction
For a cell to become cancerous, it must overcome several evolutionary obstacles [1]. Among these,
a cancerous cell must proliferate readily and avoid immune destruction [2,3]. Achieving this state is
complex. While mutations to tumor suppressors and proto-oncogenes contribute to these changes,
over the past few decades it has become obvious that cancer cells also repurpose several endogenous
survival systems to assist in their formation and progression.
We must consider both the tumor cells and their microenvironment to understand how tumor–host
interactions drive transformation and carcinogenesis, and subvert these survival systems. The tumor
microenvironment has been extensively investigated (reviewed in [1,4,5]). Of note are the tumor
Int. J. Mol. Sci. 2020, 21, 169; doi:10.3390/ijms21010169 www.mdpi.com/journal/ijms1
Int. J. Mol. Sci. 2020, 21, 169
immune infiltrates, metabolite availability, and stress effects of the tumor microenvironment. Tumors
have been referred to as “wounds that never heal” [6]. Healing mechanisms associated with normal
tissue injury promote tumor formation and metastasis. Immune infiltrating cells induce wound-like
inflammation in the tumor microenvironment, further assisting in the development of malignant
cancers. Poor perfusion of solid tumors leads to high levels of hypoxia and low metabolite availability,
and the healing response responds to these via angiogenesis [7,8]. Leaky vasculature results in high
osmolarity in the tumor microenvironment. Recent studies have even demonstrated that microbial
flora in cancers differ from normal tissues, and these enhance tumor progression [9].
The combination of these factors creates a ‘perfect storm’ to subvert evolutionary pathways
and repurpose them to be procancer. One such system of interest is the unfolded protein response
(UPR). The UPR is an evolutionarily conserved mechanism discovered somewhat serendipitously [10].
In the mid-1970s studies found that virally transformed cells increased the expression of protein p78.
Unknowingly, Hass and Wabl identified the same protein in 1983 [11]. This protein was localized
to the endoplasmic reticulum (ER) and bound unsecreted Ig heavy chains, thus named binding
immunoglobulin protein (BiP). In 1987, Lee et al. reported that p78 expression in highly proliferative
transformed cells was due to media glucose depletion [12]. The protein was named glucose-regulated
protein 78 (GRP78). This protein was also identified as heat shock 70 kDa protein 5 (HSPA5). Additional
research led to the discovery that BiP and GRP78 were the same protein, and bound to unfolded
or incomplete Ig intermediates, identifying GRP78 as the first ER chaperone protein. GRP78 has
since become recognized as the primary regulator of the UPR. The UPR is triggered by accumulation
of unfolded proteins in the ER, conditions that are often found in highly proliferative, secretory, or
pathogen-infected cells [13].
Recent evidence indicates that the UPR is critical in multiple systems, such as cell differentiation,
proliferation, immune response, and cell maintenance. This review focuses on the role of the UPR
in tumor microenvironment stress, its effect on cancer cell progression, and immune response to
cancer cells.
2. Body
2.1. ER Stress and UPR Signaling
When stressed, the ER is overwhelmed with an accumulation of proteins due to improper folding,
insufficient glycosylation, and/or inhibited transport [14]. These often arise due to a sudden increase
in protein expression leading to insufficient chaperone proteins, saturation of the ER lumen space,
or insufficient nutrients for post-translational modification. These situations are often found in both
immune and cancer cells. This accumulation and subsequent ER stress results in canonical UPR
signaling through three different proteins: IRE1, PERK, and ATF6.
Each of the three proteins initiate an ‘arm’ of UPR signaling and are thought to be regulated, in
part, by association with ER membrane-bound GRP78. Current understanding of this system suggests
that, under non-stressed conditions, IRE1, PERK, and ATF6 are primarily bound to GRP78, maintaining
an inactive state and preventing UPR signaling. While it does not directly assist in folding, GRP78
binds unfolded proteins to maintain them in a foldable state. When unfolded proteins accumulate,
i.e., induction of ‘ER stress’, GRP78 releases IRE1, PERK, and ATF6, preferentially binding unfolded
polypeptide chains. This release allows each of these three proteins to initiate their portion of the UPR.
The pathway and function of these arms and their effects are briefly described below.
IRE1: Inositol-requiring enzyme 1, also known as endoplasmic reticulum to nucleus signaling
1 (ERN1). IRE1 oligomerizes and autophosphorylates upon release from GRP78. Phosphorylation
activates an endonuclease domain that cleaves an intron from the X-box binding protein 1 (XBP-1)
mRNA. This cleaved mRNA is then translated to the transcription factor XBP-1s. It is unclear whether
cleavage occurs in the ER or the nucleus, as IRE1 has been found in the inner nuclear envelope [15].
XBP-1s induces the expression of ER chaperone proteins and ER-associated protein degradation (ERAD)
2
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proteins, and induces differentiation of metabolic regulators. XBP-1s also induces XBP-1 transcription
in the form of self-regulation. In addition to effects mediated by XBP-1s, IRE1 continues nuclease
function in the ER, degrading ribosomal-associated mRNA through regulated IRE1-dependent decay
(RIDD). This degradation prevents the translation and further accumulation of unfolded proteins. IRE1
also contains a kinase function, which phosphorylates c-Jun N-terminal Kinase (JNK), contributing to
apoptosis under prolonged UPR signaling [16]. Although GRP78 association is the primary inhibitor
of IRE1 activation, there is evidence for alternate methods of IRE1 activation, including direct binding
by unfolded proteins [17].
PERK: Protein kinase R (PKR)-like endoplasmic reticulum kinase, or eukaryotic translation
initiation factor 2-alpha kinase 3 (EIF2AK3). Release from GRP78 suppression induces PERK
oligomerization and transphosphorylation similar to IRE1. PERK then phosphorylates eukaryotic
translation initiating factor 2A (eIF2α), preventing the formation of ribosomal pre-initiation complexes
and reducing cap-dependent protein translation. An open reading frame in the 5’-untranslated region
of activating transcription factor 4 (ATF4) mRNA allows cap-independent translation during eIF2α
phosphorylation. PERK activity thus increases ATF4 function to propagate UPR signaling. ATF4
expression results in products enhancing metabolic changes and ERAD, in concert with transcription
products from XBP-1s activity. Prolonged UPR leads to cell cycle arrest and, under certain conditions,
apoptosis via CCAAT-enhancer-binding protein homologous protein (CHOP) expression downstream
of PERK activation. Independent of PERK-mediated ATF4 expression, PERK activation results in an
antioxidant response via nuclear factor erythroid 2-related factor 2 (NRF2)-induced expression of genes
containing antioxidant response elements (AREs) in their promoters [18].
ATF6: Activating transcription factor 6. ATF6 translocates to the Golgi complex upon GRP78
release. Golgi-localized site-1 and site-2 proteases (S1P and S2P) then cleave ATF6, releasing a cytosolic
basic leucine zipper (bZIP) domain. This bZIP domain translocates to the nucleus and induces the
transcription of ER chaperones, lipid biosynthesis, and ERAD proteins. These allow expansion of the
ER, reducing the density of unfolded proteins and increasing chaperone protein availability, further
assisting with reducing the unfolded protein burden and ER stress. Additionally, like XBP-1s, ATF6
induces XBP-1 expression for UPR autoregulation. Prolonged ATF6 activation also leads to a form of
CHOP-independent apoptosis.
For this review, we will be focusing on UPR signaling through IRE1, PERK, and ATF6 (Figure 1).
This is a simplified model of UPR signaling, omitting numerous additional proteins involved in
glycosylation, folding, and quality control. IRE1, PERK, and ATF6 signaling pathways work together
to reduce ER burden. While this traditional role of UPR is widely agreed upon, recent research suggests
that this model requires further refinement and may not be applicable in all cell types, particularly in
immune and cancer cells, both of which have atypical expression needs.
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Figure 1. ER-stress induced UPR signaling. Summary mapping of the UPR signaling pathways and
locations in which they occur. Each of the three ‘arms’ of UPR signaling are bound by inhibition due
to GRP78 sequestration (right, green ER). Under ER stress, GRP78 binds unfolded proteins, releasing
IRE1, ATF6, and PERK (left, red ER).
2.2. ER Stress and the UPR in the Tumor Microenvironment
UPR signaling is frequently upregulated in the tumor microenvironment due to inflammatory
factors, the high metabolic rate of cancer cells, elevated hypoxia, and poor nutrient availability.
In prostate cancer, tumor cells induce an UPR in the local microenvironment, termed Transmissible ER
Stress (TERS), leading to an UPR in neighboring cells [19]. What secreted factors are responsible for
TERS are unclear, though TERS appears to be dependent upon Toll-like Receptor 4 (TLR4) activation [20].
It is likely that transmissible ER stress will be found in other cancers as well.
Much like inflammation, UPR in the tumor microenvironment increases tumorgenicity and is
associated with a stem-like phenotype, proliferation, angiogenesis, and survival during starvation or
hypoxic conditions [21–27] (reviewed in Figure 2). Increased UPR in neighboring tissues supports
tumor development via Wnt signaling. Wnt signaling reduces pro-apoptotic UPR signaling in prostate
cancer cells [19]. The UPR may further assist in metastasis of circulating cancer cells to hypoxic regions.
UPR signaling is increased in bone metastases of breast, lung, and prostate cancers [28–30]. However,
the role of the UPR is not clear; there are also reports that UPR activation, through increased ER stress,
can induce immunogenic or apoptotic cancer cell death [22,31–33]. Simultaneously, reducing UPR
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signaling can induce immunogenicity and clearance of cancer cells [34–36]. There is a balance to UPR
signaling that allows cancer progression, without activating cell death pathways.
Figure 2. UPR signaling in a tumor and the surrounding microenvironment. The composition of the
tumor and its microenvironment promote UPR signaling in cancer cells via various mechanisms. Poor
perfusion, low oxygen, and reduced growth factor availability contribute to increased UPR signaling.
The ability of cancer cells to exert ‘transmissible UPR signaling’ to the surrounding normal tissue has
been associated with increased survival via JNK signaling. TAM, tumor associated macrophage; Treg,
regulatory T-cell; regDC, regulatory dendritic cell; JNK, c-Jun N-terminal kinase.
The role of UPR signaling in various cancers has been a topic of interest for many years, though
parsing the exact role of UPR signaling has been difficult. For example, activation of the UPR is reported
to prevent apoptosis in prostate cancer cells [37,38], but in another report, UPR was downregulated in
murine models of prostate cancer [39]. Interestingly, the arms of UPR signaling had divergent effects
in androgen-dependent prostate cancer; IRE1α activity and XBP-1 expression were increased, but
PERK activation was reduced [40]. UPR activation in the microenvironment also induces resistance
to bortezomib and paclitaxel in prostate cancer cells [19]. Although UPR activity has a clear role in
prostate cancer progression, the subtleties of its activation and how they affect survival are not well
understood. Investigating the characteristics of the UPR in prostate and colorectal cancers may still
yield effective therapeutic targets [41].
Our group and others have shown breast cancers, that overexpress GRP78 in response to
chemotherapies, exhibit resistance to said chemotherapies [35,42–44], resistance to anti-estrogen
therapies [13,45], and increased tumor anti-immunity [35,36]. This overexpression response is
5
Int. J. Mol. Sci. 2020, 21, 169
associated with hypoxic [44] and triple-negative [46] breast cancers. UPR-induced resistance may be
downstream of MYC (cellular Myelocytomatosis; or c-Myc) [26], though MYC activation is unlikely
to be the only contributor. Expression of ATF6α is correlated with resistance to chemotherapy and
reduced time to breast cancer reoccurrence [47]. UPR stress aids age-related breast tumor development,
and overcoming estrogen receptor-positive status is associated with UPR induction [48]. Recently,
Ypt-interacting protein 1A (Yip1A) regulation of IRE1 and PERK signaling facilitated survival in
cervical cancer cells [49].
Although the intricacies of UPR signaling in cancer microenvironment have not yet been
deciphered, there is a clear trend that optimal levels of UPR signaling confer immune protection and
may assist in the progression of cancer. Due to these findings, investigation of UPR targeting in cancer
therapies is of particular interest.
2.3. Tumor Immunology
Among the many challenges of cancer formation is immune escape. Mutations in cancer cells
lead to increased antigen presentation which stimulates an immune response. Indeed, tumors arise
with greater frequency and grow more rapidly in immunodeficient models [50,51]. To overcome this,
cancer cells must maintain presentation as ‘self’ or have sufficient immunosuppressive capability in
their microenvironment; often, a combination of both. A model used to describe how cancer cells
can overcome immune system destruction is ‘immunoediting’. In this model, the immune system
effectively prevents tumor development, most often by destruction of tumor cells. In some cases,
the immune system can only delay tumor cell growth. This stasis, rather than destruction, allows
time for further mutations and resistance to occur, thus selecting for tumor cells resistant to the
immune system [50,52]. This model gives rise to an interesting parallel between cancer cells developing
immunoresistance and microbes developing antibiotic resistance.
To overwhelm immune response to novel and mutated antigens, cancer cells can simply
overexpress ‘self’ markers, inactivating cytotoxic cells [53–55]. Beyond identifying as ‘self’, cancer
cells can subvert immune system effects to promote growth. While the immune system can induce
cancer cell death and quiescence [56–60], it can also promote tumor development and establish a
favorable tumor microenvironment [57,61–68]. Which of these effects occur is highly dependent on
the microenvironment, what immune infiltrates are present, and the cancer type [69–74]. Infiltrates
to consider are antigen-presenting cells (APCs), including tumor-invading macrophages (TAMs),
neutrophils (TANs), and dendritic cells (DCs). In specific contexts, these cells are associated with
survival in multiple cancer types [58–60,68,75,76]; however, they can also promote cancer progression
in different contexts.
A characteristic of the tumor microenvironment strongly associated with tumor progression
and inhibition of therapeutic efficacy is inflammation [63,64,77]. Inflammatory cell infiltrates,
including macrophage subtypes, regulatory T-cells (Tregs), neutrophils, and myeloid-derived
suppressor cells (MDSCs), create a microenvironment that suppresses cytotoxic cell activity [72,78–86].
Counterintuitively, many of these inflammatory infiltrates are recruited by B and T cells in efforts to
increase immune response, but instead promote tumor development [83,84,87].
Beyond immunosuppression, the inflammatory environment generated by these immune
cells assists in establishing a metastatic niche, inducing cancer cell “stemness” [88]. These cells
can induce stemness by multiple means, including adjusting metabolism and further enhancing
immunosuppression and tolerance in tumor microenvironment [61,79,82,84–86,89,90]. This state
includes many features associated with undifferentiated cells, inducing proliferative potential, survival
and durability advantages, migratory potential via epithelial-to-mesenchymal transition (EMT), and
inducing angiogenesis of solid tumors [74,81]. Increased ‘stemness’ is additionally associated with
increased metastatic potential, more malignant cancers, and poorer patient outcomes [91].
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Another aspect that must be considered is the function of UPR signaling in tumor immunology. In
the context of a highly stressful tumor microenvironment, the function of UPR signaling in individual
immune cell types is worth consideration (summarized in Table 1).
2.4. UPR Signaling in Dendritic (Myeloid-Derived Suppressor) Cells
Myeloid-derived suppressor cells (DCs) are key regulators in immune cell response [92].
Once mature, DCs are tissue-imbedded and function as APCs. DCs additionally release cytokines to
recruit and/or activate other immune cells. DCs regulate T-cell activation through a combination of
presenting foreign and dead cell antigens. These steps are important in immune cells recognizing
which pathogens and mutated cells must be cleared, and preventing an autoimmune response to
healthy self-cells [93].
The ability of DCs to induce immune response requires maturation, presentation of antigens,
and cytokine expression/release. Successful maturation of DCs is dependent upon IRE1α activation
and XBP-1 splicing. Inhibition of IRE1 function or abrogation of XBP-1S signaling reduces successful
maturation and increases apoptotic death in DCs [94]. High mobility group box 1 protein (HMGB1),
known to instigate DC maturation, induces GRP78 expression and XBP-1 signaling [95]. DCs that do
mature under these conditions fail to stimulate T-cell proliferation due to decreased CD80, CD86, and
major histocompatibility complex (MHC)-II expression and cytokine secretion [94,95].
Inhibition of UPR signaling in matured DCs also reduces their ability to activate T cells. CD80,
CD86, MHC-II, and cytokine secretion are all reduced in XBP-1-inhibited mature DCs [95,96]. Inhibition
of XBP-1 signaling may prevent cytokine expression and antigen presentation due to compensatory
RIDD hyperactivity [97]. IRE1α/XBP-1 signaling is prioritized in DC function and it is generally
believed that the PERK/ATF6 arms of the UPR do not significantly contribute to DC function [97].
The inhibition of CHOP, however, specifically prevents the expression of the inflammatory cytokine,
interleukin-23 (IL-23) [96]. These findings suggest that the role of UPR signaling in antigen-presenting
DCs may be more complex than currently appreciated.
Two additional classes of DCs are functionally defective DCs, which do not successfully migrate
or present antigens, and regulatory DCs (regDCs), which are immunosuppressive (reviewed in [98]).
Unlike APC DCs, regDCs are associated with progression in cancers and poorer prognosis [99,100].
Tumor-supporting regDCs were reported as early as 1997 [101]. In that study, Enk et al. reported
that tumor-suppressive APC DCs converted to immunosuppressive regDCs. RegDCs exist in normal
tissues to prevent a hyperactive immune response, along with other forms of regulatory or alternatively
activated immune cells (discussed further below). Much like normal tissues, tumor-infiltrating DCs
can be ‘reprogrammed’ into regDCs by the tumor microenvironment [102].
DCs in the tumor microenvironment can affect responsiveness or tolerance to therapies [101].
In one study, DCs were isolated from patients exhibiting metastatic melanomas, of which some
metastases were responsive to chemotherapy and some metastases remained progressive. In vitro,
the DCs isolated from responsive metastases activated T lymphocytes five-fold higher than DCs
from progressive metastases, suggesting that the latter exhibited a regulatory DC phenotype and
induced chemotherapeutic resistance. Another group showed that regulatory DCs promote metastatic
expansion of pancreatic ductal adenocarcinoma [103]. Metastatic sites were enriched in regulatory
DCs (CD11b+CD11c+MHC-II+CD24+CD64lowF4/80low) that produced Treg cells via secretion of
programmed death ligand 2 (PD-L2), a T-cell checkpoint inhibitor ligand. This study also showed
the depletion of regulatory DCs, blockade of PD-L2-reduced expansion, and metastatic pancreatic
ductal adenocarcinoma in vivo. The role of the UPR in regulatory DCs has yet to be determined; it
may play a key role in their formation. Given the role of regulatory DCs in tumor progression and
immunotherapy resistance, this area requires further investigation.
7
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2.5. UPR Signaling in Macrophages
Macrophages are another class of APC immune cells that regulate the innate immune response.
Macrophages rival DCs in antigen presentation to and activation of T cells. This is characteristic
of M1 (‘killer’ or ‘classically activated’) macrophages, which induce inflammation and anti-antigen
responses. M1 macrophages form from circulating monocytes that infiltrate tissues in response to
chemoattractants. M1 macrophages then release inflammatory factors; phagocytize pathogens, cell
debris, and unhealthy cells; and present antigens to activate T cells. In contrast, M2 (‘repair’ or
‘alternatively activated’) macrophages suppress inflammatory responses and inhibit T-cell activation.
In these contexts, macrophages need to induce sufficient immune response without deleterious effects
to host tissues. Poor regulation of this process, or loss of M1 and M2 macrophage function, is associated
with progression or initiation of several diseases, including cancers [103].
Macrophages were found to initiate UPR signaling upon differentiation [104]. This study
examined both peripheral blood and atherosclerotic-infiltrating macrophages, the latter are comparable
to tumor-infiltrating macrophages. Although initiation timing was unclear, GRP78 expression was
increased and XBP-1 transcripts were primarily found in their spliced forms upon monocyte infiltration
and macrophage differentiation [104]. GRP78 heterozygous macrophages can differentiate and mature,
but expend more energy and have reduced capacity for inflammation [105]. Spliced XBP-1 expression
is also associated with survival in macrophages, potentially through UPR regulating macrophage
metabolism via induced autophagy [106]. Importantly, UPR signaling is required to maintain the ratio
of inflammatory M1 to suppressive M2 cells via ATF4 expression [51].
Macrophage-induced inflammatory response is associated with IRE-1 in models of arthritis,
while data in microglia (neurological tissue equivalent of macrophages) show that PERK activation is
required [107,108]. The UPR is further necessary for successful macrophage response under induced ER
stress. Chemically induced ER stress prevents macrophage function, but upregulation of PERK/ATF4
signaling can compensate for this effect [109].
Loss of UPR function in macrophages is strongly correlated with disease, including fibrosis [110],
obesity-induced inflammatory disease [111,112], tuberculosis [113], and fatty liver disease [114].
These studies associate macrophage-induced inflammation via UPR signaling in these diseases, such
that inhibition of UPR signaling abrogated or ablated disease.
Atherosclerosis, narrowing of arteries by plaque lesions, is a macrophage-associated disease in
which the role of UPR signaling has been extensively studied (reviewed in [115]). In atherosclerosis,
M1 macrophages are recruited to arterial plaques, whereupon they accumulate lipids, becoming foam
cells. Foam cells accumulate free cholesterol due to the presence of low-density lipoprotein (LDL),
which then induces UPR signaling [116–118]. UPR signaling induces CD36 expression, increasing the
uptake of oxidized LDL and leading to further upregulation of all UPR signaling arms [119]. PERK
activation leads to Glycogen Synthase Kinase 3 Alpha/Beta (GSK3a/b) signaling, further inducing lipid
accumulation [120]. These pathways lead to a macrophage–foam cell–UPR self-potentiating cycle.
Perpetuated UPR signaling leads to foam cell death via the CHOP pathway [113].
The changes found in atherosclerosis plaques are similar to those in the tumor microenvironment.
Fittingly, macrophages have been associated with regulation and immune response in the cancer
microenvironment. Increased M1 macrophages are associated with clearance and good prognosis,
while M2 macrophages are immunosuppressive and procarcinogenic. Our lab has shown that UPR
signaling mediates lipid metabolism in breast cancer, and as a result, macrophages infiltrate into
breast cancers [35]. Reducing whole body GRP78 levels by antisense morpholino injection increased
macrophage infiltration of breast tumors and reduced the expression of CD47 (“do not eat me”/“self”)
signaling in tumor samples. These results were replicated with the administration of linoleic acid, the
polyunsaturated fatty lipid cleared downstream of GRP78 activation. Our lab has also demonstrated
that inhibition of PERK, but not GRP78 or IRE1 inhibition, is responsible for the increased proliferation
of M1 macrophages and cancer cell clearance in melanoma [36]. This study showed that cancer cell
UPR activity regulates macrophage response. The inhibition of GRP78 or IRE1 in cancer cells increased
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macrophage-mediated clearance. The effects of UPR signaling in cancer cells, and their ability to induce
UPR signaling in the microenvironment, doubly inhibit macrophage-mediated immune response
to cancers.
2.6. UPR Signaling in T Cells
T cells are lymphocytes that participate in the adaptive immune response. The T-cell family
includes various lymphocytes that mature in the thymus. Each of these cell types contribute to
an immune/apoptotic (CD4+ helper, CD8+ killer, memory, or natural killer) or immunosuppressive
(regulatory) role. In proper orchestration, T cells and the APCs that activate them induce an effective
response against invading pathogens and malignant cells. Dysregulation of T cells can lead to a
compromised immune system or autoimmune diseases.
The UPR is required for successful T-cell formation and activation. Interestingly, different
lymphocyte classes exhibit distinct patterns of UPR signaling during differentiation. UPR signaling
is activated upon differentiation of both B and T cells. In the presence of a differentiation stimulus,
both B and T cells increase GRP78 protein levels, initiate XBP-1 transcript cleavage, and induce ATF6
signaling [121–124]. The inhibition of GRP78, ATF6, or XBP-1 signaling pathways greatly reduces
plasma cell differentiation and efficacy upon maturation [121,125]. Cell fate determines whether UPR
signaling is maintained. For example, early B-cells exhibit UPR signaling, but it is absent in mature
B-cells. Similarly, CD4−/CD8− progenitor T-cells do not exhibit an UPR, but greatly increase UPR
during maturation as CD4+/CD8+ T-cells. Upon differentiation to CD4+ T-cells, the UPR is once again
repressed [122].
Unlike B cells and CD4+ T-cells, mature CD8+ T-cells maintain UPR signaling [122]. XBP-1
signaling downstream of IRE1 is increased during acute infection, and inhibition of XBP-1 signaling
prevents terminal differentiation and immune response in CD8+ T-cells [123]. T-cell trafficking and
homing under oxidative stress also requires UPR signaling [126]. Inhibited signaling, specifically via
the GRP78, ATF6, and XBP-1 pathways, greatly reduces plasma cell differentiation and efficacy upon
maturation [121,125].
Another area in which the UPR plays a role is T-cell exhaustion [127]. This is a state in which
sufficient stimulation does not induce T-cell activation, and thus, the T cell will not proliferate and/or
generate the cytolytic compounds required for inducing targeted cell death [128]. The causes for
this abnormality may be varied. We do know that a lack of appropriate metabolites and inhibitory
signals contribute to this exhausted phenotype. T-cell exhaustion is a concern in numerous diseases,
including cancers [127,129–132]. As stated previously, the microenvironment is hostile and frequently
features hypoxia, low metabolite availability, inflammation, and transmissible ER stress responses. All
these factors induce UPR signaling, which is directly associated with T-cell exhaustion in models of
infectious disease [123,128,133]. T-cell exhaustion in the tumor microenvironment has become an area
of interest and potential immunotherapeutic target [127,129,130,132,134].
The specific roles of UPR signaling in T-cell differentiation and activity are incompletely understood.
Similarly, the role of UPR signaling in the microenvironment and during activation of helper T-cells
has yet to be investigated.
2.7. UPR Signaling and Cancer-Associated Fibroblasts
Cancer-associated fibroblasts (CAFs) play a significant role in the development, protection, and
metastasis of cancers [135]. CAFs are known to regulate tumor-associated immune cells and warrant
mention [136]. Recent findings suggest that UPR signaling plays a large role in the generation of the
tumor environment, including the differentiation of CAFs [137]. In turn, CAFs have been shown to
stimulate non-small-cell lung cancer invasion by upregulating GRP78 expression [138]. As a regulator
of the tumor microenvironment and immune cells, the role of the UPR in CAFs and their function
should be further investigated.
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2.8. Implications for UPR-Targeting Drugs in Cancer Therapy
Interestingly, the efficacy of some chemotherapeutic agents may be due to previously unknown
effects on UPR signaling. Triptolide activates UPR signaling (IRE1 and PERK) in breast cancer, inducing
cell death, and simultaneously reduces the expression of GRP78. This may be characteristic of several
chemotherapeutic agents, for example, nemorosone and ONC212 in pancreatic cancer and nelfinavir in
ovarian cancer [139–141].
The associations among the UPR, development of clinically diagnosed cancer, and
chemotherapeutic resistance have increased interest in targeting the UPR as a strategy for cancer
therapy [142]. There is a delicate balance between surviving ER stress and UPR-initiated apoptosis
in cancer cells [143]. Disrupting this balance via UPR inhibition [47,48,142,144–148] induces cell
death via apoptotic means or immunogenic clearance. Conversely, the overstimulation of the IRE1
and PERK/CHOP pathways [37,149–155] effectively induces cancer cell apoptosis, likely through
pro-apoptotic effects of CHOP. An indirectly activation of UPR signaling by inducing the generation of
reactive oxygen species via small molecule therapy leads to cancer cell death in xenografts [153].
Altering UPR signaling may resensitize cancers to chemotherapeutic agents and may increase the
efficacy of as yet unknown chemotherapeutic agents. To date, several studies have shown that disrupting
UPR signaling increases drug sensitivity. These include reports of abrogating UPR signaling with
concurrent drug treatment in murine xenografts [156] and in vivo colorectal cancer models [157,158],
and resensitizing breast cancer cells to chemotherapy and immunotherapy [35,36,43,45]. Alternatively,
inducing UPR signaling sensitizes non-small-cell lung cancer to doxorubicin [159], instigates ovarian
cancer cell death when paired with mifepristone [160], and increases the efficacy of viral antineoplastic
therapies [161]. Inducing the UPR was shown to sensitize ovarian cancer cells to chemotherapy via
increased JNK signaling [162], which may implicate the IRE1 signaling arm.
There is a growing interest in immunotherapies for cancer treatment. The immune system
regularly clears mutated and senesced cells from the body. The goal of immunotherapy is to
re-enable the immune system to recognize and clear cancer cells. In general, accomplishing this
goal means that immunotherapy must alter cancer cells to present antigens resulting in clearance,
or prevent immunosuppressive effects exhibited by cancers. The latter generally focuses on “self”
markers expressed by cancers, including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4),
programmed cell death protein 1 (PD-1), and lymphocyte activation gene 3 (LAG3). These are
checkpoint inhibitor proteins. When immune cell–cancer cell interactions engage these receptors,
immune cells cannot begin to activate or proliferate. Our lab has demonstrated that targeting the UPR
could induce immune response both through increasing antigen presentation and preventing immune
cell inhibition. Targeting GRP78 induces the accumulation of immunogenic polyunsaturated lipids in
breast cancer models, inducing macrophage infiltration and clearance [35]. Resistance to (CTLA-4)
immunotherapy was also associated with increased UPR signaling [36]. Peripheral blood mononuclear
cells (PBMCs) of melanoma patients were collected prior to and post-development of resistance to
CTLA-4 immunotherapy with ipilimumab. Arginase 1 (Arg-1) was increased in resistant PBMCs,
indicating a shift from M1 cancer-clearing macrophages to M2 immune-inhibitory macrophages.
These PBMCs exhibited increased PERK and IRE-1 expression, suggesting that UPR signaling induced
the shift to M2 macrophages and subsequent resistance to immunotherapy.
3. Conclusions
While the mechanism is still incompletely understood, our knowledge in the functions and
activity of the unfolded protein response allows us to examine its role in complex contexts [14,163].
Each of the three arms of the UPR—IRE1, PERK, and ATF6—exhibit unique effects dependent upon the
cellular context. Immune cells are particularly reliant upon UPR to handle the stress of rapid division
and expression of critical proteins. UPR regulates immune function both in induction of pathogen
response and inhibition of autoimmunity [164]. Another context in which UPR is of particular interest
is tumor development and tumor microenvironment [21,23,29,31,32,39,48,165–168]. The role of UPR
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has been investigated in many types of cancer, suggesting that targeting UPR will be a viable strategy
regardless of cancer origin and mutations. Indeed, there are numerous studies targeting UPR as a
cancer therapy [27,30,37,48,139–141,154,156,162,167,169], to increase chemotherapy efficacy [33,34,44,
48,141,142,153,159–161,165,170–172], and to enhance immunotherapy [34,36,53,132,173–176].
A better understanding of the roles of each UPR arm in cell and organism homeostasis has the
potential to increase the understanding of numerous diseases and this requires further investigation.
Given the potential of cancer immunotherapy, understanding the function of UPR in each immune
cell type and how this affects their response to cancer cells is of particular interest. In addition to
immunotherapy, targeting the UPR shows great promise for increasing the selectivity and efficacy
of cancer therapy, and may be a key target in overcoming cancer resistance to chemotherapies.
By enhancing efficacy as an adjuvant treatment, targeting the UPR may decrease required concentrations
of chemotherapies and therefore off-target effects. Similarly, increasing immunogenicity and clearance
of cancer cells by targeting the UPR is likely to be effective with minimal side effects. For these reasons,
the mechanisms and role of the UPR in cancer cells, immune response, and how to best target these
pathways are high priority targets in furthering cancer treatment.
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Abstract: Functional, tumor-specific CD8+ cytotoxic T lymphocytes drive the adaptive immune
response to cancer. Thus, induction of their activity is the ultimate aim of all immunotherapies.
Success of anti-tumor immunotherapy is precluded by marked immunosuppression in the tumor
microenvironment (TME) leading to CD8+ effector T cell dysfunction. Among the many facets of CD8+
T cell dysfunction that have been recognized—tolerance, anergy, exhaustion, and senescence—CD8+
T cell senescence is incompletely understood. Naïve CD8+ T cells require three essential signals
for activation, differentiation, and survival through T-cell receptor, costimulatory receptors, and
cytokine receptors. Downregulation of costimulatory molecule CD28 is a hallmark of senescent T cells
and increased CD8+CD28− senescent populations with heterogeneous roles have been observed in
multiple solid and hematogenous tumors. T cell senescence can be induced by several factors including
aging, telomere damage, tumor-associated stress, and regulatory T (Treg) cells. Tumor-induced T cell
senescence is yet another mechanism that enables tumor cell resistance to immunotherapy. In this
paper, we provide a comprehensive overview of CD8+CD28− senescent T cell population, their origin,
their function in immunology and pathologic conditions, including TME and their implication for
immunotherapy. Further characterization and investigation into this subset of CD8+ T cells could
improve the efficacy of future anti-tumor immunotherapy.
Keywords: CD8+CD28− T cells; cancer immunology; glioblastoma; immunotherapy; malignant
glioma; cancer
1. Introduction
The conflict between cancer and the immune system has long been established [1].
Immunotherapies are being investigated to augment the anti-tumor effects of the immune system and
promote long-term cancer control [2]. CD8+ cytotoxic T cells (CTLs) are the main players driving the
adaptive immune response against cancer and execute tumor-specific immune responses, rendering
them the primary endpoint to most immunotherapies [3,4]. Establishment of effective antigen-specific
CD8+ T cells enabled preliminary clinical success of cancer vaccines, oncolytic viruses, adoptive cellular
therapy, and checkpoint inhibitors in several cancers including melanoma, lung cancer, renal cell
cancer, Hodgkin’s lymphoma, etc. [5–7]. Unfortunately, despite their promise, the efficacy of these
treatments varies depending on the type and location of the tumor, and has been ineffective in poorly
immunogenic cancers such as glioblastoma (GBM) [7–13].
A variety of T cell deficiencies have been identified in immunosuppressive tumors that contribute
to the ultimate ineffectiveness of CD8+ CTL-mediated tumor killing [14]. Immune tolerance, anergy,
and exhaustion of CD8+ T cells have been studied extensively in the past [14–17]. While the concept
of immune senescence, defined by terminally differentiated cells in cell cycle arrest after extensive
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replication or in response to cellular damage or stress, has been well established with aging and
chronic infections [18–21], our knowledge of its role in cancer is still in its early stages. CD28 is an
indispensable costimulatory molecule needed for the activation of T cells and its role is critical to the
proper activation of CD8+ CTLs [22]. Current evidence shows that the downregulation of CD28 is a
hallmark of senescent CD8+ T cells and CD28− senescent T cells display immunosuppressive functions
in cancer [23–26].
In this review, we will focus on the recent advances in our understanding of CD8+CD28− T cells.
We first will discuss cellular senescence and the evolution of the CD28− T cells. Next, we will review
the significance of CD8+CD28− T cells in multiple disease processes, including transplant, autoimmune
disease, chronic viral infection, and cancer, including CNS tumors. Finally, we will discuss the
functional implications of CD28− T cells in onco-immunology and the important areas of future
investigation on novel immunotherapeutic strategies.
2. Role of CD8+ T Cells in Cancer Immunology
CD8+ T cells are a subset of lymphocytes committed to detecting peptide antigens presented by
major histocompatibility complex (MHC) class I molecules (Figure 1) [27,28]. CD8+ T cells arise from
common lymphoid progenitors that migrate from the bone marrow to the thymus where they pass
through a series of distinct phases of maturation [29,30]. The naïve CD8+ T cell pool is comprised of
polyclonal T cells that express CD28, CCR7, and CD62L, the latter two allowing them to recirculate
between blood and secondary lymphoid organs [31,32]. Initial priming of CD8+ T cells involves T cell
receptor (TCR) recognition of peptide/MHC complexes presented by professional antigen presenting
cells (APCs), such as dendritic cells (DCs). DCs also express surface markers CD70 and CD80/CD86 for
binding to CD27 and CD28 receptors expressed on CD8+T cells. This provides a critical secondary
signal for T cell activation. Host cells, including cancer cells, can serve as targets for previously
activated CD8+ T cells by processing and presenting antigenic tumor peptides by MHC class I.
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Figure 1. The priming and inactivation of CD8+ T cells. The interaction between TCRs and the
peptide-MHC complex is the first step toward antigen-induced CD8+ T cell activation. This creates a
site of extensive contact between T cells and APC, also called immunological synapses, where binding
of CD28 on T cells with CD80/CD86 on APCs transduces a pivotal secondary costimulatory signal to
complete the priming of naïve CD8+ T cells. In addition, CD4+ T helper (Th) cells when activated
by DCs acquire not only the synapse-composed MHC class II and costimulatory molecules (CD54
and CD80), but also the bystander peptide-MHC-I complex from DC and become CD4+ Th-APCs,
resulting in direct CD4+ T–CD8+ T cell interactions and subsequently delivery of CD40L signaling
to CD40-expressing CD8+ T cells [21]. Furthermore, CD4 Th cells also secrete cytokines, such as IL-2,
which promotes the differentiation of naïve CD8+ T cells into effector CTLs and memory CD8+ T cells.
CTLs destroy antigen-specific target cells (such as cancer cells or viral infected host cells) via pathways
including granule exocytosis, Fas ligand, and TRAIL-mediated apoptosis leading to tumor control
or virus clearance and subsequent physiological T-cell inactivation as well as memory CD8+ T-cell
formation [33]. Whereas pathological T-cell inactivation or conversion of CTL to CD8+ senescent T cells
leads to tumor progression and virus replication.
In addition, CD4+ T helper cells interact with CD8+ T cells and modulate CD8+ T cell activation [34–36].
Activated CD4+ T helper cells can secrete a variety of cytokines, such as interferon-gamma (IFN-γ)
and IL-2, and facilitate CD8+ T cells’ optimal proliferation and activation [28,37]. CD4+ T cells could
also help with DC maturation for expression of costimulatory molecules and secretion of cytokines
that contribute to CD8+ T cell priming [38]. A similar mechanism is also carried out by natural killer
(NK) cells, showing that there is collaboration between CD4+ T cells with NK and DCs for induction of
CD8+ T cell priming [28,38].
Upon activation, effector CD8+ CTLs destroy antigen-expressing cancer cells primarily
utilizing two main pathways: granule exocytosis (such as perforin and granzyme) and death
ligand/receptor-mediated apoptosis (such as Fas ligand and TRAIL) [39]. Additionally, activated CD8+
T cells release IFN-γ and tumor necrosis factor alpha (TNF-α) to induce cytotoxicity in the target
cells and stimulate M1 macrophage-mediated anti-tumor response [28]. In multiple solid tumors,
tumor-infiltrating CD8+ CTLs can be used as a prognostic factor [40–48]. For example, in breast cancer,
significantly increased CD8+ T cells at tumor sites have been shown to have an inverse correlation with
advanced tumor stages and a positive correlation with clinical outcomes [41,49,50]. Similar findings
of a favorable prognosis associated with the accumulation of tumor-infiltrating CD8+ T cells were
reported in colorectal, oral squamous cell, pancreatic, and ovarian carcinomas [43–45,47,48,51].
3. CD28 Costimulatory Receptor
The CD28 costimulatory receptor, a 44-kDa membrane glycoprotein, is expressed on nearly all
human T lymphocytes at birth [52]. Binding of the CD28 receptor on T cells provides an essential second
signal alongside TCR ligation for naïve T cell activation. CD28 signaling has diverse effects on T cell
function, including orchestrating membrane raft trapping at the immunological synapse, transcriptional
changes, downstream post-translational modifications, and actin cytoskeletal remodeling [52–54].
This leads to intracellular biochemical events such as survival and proliferation signals, induction
of IL-2, activation of telomerase, stabilization of mRNA for several cytokines, increased glucose
metabolism, and enhanced T cell migration and homing [52,55,56].
CD28 family of costimulatory molecules also includes ICOS, CTLA-4, PD-1, PD1H, TIGIT, and
BTLA [41]. This family of receptors and ligands has considerable complexity in both binding pattern
and biological effects. For instance, CD28 (activating) and CTLA-4 (inhibitory) are highly homologous
and compete for the same ligands (CD80 and CD86) and regulate immune response by providing
opposing effects [51,52].
The critical role of CD28 in induction of immune response was demonstrated in mice treated
with CD28 antagonist, which induced antigen specific tolerance and prevented the progression of
autoimmune diseases and organ graft rejection [57]. This has led to the development of abatacept
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(Orencia® Bristol-Myers Squibb, New York, NY, USA) [58] and belatacept (Nulojix® Bristol-Myers
Squibb New York, NY, USA) [59], a modified antibody composed of Fc region of IgG1 fused to the
extracellular domain of CTLA-4, which bind to CD80/86 on APCs and block the costimulatory signaling
by CD28. Abatacept and belatacept are used clinically to treat rheumatoid arthritis and organ transplant
rejection, respectively [56,60].
On the other hand, the use CD28 agonists to awaken T cells from the tolerant state could lead
to new therapies to re-activate the immune system for the treatment of infectious disease [61] and
cancer [62]. Although, in a phase I trial of systemic administration of CD28 superagonist monoclonal
antibodies (mAb) (TGN1412), uncontrolled CD28 signaling led to a potent induction of downstream
immune activation independent of TCR-CD3 complex resulting in catastrophic systemic inflammatory
syndromes in six volunteer subjects [63]. Investigation of these unexpected serious adverse events
have led to better design of clinical trials and appreciation of differences in CD28 expression and
regulation between species (critical for transitioning preclinical testing to clinical investigations) [64,65].
An updated CD28 superagonist TAB08 is under clinical testing for rheumatoid arthritis [64]. In addition,
localized or targeted use of anti-CD28 mAbs has much potential such as incorporating the intracellular
costimulatory domain of CD28 into CAR (chimeric antigen receptor) T cells for adoptive transfer
immunotherapy and the use of CD28 agonist aptamer with tumor vaccine [66–68].
Importantly, the use of these therapeutics are in clinical trials for a variety of disease states
including solid neoplasms and inflammatory diseases (Table 1). Although previous experience with
CD28 agonist mAbs has been disappointing, headway is being made in their use in solid tumors
and rheumatoid arthritis. Perhaps out of an abundance of caution, current clinical trials for the use
of CD28 agonists are testing their safety, efficacy, and tolerability in patients and are undergoing
dose escalation studies. Fortunately, significant progress has been made into CAR-T cell therapy
incorporating costimulatory domains and has led to the FDA-approval of the CAR-T cell therapy
tisagenlecleucel (KYMRIAH® Novartis Pharmaceuticals, Basel, Switzerland) for relapse or refractory
acute lymphoblastic leukemia patients [69,70].
Table 1. Clinical trials related to the therapeutic use of CD28 manipulation, such as CAR-T cell therapy
and monoclonal antibodies.
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Furthermore, recent progress in the manipulation of other costimulatory molecule such as
ICOS, CD137 (4-1BB), OX40, and GITR has also demonstrated tremendous therapeutic potential [74].
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Activation of ICOS, CD137, and OX40 via mAbs and aptamers improved T cell proliferation, function,
and overall antitumor response [74–77]. Targeting of GITR exhibited effects on both effector and
regulatory T cells. Ligation of constitutively expressed GITR on regulatory T cells caused depletion
in their number, loss lineage stability and immunosuppressive function [78,79], while GITR agonists
work synergistically with PD-1 blockage to promote CD4 and CD8 accumulation in murine ovarian
cancer [80]. Blockade of inhibitory receptor CTLA-4 have been shown to be effective in enhancing
CD28 signaling and augmenting ICOS stimulation [74,81]. Combination of checkpoint inhibitors and
costimulatory agonists presents an exciting avenue of cancer treatment and several clinical studies are
currently investigating their benefit [74].
4. Cellular Senescence in the Immune System
Cellular senescence is a state of cell cycle arrest in respond to cellular damage or stress
to prevent neoplastic transformation [82]. Cellular senescence have been identified in areas of
physiological homeostasis, such as development [82], wound healing [83], and placental natural killer
lymphocytes [84]. However, cellular senescence also contributes to the loss of function associated
with aging and age-related disease as well as chronic viral infection, neurodegenerative disease,
and cancer [18,85,86]. Two categories of cellular senescence have been described in literature: the
first is aging associated, telomere-dependent replicative senescence and the second is stress-induced
premature senescence, also known as telomere-independent senescence [82,87]. Oncogene-induced
senescence is one of the well-described mechanisms for premature senescence [87,88]. Regardless of
the initiating mechanism, cells that undergo senescence survive by exhibiting a variety of phenotypical
and molecular features (Figure 2), including morphological changes, cell division blockage, change
of sensitivity against apoptosis, metabolic dysfunction, and a specialized secretory activity termed
senescence associated secretory phenotype (SASP) [20]. Additional characteristics include nuclear p16
and p21 expression [89–91], DNA damage [92], senescence associated heterochromatin foci (SAHF) [93],
and increased lysosomal senescence-associated β-galactosidase (SA-β-gal) activity [91]. Recently,
lipofuscin accumulation was also established as a hallmark of senescent cells [94].
Figure 2. Phenotypical and molecular changes in cellular senescence. A variety of intracellular (DNA
damage, oncogenes, etc.) and/or extracellular signals (oxidative stress, chronic inflammation, etc.) can
induce cellular senescence. Senescent cells exhibit numerous characteristics including but not limited
to cell cycle arrest, increased nuclear p16 and p21 expression, increased lysosomal SA-β-gal activity,
shortened telomere, and increased lipofuscin. Senescent cells can also present as a specialized secretory
phenotype termed senescence associated secretory phenotype (SASP). Of particular interest, senescent
immune cells present with lowered expression of CD28 and CD27 but heightened expression of CD57,
KLRG-1, TIGIT, and other NK-cell associated surface receptors.
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Cellular senescence also occurs in the human immune system [18,95]. The effectiveness of the
immune response declines with age particularly in the elderly population [96,97]. Immune deficiencies
start to appear in DCs, NK cells, and monocytes/macrophages with aging, and it was proposed that
myeloid-derived suppressor cells (MDSC) could also induce senescence in T and B cells compartment
in diverse inflammatory conditions [96,97]. Importantly, lymphocytes, especially T cells, show the
most considerable changes with aging [95,98]. Among the various complex features that contribute
to the aging-associated changes in T cell immunity, the accumulation of CD28− T cells is one of the
hallmark phenomena in T cell immunosenescence [26,99,100]. TME can also induce senescence in
tumor-infiltrating T cells [14].
5. Role of CD8+CD28− T Cells
Although CD28 is expressed on the majority of the CD8+ T cells at birth [52], normal aging
process and activation of CD8+ T cells invariably leads to CD28 downregulation [101]. CD8+CD28−
cells represent a distinct population distinguishable from the general population of CD8+CD28+
T cells [99], which are known for their crucial role in the clearance of cancer and intracellularly infected
cells, in terms of their phenotype and function [102]. In vitro studies showed purified CD28+ T cells
progressively lose CD28 during each successful stimulation, with the CD8+ T cells losing their CD28
more rapidly than the CD4+ T cells [26,103,104]. The differential rate of CD28 loss is associated
with the rapid inactivation of telomerase and CD8+ T cells reach replicative senescence faster than
CD4+ T cells, at which stage T cells are no longer able to enter mitosis but still remain viable [105].
Thus, these CD8+CD28− T cells are defined as senescent T cells. Less than 50% of the CD8+ T cell
compartment of elderly or chronically infected individuals are CD28+ while up to 80% of CD4+ T cells
maintain their CD28 expression even in the centenarians [26,103]. Interestingly, a large proportion of
CD8+CD28− T cells of elderly persons also have lower levels of CD8 expression [106,107]. Although
the significance of this observation is unknown, downregulation of the expression of CD8 and CD4
molecules is characteristic for activated T cells, suggesting that those CD8lowCD28− T cells subset
represent senescent lymphocytes that are chronically activated from either common persistent antigens
(in the setting of aging) or persistent infection or inflammation (in the setting of cancer) [25,108].
6. Characteristics of CD8+CD28− Senescent T cells
CD8+CD28− T cells are highly oligoclonal and terminally differentiated effector lymphocytes that
have lost their capacity to undergo cell division [23,108]. They are functionally heterogeneous and
their characteristics vary depending on the context where they are found (Figure 3) [23,108]. They also
express a variety of other NK cell-related receptors including KIR, NKG2D, CD56, CD57, CD94, and Fc-γ
receptor IIIa and have features crossing the border between innate and adaptive immunity [109,110].
Alterations in the costimulatory receptor NKG2D signaling and expression levels in CD8+ T cells can
lead to autoimmune conditions that are either TCR dependent or TCR-independent [111–113]. Gained
expression of CD57, also known as HNK-1 (human natural killer-1), is a common feature associated
with circulating senescent T cells, and increased CD8+CD28−CD57+ senescent T cells were identified in
multiple pathological conditions, including HIV infection, multiple myeloma, lung cancer, and chronic
inflammation conditions such as diabetes and obesity [99,114,115]. Although expression of CD57 is
linked to antigen-induced apoptosis of CD8+ T cells [116], the acquisition of CD94 has been reported
to confer resistance to apoptosis in CD8+CD28− T cells. [117] Similarly, CD8+CD28− T cells are often
associated with the lack of perforin, rendering them ineffective Ag-specific killers in chronic viral
infections [21,118–120]. On the other hand, in certain disease processes such as chronic obstructive
pulmonary disease (COPD) and rheumatoid arthritis, they have been reported to express increased
levels of cytotoxic mediators, perforin and granzyme B, and pro-inflammatory cytokines, IFN-γ and
TNFα, where CD8+CD28− T cells can cause significant damages to normal surrounding tissue in an
antigen-nonspecific manner [121].
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Figure 3. The heterogeneous functions of CD8+CD28− T cells. CD8+CD28− T cells originate from
activated CD8+CD28+ T cells or from interaction with tolerogenic APCs. CD8+CD28− T cells exhibit
both cytotoxic and immunoregulatory phenotypes and vary in pathological states such as across
different cancer types or inflammatory/autoimmune conditions.
CD8+CD28− T cells are also shown to be immunosuppressive and function as regulatory
T cells [122–125]. For example, CD8+CD28− T cells directly inhibit Ag-presenting function of
DCs by inducing inhibitory receptors, such as immunoglobulin like transcript 3 (ILT3) and ILT4,
which leads DCs to be immune tolerant than immunogenic [122,126]. Such tolerogenic DCs anergize
alloreactive CD4+CD25+ T cells and convert them into regulatory T cells, which in turn, continue the
immunosuppressive cascade by tolerizing other DCs and amplify T cell immunosenescence [126,127].
In vivo, CD8+CD28− T cells have been directly correlated with the suppression of antigen-specific T cell
responses in patients with plasma cell dyscrasia [123]. Therefore, their characteristics and functions in
immunity range from reduced antigen-specific killing to enhanced cytotoxic abilities and from crossing
innate immunity function to promoting immune regulation.
7. CD8+CD28− T cells in Pathologic Conditions
CD8+CD28− T cells play a significant role in pathological conditions [18,99,100,121].
High populations of these cells have been associated with chronic viral infections including human
immunodeficiency virus (HIV), hepatitis C virus, cytomegalovirus (CMV), and human parvovirus
B19 [99]. Shortened telomeres, reduced IL-2 production, and increased IL-6 production were observed
in these cells [19]. The loss of CD28 also serves as a prognostic indicator for viral infection. For instance,
increased frequency of CD8+CD28− T cells in the early stage of HIV infection correlates with faster
progression to AIDS [99]. Additionally, higher levels of CD8+CD28− T cells are associated with
subclinical carotid artery disease in HIV-infected women [99]. Older CMV seropositive individuals,
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who had higher number of CD8+CD28− cells, responded poorly to vaccines and had early mortality
compared to aged-matched CMV seronegative counterparts [19].
A heterogeneous role was reported for CD8+CD28− T cells in autoimmune diseases [99,108].
Senescent T cell population is increased in patients with Grave’s disease and ankylosing spondylitis
and these cells’ cytotoxicity contributes to autoimmune response [128,129]. In rheumatoid arthritis
patients, clinical response to abatacept, a CD80/86-CD28 T cell co-stimulation modulator, is associated
with a concomitant decrease in CD8+CD28− T cells, suggesting prognostic value for this phenotype [56].
In contrast, patients with systemic lupus erythematosus were found to have reduced CD8+CD28−
T cells [130]. Similarly, in a mice model for multiple sclerosis, adoptive transfer of CD8+CD28−
regulatory T cells have been shown to prevent autoimmune encephalomyelitis [131]. Though treated as
a single phenotype, CD8+CD28− T cells represent a heterogeneous group that has differential activities in
different pathologic conditions. In solid organ transplant recipients, CD8+CD28− T cells have been found
to undergo oligoclonal expansion and play a suppressive role and promote allograft tolerance [108,132].
Elevated CD8+CD28− T cell population in liver transplant patients are associated with better graft
function and reduced rejection rates [133] and contribute to reducing immunosuppressant dosage [124].
In addition, the presence of CD8+CD28− T cells is associated with decreased CD80/86 expression and
increased inhibitory receptor (ILT3, ILT4) in circulating APCs, implying an immunosuppressive role of
this subset [126,133].
8. CD8+CD28− T cells and Cancer
The cycle of anti-tumor immunity starts with the presentation of cancer antigens released from
cancer cell turnover. Resident tissue DCs or lymph nodes residing DCs capture cancer antigens and
present the antigens in the form of peptide-MHC I complex to activate naïve CD8+ T cells. Activated
effector CD8+ T cells travel through blood and lymphatic to reach tumor beds where they execute
cancer-specific killing. This leads to further endogenous antigen release and DC activation, thereby
closing the cycle for anti-tumor immune response [1,28].
The presence of lymphoid aggregates is linked with improved responses to cancer therapies such
as standard cytotoxic therapies, vaccine-based treatments, or immune checkpoint blockades. [5,134]
Immunologically ‘hot’ tumors, such as melanomas and lung cancers, are thus more amenable to
control than ‘cold’ tumors, i.e., tumors with diminished T cell infiltrates, such as GBM. [135,136]
This drives modern cancer therapy to investigate how to redirect the TME to attract the right types of
immune infiltrates.
Effector arm insufficiency, especially CD8+ T cell dysfunction, is a hallmark of inadequate
anti-tumor immune response [16]. Four forms of T cell dysfunction—tolerance, anergy, exhaustion,
and senescence—have all been reported in cancer microenvironment [17,35,137]. Immune tolerance
is a physiological process where the body eliminates self-reacting T cells. Tumor cells, such as GBM,
can mimic peripheral tolerance and facilities FasL-mediated deletion of T cells [17]. Tolerance can
be enforced by TGF-β and IL-10 secreted by Tregs that are recruited in the TME as well as cancer
cells. [17,138,139]. T cell anergy is a T cell hypo-responsive state with low IL-2 production and poor
proliferative capacity [17]. It results from the lack of co-stimulation of TCRs through CD28. This is due
to the competitive binding of CTLA-4 expressed on Tregs to CD80 and CD86 on the APCs [14,17,139].
Anergic T cells display very little to no effector function, but expression on inhibitory markers is
unclear [15]. T cell exhaustion occurs after excessive and continuous stimulation of the TCR and
inflammatory cytokines like IFNα/β. Exhausted T cells have diminished proliferative capacity and
have poor cytokine production and effector function. However, they express high levels of inhibitory
receptors, or immune checkpoints, such as PD-1, CTLA-4, TIM3, LAG3, etc. [15,140]. The degree of
T cell exhaustion can vary with tumor types as well. It is more severe in GBM compared to other
cancers such as breast, lung, and melanoma [137]. T cell senescence can be distinguished from anergy
and exhaustion in their origins and their surface receptors. For example, senescent T cells express
fewer CD28 but more NK receptors, whereas exhausted or anergic T cells express more inhibitory
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receptors such as PD-1 and CTLA-1 (Figure 4). While anergic and exhausted T cells are hyporesponsive
and hypofunctional, senescent T cells were considered metabolically active in their physiological or
pathological environment despite being in cell cycle arrest (Figure 3). Though both T cell anergy and
T cell exhaustion in natural occurrence are considered reversible, T cell senescence was considered
irreversible until recently [14].
Figure 4. The many facets of C8+ T cell dysfunction. In comparison to activated effector T cells,
T cell anergy, exhaustion, and senescence can be distinguished by their unique expression or lack of
expression of surface receptors as well as different levels of intracellular cytokines, such as IL-2.
Targeting dysfunctional effector T cells has revolutionized the paradigm of tumor immunotherapy
and immune checkpoint inhibitors set a paramount example [141]. Utilizing tumor dysregulation
of immune checkpoint expression in exhausted dysfunctional T cells, immune checkpoint inhibitors
were developed to promote protumor immune landscape [141]. Ipilimumab, CTLA-4 inhibitor, the
first immune checkpoint inhibitor approved by FDA, was used to treat patients with advanced
melanoma and has demonstrated improved survival when given with gp100 melanoma vaccine [142].
PD-1 inhibitors, pembrolizumab and nivolumab, and PD-L1 inhibitors, atezolizumab, durvalumab, and
avelumab soon followed showing promising results. Pembrolizumab and nivolumab demonstrated
40–45% objective response rate in melanoma and non-small cell lung cancer [143]. In urothelial
bladder cancer, use of PD-1/PD-L1 inhibitors showed overall response rate between 13% and 24% [144].
With metastatic brain disease, the combination of ipilimumab and nivolumab showed 56% intracranial
response with 19% complete response from metastatic melanoma, and pembrolizumab have been
shown to demonstrate intracranial activity against melanoma and NSCLC metastasis [145]. Continued
investigation of the safety and efficacy of these novel immunomodulating drugs are ongoing in various
malignancies [146]. However, it has been reported that the presence of functionally aberrant senescent
T cells with loss of CD27 and CD28 and gained expression of CD57 cells was associated with resistance
31
Int. J. Mol. Sci. 2019, 20, 2810
to checkpoint inhibitor blockade [8]. Therefore, senescent T cell phenotypes are possible predictive
biomarkers for clinical response to checkpoint inhibitor therapy and potential targets to improve
checkpoint inhibitor efficacy.
Increased CD8+CD28− senescent populations displaying heterogeneous roles have been observed
in multiple solid and hematogenous tumors [24]. This immunosuppressive phenotype was initially
observed in patients with plasma cell dyscrasia, where increased number of CD8+CD28− T cells was
present in the bone marrow (i.e., TME) and the amount directly correlated with the suppression of
antigen-specific T cell response [123]. Similarly, in patients with lung cancer, the CD8+CD28− T cells
express elevated Foxp3 and have been shown to play an immunoregulatory role [147]. High levels
of CD8+CD28− T cells were found in patients with advanced stages of non-small-cell lung cancer.
Their numbers declined with resection of the tumor, and the decreased level of CD8+CD28− T cells
correlates with favorable prognosis in tumor management [148]. In contrast, the CD8+CD28− T cell
populations in melanoma patients express perforin, where they contribute to anti-tumor immune
response [149].
CD8+CD28- T cell senescence is triggered by a variety of biological processes including telomere
damage, Treg cells and tumor-associated stresses [150]. Naturally occurring CD4+CD25hiFoxp3+
Treg (nTreg) and tumor-derived γδ Treg cells can induce responder T cell senescence as an
immunosuppressive mechanism [127,151]. Senescent T cells induced by Treg cells have phenotypic
changes, including expression of SA-β-Gal, downregulation of co-stimulatory molecules CD27
and CD28, and promotion of cell cycle and growth arrest in G0/G1 phase [127,151]. Importantly,
CD8+CD28− senescent T cells induced by Treg cells have potent regulatory activities [150] and deepen
immunosuppression in TME [152]. Therefore, CD8+CD28− senescent T cells are important mediators
and amplifiers of immunosuppression mediated by Treg cells. The blockage of Treg-induced senescence
in responder immune cells is critical in controlling tumor immunosuppression and restoring effector
T cell function.
One of the mechanisms for Treg-induced CD8+ T cell immunosenescence is mediated by nuclear
kinase ataxia-telangiectasia mutated protein (ATM)-associated DNA damage in responder T cells
triggered by glucose competition [150]. MAP ERK1/2 and p38 signaling functionally cooperate with
transcription factors STAT1/STAT3 to control Treg-induced senescence in responder T cells [150].
Utilizing these mechanisms, Treg-induced T cell senescence was successfully prevented by inhibiting
the DNA damage response and/or STAT signaling in a recent in vivo mice study [150]. Another
study has shown that senescent T cells are in fact able to regain function by inhibiting the p38
MAPK pathway [153]. Furthermore, human Toll-like receptor 8 (TLR8) signaling can directly target
multiple types of tumors and prevent tumor-induced cell senescence through modulation of levels of
endogenous secondary messenger cAMP in tumor cells [154].
9. CD8+CD28− T cells and Glioblastoma
Despite being isolated in the intracranial compartment by the blood brain barrier, GBM,
the most common and aggressive primary brain tumor in adults, demonstrates a remarkable
level of immunosuppression [155]. Current standard of care for patients with GBM includes
surgery, temozolomide chemotherapy, radiotherapy, and corticosteroids, all of which have potent
immunosuppressive effects. Tumor cells express surface ligands such as PD-L1 and CD95 (Fas/apoptosis
antigen 1) that can lead to T cell suppression via apoptosis and immunosuppressive cytokines like
TGF-β, IL-10, and other tolerance factors [139]. Tumor-associate macrophages, modified neutrophils,
and Foxp3+ Tregs, are also recruited by the tumor to promote its progression [156–158].
T cell dysfunctions including tolerance, anergy, and exhaustion have also been well documented
in GBM [14,17]. However, despite of promise of checkpoint inhibitors in the treatment of several solid
tumors, their therapeutic efficacy in GBM remains to be validated. Phase III clinical trial Checkmate
143 reported that PD-1 monoclonal antibody (nivolumab) monotherapy failed to demonstrate survival
benefits compared to bevacizumab in recurrent GBM patients who were previously treated with
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chemotherapy and radiotherapy [17,69,155]. Ongoing clinical trials are investigating the tolerability
and drug toxicity in combination treatment and in patients with newly diagnosed GBM patients as
well as recurrent GBM patients. The muted response to immune activators seen thus far highlights to
the need for novel strategies to boost immunity to GBM.
The role of T cell senescence in GBM has been reported but is yet to be fully elucidated.
The presence of circulating senescent CD4+CD28−CD57+ T cells was correlated with poor prognosis in
GBM patients [159]. CD8+CD28−Foxp3+ T cells, which have been found in other cancers to cause APC
dysfunction [160], were also identified in TME from patients with GBM [161]. The APCs isolated from
these patients displayed dysfunctional phenotype associated with high levels of ILT2, ILT3, and ILT4
and low levels of CD40, CD80, and CD86 [162]. It is speculated that CD8+CD28− T cells help sculpt an
immunosuppressive environment in a similar fashion in GBM.
The potential pro-tumoral effect of CD8+CD28− cells can also be inferred from worse prognosis
observed in older GBM patients [163]. Since CD8+CD28− cells are derived from the general population of
immature CD8+CD28+ T cells originating from the thymus [99], the production of immature CD8+CD28+
decreases as thymic involution occurs through aging, but also with cancer [164]. This decrease in
immature CD8+CD28+ cells due to thymic senescence has also been associated with poor outcome in
GMB patients [17].
10. Implications of CD8+CD28− T Cells for the Future of Immunotherapy
Since success of immunotherapy largely relies on addressing effector arm dysfunction, as evident
from the success of checkpoint inhibitors, future investigations into new treatment methods should
explore strategies to deplete or inhibit regulatory CD8+CD28− T cells and reverse T cell senescence
as an adjuvant for more effective immunotherapy. There are four main approaches to rejuvenate T
cell pools (1) replacement of senescent cells, (2) reprogramming of the senescent cells to be functional,
(3) adoptive transfer of proficient T cells, and (4) restoration of naïve T cell pool [165].
Replacement strategies include selectively removing senescent cells from the circulation and then
subsequent expansion of memory and effector T cells. Removal of senescent cells is of particular
importance, not only due to their own dysfunction but also due to their ability to and spreads senescence
in bystander cells [166]. A possible approach for their removal is to promote selective apoptosis in
senescent T cells. In a recent study, an engineered peptide that interferes with FOXO4/p53 interaction
induced p53-mediated intrinsic apoptosis in senescent fibroblasts and neutralized doxorubicin-induced
chemotoxicity in vivo [167]. Whether this also can be used in inducing apoptosis of senescent T cell
remains to be investigated. Targeting commonly known senescent cell anti-apoptotic pathways such
as Bcl-2 and ephrins in senescent T cells is also warranted [168]. Homeostatic expansion in the form
of autologous stem cell transplantation has been used to reconstitute functional naïve, memory, and
affect T cell pools in both autoimmune diseases and hematologic malignancies [169,170]. More recently,
senolytic treatment of amyloid-beta (Aβ) peptide -associated senescent oligodendrocyte progenitor
cell in mice with Alzheimer’s disease showed successful selective removal of senescent cells from the
plaque, reduced neuroinflammation, lessened Aβ load, and ameliorated cognitive deficits [171]. This is
of particular interest as a successful application of senolytic therapy in the CNS pathology, such as
GBM. CD8+CD28− cells replacement strategies are still in early phases of development, however their
successful implementation has the potential to complement the current paradigm of immunotherapies.
Re-programming involves differentiating T cells away from dysfunctional states by enhancing
telomerase activity to extend cellular lifespan and preclude replicative senescence [172]. For example,
restoring CD28 expression slows replicative senescence in human T cells through increased telomerase
activity to increase proliferative potential [173]. Additionally, pharmacological inhibition of SRC
homology 2 domain-containing phosphatase-1 (SHP-1), a key regulator of T cell signal transduction
machinery, improved TCR/CD28 signaling and successfully improve T cell functions in elderly
donors [174]. Aptamers, short, single-stranded DNA or RNA molecules, have been engineered to
target immune costimulatory receptors (CD28, OX40 and 4-1BB) and have shown to improve T cell
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activation and induce antitumor response. Aptamers have the benefits of being chemically synthesized,
versatility of targeting motifs, high penetration rate, and ease of neutralization [75]. Re-programming
of T cells present the most promising avenue for anti-CD8+CD28− therapy with wide selection of
potential targets and treatment mechanisms.
Adoptive transfer is to bypass the co-stimulation requirement to re-differentiate pluripotent stem
cells into naïve and cytotoxic T cells to fight malignancy [175]. The development of T cell adoptive
immunotherapy using the third generation of CAR technology by incorporating the intracellular
costimulatory domains to bypass the requirement for CD28 activation is underway. The third generation
CARs T cells were investigated in hematological malignancies and xenograft model of solid tumors
and have shown preclinical success [176–180]. While other types of immunotherapy can cause systemic
side effects, antigen specificity of CAR therapy limits the adverse effect of immunotherapy to its targets,
and they are reversible when the target cell is eliminated, or the engraftment of the CAR T cells is
terminated [181]. However, its high specificity can be a weakness in heterogeneous tumors with
high mutational profiles since CAR therapy can select for cells negative for the targeted antigen [155].
Such was the case for IL-13Rα2 CAR therapy for GBM where recurrence occurred 7.5 months after
treatment despite shrinking all lesions by 77–100% [155].
Finally, restoring and maintaining the thymic environment reverse effects of thymic involution.
Using bioengineered thymus organoids with the help of growth-promoting factors and cytokines
such as IL-21, it has been shown that significant immune restorative function and rejuvenation of the
peripheral T cell pools were achieved in murine models [182]. Unfortunately, current understanding of
thymic restoration is not complete enough for clinical implementation, and there are still unanswered
questions regarding its feasibility in establishing functional naïve T cell production [183,184]. The safe
removal of senescent CD8+ T cells and restoration or differential induction of functional CD8+
cytotoxic T cells would add a promising mechanism to defend host against cancer invasion and fight
immunotolerance of malignancy.
There is theoretical concern that reversing the growth arrest by selective blockage of senescent
T cells carries a risk of malignancy, which is less of a concern for targeting functionally exhausted
T cells [185]. Nevertheless, one may argue that increased theoretical lifetime risk of malignancy is
outweighed by the potential immediate benefit of extending the life expectancy, even by a few months
to years, in the battle against aggressive cancers, such as GBM with a median overall survival of only
20.6 months. Furthermore, the benefits of targeting both immunosenescence and exhaustion may be
more evident with reduced dose requirement for each, thereby reducing risks of drug-associated adverse
events. Potential synergistic efficacy to boost immunity against cancer may also be implemented as
already seen with GITR stimulation/PD-1 blockade and CTLA-4/ICOS stimulation [74,80,81].
11. Conclusions
In summary, functional, tumor specific CD8+ cytotoxic T cells drive the adaptive immune response
to cancer and are the primary endpoint to most immunotherapies. However, the promise of current
cancer immunotherapy has been limited by marked immunosuppression in the TME defined by CD8+
T cell dysfunction, especially in immune ‘cold’ cancers, such as GBM. Among the many facets of
CD8+ T cell dysfunction, including tolerance, anergy, and exhaustion, CD8+ T cell senescence, as
represented by the CD8+CD28− population, is an emerging field and their presence has been described
in many cancers. CD8+CD28− T cells contribute to tumor immunosuppression and resistance to
immunotherapy. Further characterization and investigation into this subset of CD8+ T cells will
provide novel targets for effective immunotherapy and successful cancer control.
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Abstract: HER2 positive JIMT-1 breast tumors are resistant to trastuzumab treatment in vitro and
develop resistance to trastuzumab in vivo in SCID mice. We explored whether these resistant tumors
could still be eliminated by T cells redirected by a second-generation chimeric antigen receptor (CAR)
containing a CD28 costimulatory domain and targeting HER2 with a trastuzumab-derived scFv.
In vitro, T cells engineered with this HER2 specific CAR recognized HER2 positive target cells as
judged by cytokine production and cytolytic activity. In vivo, the administration of trastuzumab twice
weekly had no effect on the growth of JIMT-1 xenografts in SCID mice. At the same time, a single dose
of 2.5 million T cells from congenic mice exhibited a moderate xenoimmune response and even stable
disease in some cases. In contrast, when the same dose contained 7% (175,000) CAR T cells, complete
remission was achieved in 57 days. Even a reduced dose of 250,000 T cells, including only 17,500
CAR T cells, yielded complete remission, although it needed nearly twice the time. We conclude
that even a small number of CAR T lymphocytes can evoke a robust anti-tumor response against an
antibody resistant xenograft by focusing the activity of xenogenic T cells. This observation may have
significance for optimizing the dose of CAR T cells in the therapy of solid tumors.
Keywords: breast cancer; trastuzumab; chimeric antigen receptor; immunotherapy; cell therapy
1. Introduction
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20–25% of breast cancer
tumors [1]. HER2 expression is associated with an aggressive disease with a high recurrence rate
and increased mortality [2]. Specific monoclonal antibody therapy has revolutionized the treatment
of HER2 positive breast cancer since the FDA (U.S. Food and Drug Administration) approval of
trastuzumab (Herceptin®) in 1998 [3]. The addition of trastuzumab to chemotherapy results in a lower
rate of death after one year (22 percent vs. 33 percent, P = 0.008), longer survival (median survival,
25.1 vs. 20.3 months; P = 0.046), and a 20 percent reduction in the risk of death [4]. Despite the success,
resistance to therapeutic antibodies is a clinical reality that affects the outcome of 60–80% of HER2+
breast cancer patients [5]. One of the underlying mechanisms is epitope masking by components of the
tumor microenvironment (TME) such as the MUC4 (mucin 4) or the CD44/Hyaluronan complex [6–11].
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The JIMT-1 cell line was established from the pleural metastasis of a breast cancer patient and has
recapitulated the trastuzumab resistance of the original tumor in vitro and also in vivo if treatment of
JIMT-1 xenografts SCID mice was initiated at a few hundred mm3 tumor volumes [12–14]. Our recent
data indicate that simultaneous targeting of two epitopes on the HER2 molecule with clinical doses
of trastuzumab and pertuzumab additionally improves the efficacy of antibody-dependent cellular
cytotoxicity and thereby also the anti-tumor response; however, eventually all JIMT-1 xenografts
become resistant to antibody treatment at a certain tumor size [15].
In such cases of antibody resistance, Chimeric Antigen Receptor (CAR) engineered T cells [16]
represent an appealing option for improving the outcome for patients with advanced breast
cancer [17–20]. Several tumor-associated membrane proteins are targeted in clinical trials by CAR T cells,
including HER2 (NCT02547961, NCT02713984), CEA (NCT02349724) and mesothelin (NCT02792114).
While no results have been disclosed of current HER2 targeting trials, the first reported clinical use
of HER2 specific CAR T cells resulted in a serious adverse event following CAR T cell infusion [21].
In this trial, a HER2 positive colon cancer patient was treated with a large number (1010) of CD28-41BB
costimulatory (3rd-generation) CAR T cells, which derived their antigen specificity from trastuzumab.
The patient developed respiratory distress, followed by multiple cardiac arrests over the course of
5 days, leading to death. The death of this patient may have occurred due to the result of HER2
recognition of highly active and numerous anti-HER2 CAR T cells in the normal lung tissue that
caused pulmonary toxicity and edema followed by a cytokine release storm causing multiorgan failure.
The immune-mediated recognition of tumor antigens in normal tissues is referred to as “on-target,
off-tumor” toxicity. It is thus clear from both preclinical experiments and clinical trials that while
CAR T cell-based immune therapy has great potential to improve the outcome for patients with HER2
positive tumors, it still needs plentiful optimization.
Here, we report the generation of mouse T cells that are genetically modified to express a
chimeric antigen receptor that consists of a HER2 specific single-chain variable fragment (scFv) derived
from trastuzumab, a CD28 costimulatory endodomain, and a CD3z intracellular signaling domain.
We demonstrate that these T cells recognize and kill HER2+ tumor cells in vitro and significantly
improve the xenogenic immune response against human breast cancer even at very low numbers
(17,500), resulting in complete tumor regression, and significant survival advantage.
2. Results
2.1. Generation of Murine HER2 Specific CAR T Cells
To genetically modify mouse T cells (Figure 1), first, we generated VSVG-pseudotyped retroviral
particles encoding HER2 specific chimeric antigen receptors (Figure 1A). T cells were isolated from the
freshly dissected spleen of congenic Balb/c mice and activated by anti-mouse CD3e and anti-mouse
CD28 antibodies. After 24 h, the medium was supplemented with mouse interleukin 2. Finally,
activated mouse T cells were retrovirally transduced on RetroNectin-coated plates (Figure 1B).
The CAR contains an scFv obtained from trastuzumab, an IgG1 CH2-CH3 extracellular stalk,
a CD28 costimulatory endodomain and a CD3z effector domain (Figure 2A). Using trastuzumab as a
recognition domain allowed us to compare the impact of CAR T cells as living drugs with the impact
of antibodies. The mean transduction efficiency was 8.7% (range: 5.58–11.84%; n = 8) as judged by
flow cytometric analysis of the HER2 specific scFv (Figure 2B,C). We confirmed that CARs are stably
expressed and re-confirmed CAR expression on day 10.
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Figure 1. Genetic modification of mouse T cells with chimeric antigen receptors: (A) Scheme of
retrovirus production. (B) Scheme of mouse T cell separation and activation.
Figure 2. Generation of HER2 specific mouse CAR T cells: (A) Schematic diagram illustrating the
modular composition of the retroviral vector encoding HER2 specific CAR. (B,C) Representative flow
cytometry dot-plots and summary data (HER2 CAR mouse T cells (n = 8) and non-transduced (NT)
mouse T cells (n = 8)).
2.2. HER2 Specific CARs Redirect Mouse T Cells to HER2 Positive Trastuzumab Resistant Tumor Cells
To demonstrate that the HER2 specific CAR redirects mouse T cells to HER2 positive target
cells, we co-cultured HER2 CAR T cells with JIMT-1 cells in various effector to target ratios (from
2.5:1 to 0.01:1). HER2 specific CAR T cells recognized the HER2 positive tumor cells indicated by a
significant increase in IFNg secretion (p < 0.001). Unmodified (NT) T cells did not induce mIFNg
release (Figure 3A). While HER2 specific CAR induced T cells killed JIMT-1 tumor cells, no killing
was observed in co-cultures with unmodified T cells (p < 0.001; Figure 3B). Taken together, the HER2
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specific CAR activates mouse T cells in an antigen-dependent manner and induces antigen-dependent
tumor cell killing.
Figure 3. In vitro anti-tumor function of HER2 specific mouse CAR T cells: (A) HER2 CAR or
non-transduced (NT) mouse T cells were co-cultured with HER2+ JIMT-1 cells at various (2.5:1–0.01:1)
T cell to tumor cell ratios. After 48 h, IFNγ release was determined by ELISA (n = 2, assay performed
in duplicates; HER2 CAR versus non-transduced (NT) T cells: * p < 0.05, *** p < 0.001). (B) XTT-based
cytotoxicity assay using HER2 CAR T cells or non-modified mouse T cells and HER2 positive JIMT-1
cells as target at various (2.5:1–0.04:1) T cell to tumor cell ratios (n= 2; assay was performed in duplicates;
HER2 CAR versus NT T cells: *** p < 0.001).
2.3. HER2 Specific CAR T Cells Have Antitumor Activity In Vivo against HER2+ Trastuzumab-Resistant
Tumor Xenografts
To compare the anti-tumor function of antibody treatment and HER2-redirected CAR T cells,
we established subcutaneous JIMT-1 xenografts (3 × 106 cells) in SCID mice (day −35, Figure 4).
Mice were injected with 100 μg trastuzumab intraperitoneally twice weekly from day 0 (35 days after
tumor cell injection), when average tumor size reached 800 mm3. Control animals were injected with
PBS (Figure 4) and did not show delayed tumor growth and consequently their overall survival was
not improved (p = 0.79, Figure 5). These data are in line with our previous observations [13].
Figure 4. Outline of in vivo animal treatment schedule: Mice were s.c. injected with 3 × 106 JIMT-1
cells. 35 days later (on day 0), mice received 100 μL PBS buffer twice weekly (untreated, n = 5), 100 μg
trastuzumab in 100 μL PBS buffer twice weekly (trastuzumab, n = 5), or an i.v. dose of 2.5 × 105 HER2
CAR mouse T cells (low-dose HER2 CAR, n = 5), or an i.v. dose of 2.5 × 106 HER2 CAR mouse T cells
(HER2 CAR, n = 5). Tumor growth was followed by caliper and was derived as the product of the
length, width and height.
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Figure 5. Antitumor activity of HER2-CAR mouse T cells in a xenograft model: (A) Quantitative
measurement of tumor volumes (volume = mm3; low dose HER2-CAR versus HER2-CAR groups:
*** p < 0.001; NT T cell versus HER2-CAR groups *** p < 0.001). (B) Kaplan-Meier survival curve
(NT T cell versus both HER2 CAR groups *** p < 0.001). (C) Representative images of animals.
(D) Representative images for the detection of HER2-CAR mouse T cells in JIMT-1 xenografts (field
of view: 92 μm × 92 μm). HER2-CAR mouse T cells were visualized by AlexaFluor647 conjugated
anti-mouse CD3e and HER2-GFP co-staining.
To evaluate the in vivo efficacy of HER2-CAR T cells against these trastuzumab resistant xenografts,
35 days after JIMT-1 inoculation mice were injected iv. with a single dose of 2.5 × 106 (HER2-CAR T cell
group), or 2.5 × 105 (Low Dose HER2-CAR T cell group) congenic mouse T cells, 7% of them expressing
the HER2-CAR. Control mice were treated with 2.5× 106 unmodified T cells (NT T cell group) (Figure 4).
In this group, the high number of mouse T cells, in some cases, delayed the progression of the human
xenografts resulting in better overall survival in comparison to the untreated group (Figure 5A–C).
In contrast, the same dose of mouse T cells, when transduced with the CAR at 7% efficiency, completely
eradicated the tumors in 57 days and resulted in long-term tumor-free survival. Moreover, complete
tumor regression was also observed, by day 105, in the low dose HER2-CAR T cell group in which
animals received only 250,000 T cells, among them 17,500 CAR T cells (Figure 5A–C). There is a cell
dose dependence of the rate of tumor regression (p < 0.001). Despite the difference in time to complete
regression, all CAR T cell treated mice remained tumor free until the termination of the experiment
(day 150). To assess on-target off-tumor toxicity, formaldehyde-fixed paraffin-embedded tissue section
weremade from the heart and lungs of each sacrificed animal. HE-stained sections were characterized
based on morphology by an expert histopathologist and showed no signs of mononuclear infiltration
(Figure S1A,B). Visual inspection upon dissection also did not show signs of inflammation.
To demonstrate that HER2 specific CAR T cells penetrated the JIMT-1 xenografts, tumor samples
from week 3 after CAR T cell injection were immunostained and analyzed by confocal microscopy.
We found T cells positive for the CAR and mouse-CD3e confirming the presence of CAR T cells in
tumor xenografts (Figure 5D). Taken together, we conclude that HER2 specific CAR T cells have
potent in vivo antitumor activity and penetrate HER2 positive xenografts, which are not eliminated by
trastuzumab treatment.
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3. Discussion
In this study, we described the generation of HER2 specific CAR-modified mouse T cells that
obtained their antigen specificity from trastuzumab, a HER2 specific monoclonal antibody applied in
clinical practice. We demonstrated that these cells specifically recognize trastuzumab resistant HER2
positive JIMT-1 target cells in vitro. Moreover, in vivo a low dose of HER2 CAR T cell expressed potent
anti-tumor activity in a trastuzumab-resistant mouse xenograft model.
Although HER2 specific CAR T cells are effective against breast cancer cells [19,22], the tumor
cells preferentially used as targets were trastuzumab sensitive cell lines (SKBR3 or BT474) leaving
the question unanswered whether trastuzumab-resistant xenografts can be successfully treated with
trastuzumab-derived CAR T cells.
Incorporation of the trastuzumab scFv into the CAR backbone allowed us to compare the efficacy
in tumor eradication by cytolytic CAR T cells versus antibody mediated cytotoxicity.
SCID mice exhibit natural killer cell (NK) activity [23], through which trastuzumab treatment
induces antibody dependent cellular cytotocixity against therapy sensitive xenografts (MCF7;
BT-474) [24], which makes a direct comparison possible. In vivo, we confirmed that trastuzumab
treatment has no potential to delay or revert the growth of established JIMT-1 tumors. which is in line
with previous observations [11–14].
Although unmodified mouse T cells in co-cultures with JIMT-1 cells did not release cytokine and
did not exhibit cytotoxicity, we wanted to confirm that xenogenic immune response does not reject
human tumor xenografts in vivo [23]. A single injection of 2.5 × 106 unmodified mouse T cells on day
35 following JIMT-1 implantation could not eradicate the human tumor xenografts; however, in some
cases, it caused tumor regression and resulted in stable disease.
In contrast to the control and trastuzumab-treated groups, 2.5 million mouse T cells with a
proportion of 7% CAR-transduced cells (total ~175,000) caused a complete remission in 57. Even a
tenth of this dose, 250,000 T cells including ~17,500 CAR T cells, was fully curative, although only in
105 days. The number of CAR T cells yielding complete remission in the latter case is only 0.2–0.3% of
the usual 5 to 10 million CAR T cells used in successful mouse CAR-T therapy models [25]. Thus, it is
likely that this small fraction of specifically redirected T lymphocytes successfully penetrates the tumor
mass and evokes, in addition to direct tumor killing, a focusing effect that concentrates the xenogenic
response of non-transduced mouse lymphocytes against the human tumor. By extrapolation, it is
possible that in the case of HER2 positive solid tumors, a reduced number of CAR T cells could still
maintain therapeutic efficacy through actively penetrating the tumor and enhancing the activity of
tumor infiltrating lymphocytes (TILS, [26]). At the same time, while "on target off tumor” toxicity
(mainly in the cardiopulmonary system), could be avoided owing to the lower expression of the HER2
target and the lack of TILs in healthy tissues.
Overall, we conclude that even a small number of CAR T lymphocytes can evoke a robust
anti-tumor response against an antibody resistant xenograft by focusing the activity of xenogenic T
cells. This observation may have significance for optimizing the dose of CAR T cells in the therapy of
solid tumors.
4. Materials and Methods
All materials were from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise indicated.
4.1. Cells and Culture Conditions
HEK 293T packaging cells were purchased from the American Type Culture Collection (ATCC,
Manassas, VA, USA). Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 2 mmol/L Glutamax and 10% Fetal Calf Serum (FCS) and antibiotics. The JIMT-1 human breast
cancer cell line was established in the laboratory of Cancer Biology, University of Tampere, Finland [12].
These cells were cultured in 1:1 ratio of Ham’s F-12 and DMEM supplemented with 20% FCS, 300 U/L
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insulin, 2 mmol/L GlutaMAX and antibiotics. Primary mouse splenocytes, T cells and CAR T cells
were cultured in RPMI 1640 supplemented with 2 mmol/L GlutaMAX, 10% FCS and antibiotics. All of
the above-listed cells and cell lines were maintained in a humidified atmosphere containing 5% CO2 at
37 ◦C and were routinely checked for the absence of mycoplasma contamination.
4.2. Retrovirus Production and Transduction of T Cells
Retroviral particles were generated by transient transfection of HEK 293T cells with the MSGV
retroviral vector containing a trastuzumab derived HER2 specific CAR [17], a Peg-Pam-e plasmid
containing the sequence for MoMLV gag-pol, and a pMEVSVg plasmid containing the sequence for
VSVg, using jetPrime transfection reagent (Polyplus, Illkirch, France). Supernatants containing the
retrovirus were collected after 48 h (Figure 1A).
To generate HER2 specific CAR T cells, T cells of syngenic Balb/c mice were isolated from a
freshly dissected spleen by using a mouse-specific T cell isolation MACS sorting kit (130-095-130;
Miltenyi Biotech; Bergisch Gladbach, Germany). MACS sorted mouse T cells were plated on non-tissue
culture treated 24-well plates (5 × 106 cells/well), which were pre-coated with 1μg/manti-mouse CD3e
(ThermoFischer, Waltham, MA, USA) and anti-mouse CD28 (R&D Systems, Min L neapolis, MN, USA)
antibodies. After 24 h, mouse interleukin 2 (mIL2; 700 U/ml) was added to cultures. T cells were
then transduced with the previously described retroviral particles on RetroNectin-coated (Takara,
Kusatsu, Japan) plates on day 3 in the presence of mIL2 (200 U/m L). The expansion of T cells was
subsequently supported with mIL2. Anti-mouse CD3e/CD28 activated non-transduced (NT) T cells
were expanded in parallel with mIL2. Following 48-72h incubation, cells were collected and used for
further experiments (Figure 1B).
4.3. Flow Cytometry
HER2 specific CAR expression was confirmed by a HER2-GFP recombinant protein. T cell purity
was determined by Alexa Fluor 647 conjugated anti-mouse CD3 antibody (BD Biosciences, San Jose,
CA, USA) staining. Both molecules were used at 10 μg/mL final concentration for 10 minutes on ice.
Analysis was performed on at least 10,000 cells per sample using a FACS Calibur (Becton Dickinson,
Franklin Lakes, NJ, USA) instrument and FCS Express 6 software (De Novo Software, Glendale,
CA, USA).
4.4. CAR-Mediated T Cell Activation
Mouse CAR T cells and non-transduced controls were cultivated in indicator-free RPMI 1640
medium and 10% (v/v) FCS, without additional stimuli for 24 h, washed and incubated on 96-well
round-bottomed plates in the presence of JIMT-1 target cells for 48 h. Culture supernatants
were analyzed for IFN-γ by ELISA (BD Biosciences). IFN-γ was bound to a solid-phase mAb
R46A2 and detected by a biotinylated mAb XMG1.2. The reaction product was visualized by a
peroxidase-streptavidin conjugate (1:10,000) and ABTS as substrate. To monitor the cytolytic activity,
genetically modified and control T cells were co-cultured with JIMT-1 target cells with increasing
T cell numbers for 48 h in 96-well round-bottomed plates. Specific cytotoxicity was monitored
by a 2,3-bis[2-methoxy-4-nitro-5-sulphophenyl]-2H-tetrazolium-5-carboxanilide salt (XTT)-based
colorimetric assay (‘Cell Proliferation Kit II’, Roche Diagnostics, Risch, Switzerland). Reduction
of XTT was determined as OD at 480 nm for treated tumor cells (Tu), for untreated tumor cells (Max)
and for T cells only (T). Background (Bg) was measured in complete medium with XTT but no cells.
Measurements were run with minimally 3 technical replicates in three independent experiments.
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4.5. Xenograft Tumors and In Vivo Antibody Treatment
SCID (C.B-17/Icr-Prkdcscid/IcrIcoCrl, Fox-Chase) mice were purchased from Charles River
Laboratories, and housed in a specific-pathogen-free environment. All animal experiments were
performed in accordance with FELASA guidelines and recommendations and DIN EN ISO 9001
standards. Only non-leaky SCID mice with murine IgG levels below 100 ng/mL were used. Each
seven-week-old female SCID mouse participating in the study was given a subcutaneous injection in
both flanks, each containing 3 × 106 JIMT-1 cells suspended in 100 μL PBS buffer and mixed with an
equal volume of Matrigel (BD Biosciences, San Jose, CA, USA). Tumor volumes were derived as the
product of the length, width and height measured with a caliper.
The trastuzumab group was treated with 100 μg trastuzumab intraperitoneally in 100 μL PBS
twice weekly from day 35 post tumor cell injection. The untreated control group was injected with
100 μL PBS buffer i.p. twice weekly. In the HER2 CAR T cell and unmodified mouse T cell groups mice
received a single dose of 2.5 × 106 effector cells i.v. on day 35 post JIMT-1 inoculation. In the low dose
HER2 CAR T cell group mice received 2.5 × 105 cells i.v. (Figure 3A). At the end of the experiment, the
animals were euthanized. Experiments were approved by the National Ethical Committee for Animal
Research (# 5-1/2018/DEMÁB).
4.6. Tumor Xenograft Sections
At termination, mice were dissected, and fresh tumors were embedded in cryomatrix (Thermo
Fischer Scientific, Waltham, MA, USA) and snap-frozen in isopentane submerged in liquid nitrogen.
Serial 14 μm thick cryosections were made with a Shandon Cryotome (Thermo Fischer Scientific,
Waltham, MA, USA) at −24 ◦C and air-dried. Staining was carried out at room temperature and all
labeling molecules were diluted in PBS buffer supplemented with 1% BSA. After 5 min of rehydration
in PBS buffer containing 1% BSA and 0.01% TritonX-100 (Thermo Fischer Scientific, Waltham, MA,
USA) HER2 CAR mouse T cells were stained with HER2-GFP recombinant protein and Alexa Fluor
647 conjugated anti-mouse CD3e antibodies. Both molecules were used at 2 μg/mL concentration at
4 ◦C for 10 h. Sections were washed three times, for 5, 20, and 60 minutes, fixed in formaldehyde, and
mounted in Mowiol antifade.
4.7. Haematoxylin and Eosin Stained Sections
The heart and lung were resected from sacrificed mice, fixed in 4% paraformaldehyde for 4–6 h,
dehydrated in ethyl alcohol, and embedded in paraffin. Serial sections of 6 μm were cut with a
microtome. Deparaffinized sections were HE stained using standard procedures and imaged using
a Pannoramic digital histopathology scanner with a 20× objective in transmission mode. A trained
histopathologist has examined the digital slides.
4.8. Confocal Laser Scanning Microscopy
Immunofluorescence-labeled tissue sections were analyzed with a confocal laser scanning
microscope (LSM 510, Carl Zeiss GmbH, Jena, Germany) using a 40× C-Apochromat water immersion
objective (NA = 1.2). GFP was excited at 488 nm and Alexa Fluor 647 at 633 nm. Corresponding
fluorescence emissions were separated with an appropriate quad-band dichroic mirror, and detected
through 505 to 550 nm bandpass and 650 nm longpass filters, respectively. Pinhole was set for 4 μm
thick optical sections.
4.9. Statistical Analysis
GraphPad Prism 5 software (GraphPad software, Inc., La Jolla, CA) was used for statistical analysis.
Data were presented as mean ± SD or ± SEM. For comparison between two groups, a two-tailed
t-test was used. For comparisons of three or more groups, one-way ANOVA with Bonferroni’s
post-test was used. For the mouse experiments, survival, determined from the time of tumor cell
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injection, was analyzed by the Kaplan-Meier method and log-rank test. p-values < 0.05 were considered
statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/3/1039/s1.
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Abstract: The term necrosis is commonly applied to cells that have died via a non-specific pathway
or mechanism but strictly is the description of the degradation processes involved once the plasma
membrane of the cell has lost integrity. The signalling pathways potentially involved in accidental
cell death (ACD) or oncosis are under-studied. In this study, the flow cytometric analysis of the
intracellular antigens involved in regulated cell death (RCD) revealed the phenotypic nature of cells
undergoing oncosis or necrosis. Sodium azide induced oncosis but also classic apoptosis, which
was blocked by zVAD (z-Vla-Ala-Asp(OMe)-fluoromethylketone). Oncotic cells were found to be
viability+ve/caspase-3–ve/RIP3+ve/–ve (Receptor-interacting serine/threonine protein kinase 3). These
two cell populations also displayed a DNA damage response (DDR) phenotype pH2AX+ve/PARP–ve,
cleaved PARP induced caspase independent apoptosis H2AX–ve/PARP+ve and hyper-activation or
parthanatos H2AX+ve/PARP+ve. Oncotic cells with phenotype cell viability+ve/RIP3–ve/caspase-3–ve
showed increased DDR and parthanatos. Necrostatin-1 down-regulated DDR in oncotic cells and
increased sodium azide induced apoptosis. This flow cytometric approach to cell death research
highlights the link between ACD and the RCD processes of programmed apoptosis and necrosis.
Keywords: accidental cell death; oncosis; DDR; parthanatos; flow cytometry
1. Introduction
The recent re-definition of cell death from Type I (programmed cell death by apoptosis),
Type II (autophagic cell death), and Type III (programmed necrosis) to programmed cell death
(PCD, homeostatic and embryonic), accidental cell death (ACD, oncosis), and regulated cell death
(RCD), which includes apoptosis, necroptosis, autophagy, parthanatos or hyper-activation of Poly
(ADP-ribose) polymerase (PARP) caused by an excessive DNA damage response (DDR, e.g., by pH2AX
phospho H2AX histone) has been advantageous in understanding the complexity of cell death. RIP1-
(Receptor-interacting serine/threonine protein kinase 1) dependent apoptosis or RIP1/RIP3/caspase-3
cells not being included highlights that the cell death nomenclature should be reviewed on a regular
basis [1–5]. Programmed or regulated necrosis now includes necroptosis and parthanatos, amongst
other forms of reported programmed cell death. However, necrosis is also the term commonly used to
indicate the presence of dead cells that have lost plasma membrane integrity by any cell death pathway,
but is strictly a reference to the degradation of the cell contents and plasma membrane after death [6–10].
The term oncosis or ACD is a better description of cell death induced by mechanical, chemical, and
environmental factors that cause a rapid decrease in intracellular ATP leading to the deactivation
of Na+ and K+-ATPase, resulting in an influx of Na+, Cl–, and Ca2+ ions. The cell then undergoes
osmosis and swelling with a bursting of cell organelles and the plasma membrane [11]. Uncoupling
protein 2 (UCP-2), located in the inner mitochondrial membrane where protons are pumped by UCP-2
into the mitochondrial matrix or the intermembrane space, which then regulates ATP and superoxide
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production is modestly up-regulated by oncosis, resulting in a rapid depolarization of the mitochondrial
membrane, which has been measured by flow cytometry [12,13]. The signal pathways involved in
oncosis are under studied, so little information is known about these mechanisms compared to the
knowledge of pathways in RCD [1,2,6].
In contrast to oncosis, classic apoptosis is caspase-3 dependent and these cells form blebs on the
surface of the plasma membrane with a gradual loss in mitochondrial membrane potential and hence a
gradual lowering of intracellular ATP. The generation of reactive oxygen species (ROS) and loss of
cytochrome c from the mitochondria to the cytoplasm results in activation of caspases and generation
of apoptosomes and DNA fragmentation, accompanied with cell shrinkage and the formation of
apoptotic bodies [1,2,8,14].
Until recently, necrotic or oncotic cells were measured via flow cytometry using the Annexin V
assay in which such cells are gated as cell viability+ve/AnnexinV–ve and numerous researchers have
attempted to understand this dead cell population with varying success [13,15,16]. In our laboratory,
mitochondrial and plasma membrane dysfunction were detected by the multiplexing of mitochondrial
and plasma membrane probes into the Annexin V assay, leading to a better understanding of the
biological processes occurring in this oncotic population [13,15,16]. The recent development of a
polychromatic flow cytometric assay in this laboratory, which identifies most RCDs simultaneously
and demonstrates pathways affected by use of pan-caspase and RIP1 protein blockers zVAD and
necrostatin-1 (Nec-1), led us to re-investigate oncotic cell death for potential pathways by comparison
with apoptosis. The markers measured by flow cytometry included a fixable cell viability marker,
activated caspase-3 (apoptosis), up-regulated RIP3 (necroptosis, or resting when not), pH2AX (DDR),
cleaved PARP (apoptosis), parthanatos, or hyper-activation of cleaved PARP (pH2AX/cleaved PARP;
Table 1, Figure S1). Potential modulation of the oncotic response to sodium azide was further
investigated by the use of zVAD and necrostatin-1 to evaluate if the oncotic signalling pathways can be
modified by these inhibitors before the cell loses plasma membrane permeability and the cell undergoes
oncosis [3,4,13,17–19]. This approach may indicate the nature of the oncotic cell phenotype and
highlight potential mechanisms that can modify the oncotic cellular response and the ACD connection
to RCD processes. This may increase the potential for the use of therapeutic drugs to target the ACD
process in the treatment of cancer.
Table 1. Cell description and phenotypes; Figure S1 provides a diagrammatical representation.
Cell Population Phenotypic Markers
Live resting (or necroptotic) Caspase-3–ve/Zombie NIR–ve/RIP3+ve
Live double negative (DN) Caspase-3–ve/Zombie NIR–ve/RIP3–ve
Early apoptosis (EAPO) Caspase-3+ve/Zombie NIR–ve/RIP3–ve
Live RIP1-dependent apoptosis (RIP1-APO) Caspase-3+ve/Zombie NIR–ve/RIP3+ve
Late apoptosis (LAPO) Caspase-3+ve/Zombie NIR+ve/RIP3–ve
Dead/necrotic/oncotic Caspase-3–ve/Zombie NIR+ve
Dead resting (or necroptotic) Caspase-3–ve/Zombie NIR+ve/RIP3+ve
Dead double negative (DN) Caspase-3–ve/Zombie NIR+ve/RIP3–ve
Dead RIP1-dependent apoptosis (RIP1-APO) Caspase-3+ve/Zombie NIR+ve/RIP3+ve
DNA damage response (DDR) pH2AX+ve/Cleaved PARP–ve
Hyper-activation of cleaved PARP/parthanatos pH2AX+ve/Cleaved PARP+ve
Cleaved PARP pH2AX–ve/Cleaved PARP+ve
2. Results
2.1. Induction of Oncosis
NaN3 induced early apoptosis (28%, Figure 1B, lower right quadrant) and lower levels of late
apoptotic (13%, Figure 1B, upper right quadrant) and oncotic cells (17%, Figure 1B, upper left quadrant)
compared with untreated cells after 24 h (Figure 1A,B, see Materials and Methods section for details
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of cell phenotype and gating strategy, Table 1, Figure S1). A lower incidence of live resting cells was
observed (RIP3+ve/caspase-3–ve, 44%, Figure 2C, upper left quadrant) but with more early apoptosis
after treatment (RIP3–ve/caspase-3+ve, 25%, Figure 2A,C, lower right quadrant). Dead cells arising from
NaN3 treatment showed less late apoptosis (25%, Figure 2D, lower right quadrant) than untreated cells
(Figure 2B).
Figure 1. Cell death and caspase-3 activation assay. Cells were (A) untreated; (B) treated with 0.25%
sodium azide (NaN3) for 24 h; (C) pre-treated with 20 μM zVAD for 2 h, then with 0.25% NaN3; (D)
pre-treated with 60 μM necrostatin-1 (Nec-1) for 2 h, then with 0.25% NaN3; (E) pre-treated with 20 μM
zVAD and 60 μM Nec-1 for 2 h, then with 0.25% NaN3; (F) treated with 1 μM Etoposide (Etop) for 24 h;
(G) pre-treated with 20 μM zVAD for 2 h, then with 1 μM Etop; (H) pre-treated with 60 μM Nec-1 for
2 h, then with 1 μM Etop; and (I) pre-treated with 20 μM zVAD and 60 μM Nec-1 for 2 h, then with
1 μM Etop. n = 3, % Mean ± % SEM; Student’s t-test: NS (not significant), * p < 0.05, ** p < 0.01**,
*** p < 0.001; arrows indicate change compared with untreated cells.
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Figure 2. RIP3 and caspase-3 activation analysis of oncosis. After gating on live and dead cells from a
Zombie NIR vs. caspase3-BV650 dot-plot (A) untreated live and (B) dead Jurkat cells were analysed
on a RIP3-PE vs. caspase-3-BV650 dot-plot with resting phenotype indicated by RIP3+ve/caspase-3–ve,
apoptosis by RIP3–ve/caspase-3+ve, RIP1-dependent apoptosis RIP3+ve/caspase-3+ve, and double
negative RIP3–ve/caspase-3–ve. Live and dead cells treated with (C,D) 0.25% NaN3 for 24 h; (E,F)
pre-treated with 20 μM zVAD for 2 h, then treated with 0.25% NaN3; (G,H)pre-treated with 60 μM
Nec-1 for 2 h, then treated with 0.25% NaN3; and (I,J) pre-treated with 20 μM zVAD and 60 μM Nec-1
for 2 h, then treated with 0.25% NaN3, respectively. n = 3, % Mean ±% SEM, Student’s t–test: NS (not
significant), * p < 0.05, ** p < 0.01**, *** p < 0.001; arrows indicate change compared with untreated cells.
The oncotic cells resulting from NaN3 treatment were mainly double negative (55%) for RIP3 and
caspase-3 expression (dead resting oncotic cells, <10% caspase-3–ve/RIP3+ve, Figure 2D).
After NaN3 treatment, the two live and dead apoptotic populations showed increased
levels of pH2AX hyper-activation of cleaved PARP and a lower degree of apoptosis via cleaved
PARP and DDR than untreated cells (Figure 3A–C, Figure S1A,B,E,F,I,J,M,N). Whereas late
apoptotic cells showed increased DDR (Figure 3C, Figure S2B,E,M,J). The dead resting oncotic
cells (Zombie+ve/caspase-3–ve/RIP3+ve) were, 31% negative for both H2AX and PARP, whereas the dead
oncotic DN (Zombie+ve/caspase-3–ve/RIP3–ve) cells were 57% negative for both markers (Figure 3A–C,
Figure S2O,P). The live and dead DN populations showed increased levels of parthanatos and DDR
(Figure 3A–C, Figure S2D,H,L,P).
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Figure 3. Parthanatos/hyper-activation of cleaved PARP, apoptosis via cleaved PARP, and DDR analysis
of oncosis. Untreated Jurkat cells, treated with 0.25% NaN3 for 24 h, or pre-treated with zVAD (20 μM)
and/or Nec-1 (60 μM) for 2 h, then incubated with 0.25% NaN3. Gating live and dead cells from a
Zombie NIR vs. caspase-3-BV650 plot then both were analysed on a RIP3-PE vs. caspase-3-BV650 plot.
Next, early and late apoptotic, necroptotic/resting, RIP1-dependent apoptotic, and double negative
(DN) populations were analysed for pH2AX and cleaved PARP (Figures S2, S3). The incidence of (A)
parthanatos/hyper-activation of cleaved PARP, (B) apoptosis via cleaved PARP, and (C) DDR were
determined for all populations listed above. n = 3, % Mean, error bars % SEM, Student’s t-test; NS (not
significant), * p < 0.05, ** p < 0.01**, *** p < 0.001 compared with untreated cells.
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2.2. Induction of Apoptosis
Induction of apoptosis with Etop showed an increase in early and late apoptosis as well as
oncotic cells compared with untreated cells (Figure 1A,F). Live and early apoptotic cells showed
increased levels of both types of apoptosis and the DN cells, whereas dead cells showed no such change
(Figure 2A,B and Figure 4A,B).
Figure 4. RIP3 and caspase-3 activation analysis of apoptosis. Gating on live and dead cells from
a Zombie NIR vs. caspase-3-BV650 plot followed by analysis on a RIP3-PE vs. caspase-3-BV650
plot with resting phenotype indicated by RIP3+ve/caspase-3–ve, apoptosis by RIP3–ve/caspase-3+ve,
RIP1-dependent apoptosis by RIP3+ve/caspase-3+ve and double negative by RIP3–ve/caspase-3–ve. (A,B)
Treated with 1 μM Etop for 24 h; (C,D), pre-treated with 20 μM zVAD for 2 h, then treated with 1 μM
Etop; (E,F) pre-treated with 60 μM Nec-1 for 2 h, then treated with 1 μM Etop; and (G,H) pre-treated
with 20 μM zVAD and 60 μM Nec-1 for 2 h, then treated with 1 μM Etop. N = 3, % Mean ± % SEM,
Student’s t–test: NS (not significant), * p < 0.05, ** p < 0.01**, *** p < 0.001; arrows indicate change
compared with untreated cells.
Early and late apoptotic cells after Etop treatment showed increased pH2AX hyper-activation of
cleaved PARP with a decrease in apoptosis via cleaved PARP compared with untreated cells (Figure 5A,B
and Figure S2Q,U). Live RIP1-dependent cells, however, showed increased pH2AX hyper-activation of
cleaved PARP and caspase-3-dependent apoptosis via cleaved PARP with decreased DDR (Figure 5A–C
and Figure S2R). However, live and dead oncotic resting and DN phenotypes also showed increased
parthanatos and caspase-3-independent apoptosis via cleaved PARP with no increase in DDR, except
for an increase observed in the live resting population (Figure 5A–C and Figure S2S,T,V,W,X).
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Figure 5. Parthanatos/hyper-activation of cleaved PARP, apoptosis via cleaved PARP, and DDR analysis
of apoptosis. Untreated Jurkat, treated with 1 μM Etop or pre-treated with zVAD (20 μM) and/or
Nec-1 (60 μM) for 2 h, then incubated with 1 μM Etop for 24 h. Gating on live and dead cells from a
Zombie NIR vs. caspase-3-BV650 plot then both were analysed on a RIP3-PE vs. caspase-3-BV650 plot.
Early and late apoptotic, necroptotic/resting, RIP1-dependent apoptotic, and double negative (DN)
populations were analysed for pH2AX and cleaved PARP (Figures S2,S4 for detailed information). The
incidence of (A) parthanatos/hyper-activation of cleaved PARP, (B) apoptosis via cleaved PARP, and (C)
DDR were determined for all populations listed above. Mean, error bars % SEM, Student’s t-test: NS
(not significant), * p < 0.05, ** p < 0.01**, *** p < 0.001 compared with untreated cells.
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2.3. Blockade of Caspases
Pre-treatment with zVAD to block the activation of caspases by NaN3 and Etop resulted in lower
levels of early apoptosis (<20%) and late apoptosis (<10%) with no change in the incidence of oncotic
cells (Figure 1C,G, Figure 2E,F and Figure 4C,D). The proportion of live DN (RIP3–ve/caspase-3–ve) and
dead oncotic cells (RIP3–ve/caspase-3–ve) increased after zVAD blockade of both drugs (Figure 2E,F
and Figure 4C,D).
After zVAD caspase blockade of NaN3 and Etop treatments, all live populations showed increased
H2AX hyper-activation of cleaved PARP or parthanatos compared with untreated cells but decreased
compared to drugs alone (Figure 3A, Figure 5A and Figure S3A–D, S4A–D). The live RIP1-dependent
apoptotic, resting, and DN cells from both treatments also showed increased levels of apoptosis via
cleaved PARP compared with untreated cells (early apoptosis showed a decrease, Figure 3B, Figure 5B
and Figure S3A–D, S4A–D). The live DN population after zVAD/NaN3 or Etop treatment showed
a decrease or increase of DDR compared with drugs alone, respectively (Figure 3C, Figure 5C and
Figure S3D, S4D). Live RIP1-dependent apoptotic and resting phenotypes, after both treatments with
zVAD, showed increased DDR compared with drugs alone (Figure 3C, Figure 5C and Figure S3B,C,
S4B,C). Dead cells from zVAD blockade of NaN3/Etop treatments returned pH2AX and cleaved PARP
expression to that of untreated dead cells (Figure 3, Figure 5 and Figure S3E–H, S4E–H). Except after
NaN3/zVAD treatment, an increase in DDR was observed in the dead RIP1-dependent apoptotic and
oncotic DN phenotypes (Figure 5 and Figure S3F,H).
2.4. Blockade with Necrostatin-1
Blockade of NaN3 with Nec-1 resulted in very high levels of early apoptosis compared with NaN3,
but was lower with Etop treatment (Figure 1D,H). Cell death was lower with Nec-1/NaN3 but not
changed with Etop treatment (Figure 1D,H). The live cells showed a higher incidence of early and
RIP1-dependent apoptosis compared with NaN3 treatment, with no change observed with Etop or in
the incidence of dead cells (Figure 2A–D,G,H and Figure 4A,E,F).
pHA2X hyper-activation of cleaved PARP in live and dead cells after Nec-1 showed increased
values similar to that observed with only drugs, except for the lower levels in both the DN populations
and live resting cells after Nec-1/Etop treatment (Figure 3A, Figure 5A and Figure S3I–P, S4I–P).
Apoptosis via cleaved PARP was increased in live and dead cells after Nec-1 blockade of NaN3
treatment and decreased with Nec-1/Etop treatment compared with drugs alone, except for a decrease
in live resting cells (Nec-1/NaN3) and no change in RIP1-dependent apoptosis after Nec-1/Etop
treatment (Figure 3B, Figure 5B and Figure S3I–P, S4I–P). Very low levels of DDR were observed in
early and live RIP1-dependent apoptotic cells, but increased in live resting and DN cells (Figure 3C,
Figure 5C and Figure S3I–L, S4I–L). Dead cell phenotypes after Nec-1 blockade of NaN3 showed
no increase in DDR compared with untreated cells, but was increased with Nec-1/Etop treatment
(Figure 3C, Figure 5C and Figure S3, S4M–P).
2.5. Blockade with zVAD and Necrostatin-1
Pre-treatment with zVAD and Nec-1 to block the activation of caspases and RIP proteins resulted
in lower levels of early and late apoptosis (<20%), although oncosis (caspase-3–ve/Zombie+ve) was still
maintained (Figure 1E,I, Figure 2I,J and Figure 4G,H). Blocked NaN3 treated cells had a higher level of
live DN cells (and Etop), whereas dead cells showed higher levels of RIP1-dependent apoptosis, which
indicated that zVAD did not block caspases in the RIP1-dependent apoptotic pathway in the presence
of Nec-1 (Figure 2I,J and Figure 4G,H).
All cell phenotypes after dual blockade showed the same reduced levels of pH2AX hyper-activation
of cleaved PARP as that observed after zVAD blockade (no change in Etop DN cells, Figure 3A, Figure 5A
and Figure S3Q–X, S4Q–X). Apoptosis via cleaved PARP was lower in the early apoptotic and DN cells
after dual blockade of NaN3 and increased in live resting and RIP1-dependent apoptotic cells (Figure 3B
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and Figure S3Q,T). In contrast, all live cell (dual-blocked Etop) populations showed no change in
apoptosis via cleaved PARP compared with drug treatment, except for the lower levels observed in
live resting cells (Figure 5B and Figure S4Q,T). All dead cell populations after dual blockade of both
treatments showed lower levels of apoptosis via cleaved PARP compared to any treatment protocol,
except no change was observed in Etop-induced late and RIP1-dependent apoptotic cells (Figure 3B,
Figure 5B and Figure S3U–X, S4U–X). Lastly, the DDR levels after both treatment protocols showed
that all cell populations had higher levels than untreated cells (Figures 3C and 5C), except for the lower
levels found in the live RIP1-dependent apoptotic cells compared with both treatments (Figures 3C
and 5C).
3. Discussion
The use of oncosis and apoptosis-inducing drugs NaN3 and Etop, together with caspase and RIP
protein blockers, zVAD and Nec-1, has allowed the tracking of the cell death processes involved in
ACD and apoptosis a form of RCD using flow cytometry (Figure 6) [17–19]. Induction of oncosis or
apoptosis resulted in measurable oncosis (Zombie+ve/caspase-3–ve, commonly termed necrotic) but
also early and late apoptosis, which was reduced by zVAD blockade without affecting the degree of
oncosis induced by both drugs. Blockade of both drugs with Nec-1 resulted in increased NaN3-induced
early apoptosis while increasing Etop-induced oncosis. Induction of ACD and early apoptosis (by
NaN3) showed that live resting Jurkat cells move the RIP3+ve/caspase-3–ve/Zombie–ve phenotype to
the early apoptotic phenotype of RIP3–ve/caspase-3+ve/Zombie–ve, then later to the RIP1-dependent
phenotype RIP3+ve/caspase-3+ve/Zombie–ve (Figure 6B), even in the presence of RIP1 inhibitor, Nec-1.
This effect has been previously reported [17,19], where it was shown that although Nec-1 inhibited
necroptosis by abrogation of the up-regulation of RIP3 (RIP3+ve/caspase-3–ve/Zombie–ve), it did not
inhibit cells from undergoing apparent RIP1-dependent apoptosis. The limitation of the current assay
is highlighted by the use of RIP3 and caspase-3 antibodies to indirectly identify RIP1-dependent
apoptosis due to the lack availability of a fluorescenated RIP1 antibody [17,19]. The interactions of
RIP1, RIP3, TRADD (TNFR1-associated death domain), FADD (Fas associated via death domain),
and caspase-8 in apoptotic Complex IIa and IIb pathways are not completely understood, so another
explanation of the apparent presence (indirectly via RIP3) of RIP1-dependent apoptosis in the presence
of Nec-1 is required, which may be elucidated by the use of a fluorescenated RIP1 antibody [5,20,21].
Induction of apoptosis by Etop showed that a high proportion of live resting cells become DN
(losing their RIP3), as well as another population expressing caspase-3, possibly indicating that the
cells first lose RIP3, become DN, and then express caspase-3 (Figure 6B), but also that early apoptotic
cells can also later express RIP3 (Figure 6B) [5,17,19–21]. The route to RIP1-dependent apoptosis may
be that these resting cells, rather than lose their RIP3, also start to express caspase-3 (Figure 6B).
Once the cells lose plasma membrane integrity and become Zombie+ve, the cells presumably
maintain the late apoptotic phenotype RIP3–ve/caspase-3+ve/Zombie+ve before further degradation
resulting in the cells becoming DN (Figure 6C). Oncotic cells (caspase-3–ve/Zombie+ve) induced by
NaN3/Etop, however, can also be divided into those with RIP3+ve/caspase-3–ve/Zombie+ve or the DN
phenotype RIP3–ve/caspase-3–ve/Zombie+ve (Figure 6C).
63
Int. J. Mol. Sci. 2019, 20, 4379
 
Figure 6. ACD and RCD pathways. (A) Live cells can undergo either early apoptosis (EAPO) or oncosis
after drug treatment, with early apoptotic cells moving to late apoptotic (LAPO), then later with cell
degradation, to the oncotic or necrotic phenotype. (B) Live cells may express RIP3+ve/caspase-3–ve
when resting, or be RIP3high+ve/caspase-3–ve when undergoing necroptosis, or be double negative
(DN). EAPO cells lose RIP3 or, if retained, undergo RIP1-dependent apoptosis (RIP1-APO). EAPO
cells can also become RIP1+ve. (C) Loss of plasma membrane integrity or cell death results in cell
phenotypes mirrored in (B), with degradation of cells resulting in the DN population. (B,C) Live and
dead cell phenotypes can also express pH2AX (DDR) or cleaved PARP (apoptosis), both of which can
ultimately express both proteins, (D,E) resulting in pH2AX hyper-activation of cleaved PARP in the
presence of active caspase-3 or parthanatos in the absence of caspase-3. Arrows indicate movement of
cell populations.
The expression of pH2AX and cleaved PARP in the four identified phenotypes in live and dead
cells are resting, early or late apoptotic, RIP1-dependent apoptosis, and DN, the incidence of which is
modified by the action of the two drugs used in this study and can be further manipulated by blockade
of ACD and RCD processes by zVAD and Nec-1 (Figure 6D,E) [22–25]. In the first instance live resting
cells, the main phenotype of untreated Jurkat cells express RIP3 with a high degree of DDR (37%),
whereas resting DN cells showed little DDR (2%) but a high degree of cleaved PARP (39%) in the
absence of caspase-3 [25]. Induction of ACD resulted in enhanced levels of pHA2X hyper-activation of
cleaved PARP in all live cell phenotypes with consequent reduced levels of DDR in live RIP1-dependent
apoptotic cells, but with increased levels in the live DN phenotype (Figure 6D).
Once the cells undergo death, all phenotypes still showed increased pHA2X hyper-activation of
cleaved PARP above the levels observed with dead untreated Jurkat cells (Figure 6E), whereas late
apoptotic and dead oncotic DN cells showed increased DDR with no change in dead resting cells.
Similar results were observed when cells undergo Etop-induced apoptosis, except no increase in DDR
was observed in the dead oncotic or resting cells. So, NaN3-derived oncotic cells can express more
DDR than Etop-induced oncotic cells, which expressed higher levels of cleaved PARP (in the absence of
caspase-3) and parthanatos/pHA2X hyper-activation of cleaved PARP, again in the absence of caspase-3
(Figure 6E).
The main effect of blockade with zVAD was an increased incidence of live and dead DN cells
with both treatments, which displayed no change in DDR, increased cleaved PARP and reductions in
pHA2X hyper-activation of cleaved PARP, as was the case with most cell phenotypes (Figure 6D, E).
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This was with the notable exception of no change in levels of cleaved PARP in dead oncotic resting and
DN cells compared to NaN3 treatment.
In contrast, blockade of NaN3 with Nec-1 resulted in no change in the incidence of dead DN and
fewer live DN cells (as untreated cells), whereas Etop-induced levels were similar to that observed by
drug alone. However, all blocked NaN3 cell phenotypes showed increased cleaved PARP and pH2AX
activation of cleaved PARP with reductions in DDR; this observation was especially noteworthy in the
dead oncotic resting and DN cells, whereas the opposite was observed in these populations after Nec-1
blockade of Etop.
Dual blockade of both treatments again showed a high incidence of DN cells with reduced levels
of pHA2X hyper-activation of cleaved PARP and cleaved PARP expression in the various populations
of cells, whereas DDR was generally increased after Nec-1 blockade of both drugs in most populations
of cells. So, the blockade of apoptotic and/or necroptotic pathways when the cells are undergoing ACD
and RCD processes radically increased the incidence of oncotic cells, especially in the case of blockade
of apoptosis alone and necroptosis, which resulted in increased levels of DDR, whereas Nec-1 blockade
reduced ACD-related DDR but not in the case of RCD.
For decades, oncotic cells have been an undetermined population of dead cells that have been
overlooked due to the difficult in their characterisation rather than being a point of interest. They have
been detected by use of the Annexin V assay and classed as cell viability+ve/Annexin V–ve [13,15,16].
Using an active caspase-3 and RIP3 antibodies in tandem with a fixable live/dead dye, we showed that
these oncotic cells have two main phenotypes, both of which are cell viability+ve/caspase-3–ve/RIP3+/–ve,
which can be further divided into DDR, hyper-activation of PARP or parthanatos, apoptosis via PARP
or cells undergoing programmed necrosis, as well as double negative oncotic cells. All of them are
expressed to different degrees compared with cells derived from untreated cultures. This perhaps
reflects their different origins, with differences in expression of these markers when the cells are derived
from an ACD or RCD induction process. These differences in origin are further highlighted by their
differing oncotic responses to blockade by zVAD and Nec-1 or both.
4. Materials and Methods
4.1. Induction of Oncosis and Apoptosis
Jurkat cells (human acute T cell leukaemia cell line, ECACC, Salisbury, UK) were grown in RPMI
(Roswell Park Memorial Institute 1640 Medium) 1640 with 10% FBS (Fetal Bovine Serum, Invitrogen,
Paisley, UK) at 37 ◦C and 5% CO2, either untreated or treated with 0.25% sodium azide or 1 μM
etoposide (NaN3, Etop, Sigma, Poole, UK) for 24 h. Cells were pre-treated with pan-caspase blocker
zVAD (20 μM, Enzo Life Sciences, Exeter, UK) and/or necroptosis blocker necrostatin-1 (Nec-1, 60 μM
Cambridge Bioscience, Cambridge, UK) for 2 h before induction of oncosis with 0.25% sodium azide or
apoptosis with 1 μM Etop for 24 h.
4.2. Flow Cytometry Assay
Harvested cells were labelled with fixable live dead stain, Zombie near infra red (NIR; Biolegend,
San Diego, CA, USA) at room temperature (RT) for 15 min. Washed cell were fixed in Solution A
(CalTag, Little Balmer, UK) then 0.25% Triton X-100 (Sigma, Poole, UK) for 15 min each at RT. Jurkat
cells (1 × 106) were incubated for 20 min at RT with anti-RIP3-PE (phycoerythrin clone B-2, Cat. No.
sc-374639, Santa Cruz, Dallas, Tx, USA), cleaved PARP-PE-CF-595 (clone F21-852, Becton Dickinson,
San Jose, CA, USA), H2A.X-Phospho (ser139)-PE-Cy7 (clone 2F3, Biolegend, San Diego, CA, USA) and
anti- active caspase-3-BV650 (clone C92-605, Becton Dickinson, San Jose, CA, USA) for 20 min at RT.
Washed cells were resuspended in 400 μL PBS (Phosphate Buffered Saline) and analysed on a ACEA
Bioscience Novocyte 3000 flow cytometer (100,000 events, San Diego, CA, USA). Zombie NIR was
excited by a 633 nm laser and collected with a 780/60 nm detector. Caspase-3-BV650 was excited by a
405 nm laser and collected at 675/30 nm. RIP3-PE, cleaved PARP-PE-CF-595, and pH2AX-PE-Cy7 were
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excited by a 488 nm laser and collected at 572/28, 615/20, and 780/60 nm, respectively. Single colour
controls were used to determine the colour compensation using the pre-set voltages on the instrument
using Novo Express software (ver 1.2.5, ACEA Biosciences, San Diego, CA, USA). Cells were gated on
FSC (Forward Scatter) vs. SSC (Side Scatter) with single cells being gated on a FSC-A (Area) vs. FSC-H
(Height) plot. Cells were then gated on a plot of caspase-3-BV650 vs. Zombie NIR, with a quadrant
placed marking off live cells in the double negative quadrant (Figure S1A, lower left quadrant), with
caspase-3-BV650+ve/Zombie NIR–ve (Figure S1A, lower right quadrant) indicating early apoptotic
cells (EAPO), and lastly with caspase-3-BV650+ve/Zombie NIR+ve and caspase-3-BV650–ve/Zombie
NIR+ve (Figure S1A, upper quadrants) indicating dead late apoptotic (LAPO) (Figure S1A, upper right
quadrant) and oncotic cells (Figure S1A, upper left quadrant). Further labelling with RIP3 allowed
identification within the live resting and dead oncotic populations of RIP3+ve/caspase-3–ve or necroptotic
cells when RIP3 is up-regulated, early or late apoptotic (RIP3–ve/caspase-3+ve), RIP1-dependent
apoptosis (RIP3+ve/caspase-3+ve, RIP1APO), and live double negative (DN) or dead oncotic DN
cells (Figure S1B,D). Further gating on each of these eight populations for pH2AX and cleaved
PARP allowed the identification of DDR (H2AX+ve/PARP–ve), pH2AX hyper-activation of cleaved
PARP or parthanatos (H2AX+ve/PARP+ve), apoptotic cell death via cleaved PARP (H2AX–ve/PARP+ve),
and DN cells (H2AX–ve/PARP–ve) (Figure S1C,E) [19]. In particular, dead resting oncotic cells
(Zombie+ve/caspase-3–ve/RIP3+ve) and dead oncotic DN cells (Zombie+ve/caspase-3–ve/RIP3–ve) were
gated for pH2AX and cleaved PARP, revealing the phenotypic nature of these two types of oncotic
cells (Figure S1F,G).
4.3. Statistics
For all experiments, n = 3 and data are reported as mean ± SEM for percentage positive. Student’s
t-tests were performed in GraphPad software Inc. (San Diego, CA, USA) with p ≥ 0.05 considered not
significant (NS). * denotes p ≤ 0.05, ** denotes p ≤ 0.01, and *** denotes p ≤ 0.001 when treated cells
were compared to untreated cells.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/18/
4379/s1.
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Abstract: The treatment of metastatic breast cancer remained a challenge despite the recent
breakthrough in the immunotherapy regimens. Here, we addressed the multidimensional
immunophenotyping of 4T1 metastatic breast cancer by the state-of-the-art single cell mass cytometry
(CyTOF). We determined the dose and time dependent cytotoxicity of cisplatin on 4T1 cells by the
xCelligence real-time electronic sensing assay. Cisplatin treatment reduced tumor growth, number of
lung metastasis, and the splenomegaly of 4T1 tumor bearing mice. We showed that cisplatin inhibited
the tumor stroma formation, the polarization of carcinoma-associated fibroblasts by the diminished
proteolytic activity of fibroblast activating protein. The CyTOF analysis revealed the emergence of
CD11b+/Gr-1+/CD44+ or CD11b+/Gr-1+/IL-17A+myeloid-derived suppressor cells (MDSCs) and
the absence of B220+ or CD62L+ B-cells, the CD62L+/CD4+ and CD62L+/CD8+ T-cells in the spleen
of advanced cancer. We could show the immunomodulatory effect of cisplatin via the suppression of
splenic MDSCs and via the promotion of peripheral IFN-γ+myeloid cells. Our data could support
the use of low dose chemotherapy with cisplatin as an immunomodulatory agent for metastatic triple
negative breast cancer.
Keywords: single cell mass cytometry; metastatic breast cancer; myeloid-derived suppressor
cells; immunophenotyping
1. Introduction
The role of the tumor microenvironment, the interaction of cancer cells with the extracellular
matrix, endothelial cells, cancer-associated fibroblasts, and leukocytes in the tumor stroma have been
increasingly considered as a milestone in cancer development, especially in the last decade [1,2].
The deeper understanding of the disturbances in the regulation and activation of the immune system in
cancer resulted in the advancement of anti-cancer therapies, such as the immune checkpoint blockade
(ICB) [3]. However, the treatment of poorly immunogenic and metastasizing tumors remained
a challenge.
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Here, we focus on female breast cancer since it is the most frequent cancer in women and
still the deadliest cancer type between the ages of 20–49 years old in contrast to the achievements
in early diagnostics and therapeutics [4,5]. In our work the murine mammary carcinoma of the
BALB/c mice, the syngeneic 4T1 was studied [6]. The 4T1 model is among the few murine triple
negative breast cancer (TNBC) models that spontaneously metastasize to sites affected in human
breast cancer (e.g., lung) in an immunocompetent host [7]. Orthotopic transplantation of 4T1 cells
offers a relevant tumor model to study efficacy of drug candidates or immune therapy regimens [8].
Previously, we showed the tumor promoting effect of mesenchymal stem cell (cancer associated
fibroblast)-derived galectin-1 in the 4T1 model [9], and later on we screened an anti-cancer compound
library of imidazo[1-2-b]pyrazole-7-carboxamides in both two- and three-dimensional cell cultures of
4T1 cells [10,11].
We have previously reviewed how cancer-related chronic inflammation can lead to the generation
of immature myeloid-derived suppressor cells (MDSCs) and to the alternative polarization of
tumor-associated macrophages (TAMs) [12], which manifests autonomously in the 4T1 breast cancer
model [13,14]. It has been shown that the granulocytic MDSCs support metastases by suppressing
CD8+ T-cells in the 4T1 breast tumor model [15]. It was also recently shown that 4T1 cells shape
immune responses with an increase of splenic CD11b+ cells to promote cancer growth in an Shb (SRC
homology-2 domain protein B) dependent manner [16]. The 4T1 tumor cells are poorly immunogenic
and refractory to immune therapies, although the combination of anti-PD-1, anti-CTLA-4 ICB with
epigenetic modulators could have a therapeutic benefit curing more than 80% of 4T1 tumor bearing mice
via eliminating MDSCs [17]. We have previously reviewed strategies targeting these myeloid-derived
suppressors cells or tumor associated macrophages to combat cancer [18]. Here, the traditional
chemotherapeutic agent, the DNA crosslinker cisplatin was used, since cisplatin and platinum-based
chemoterapeutics are in the clinical routine as first line treatment option in several cancers such as lung,
bladder, ovarian and metastatic breast cancer [19]. Recent studies have shown the immune induction by
cisplatin in human TNBC (the TONIC trial NCT02499367) [20], or in murine carcinoma models showing
enhanced sensitivity to ICB therapy in combination with cisplatin treatment but these studies did not
deal with immunophenotyping of the myeloid compartment [21,22]. The beneficial effect of cisplatin
on the course of 4T1 tumor development was shown recently in combination with metformin or
bromelain [23,24], but these studies also did not address the characterization of the immunophenotype.
To the best of our knowledge our study is the first, where mass cytometry, a multidimensional
single cell technology with computational data analysis was carried out in order to reveal the
immunophenotype of 4T1 murine triple negative breast carcinoma and the effect of cisplatin treatment
on the splenic and circulating immune compartments.
2. Results
2.1. Real-Time Monitoring of 4T1 Cell Viability Hampered by Cisplatin
Determination of the half maximal inhibitory concentration, the IC50 of cisplatin on 4T1 cells was
carried out using the real-time electronic sensing xCelligence system [25]. The detected impedance is
proportional with the percentage of adhered living cells to the gold coated plate and the decline in
the normalized cell index corresponds to hampered cell viability (Figure 1). The effect of cisplatin on
viability was followed for 120 h after treatment in every 15 min (former studies reported endpoint
assays with cisplatin on 4T1 cells). The IC50 values were as follows 36.74 μM at 24 h, 7.608 μM at 48 h,
6.962 μM at 72 h, 4.128 μM at 96 h, and 3.995 μM at 120 h (Figure S1).
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Figure 1. Real-time monitoring of 4T1 cell viability hampered by cisplatin. The 4T1 cells were seeded
and the baseline impedance was recorded for 48 h. After that 48 h culturing treatment with 11.111 μM,
33.333 μM, or 100 μM cisplatin reduced viability of 4T1 cells on a time and dose dependent manner.
The corresponding dose-response curves with the half maximal inhibitory concentration (IC50) values
can be found in Figure S1.
2.2. Cisplatin Treatment Reduced 4T1 Tumor Growth, the Number of Lung Metastatic Nodules and the Weight
of the Spleen
The syngeneic BALB/c mice were orthotopically transplanted with 4T1 breast cancer cells in order
to establish the animal model for the addressed immunophenotyping. Tumor growth was monitored
daily. All mice treated with cisplatin showed markedly reduced tumor growth compared to untreated
4T1 tumor bearing mice represented by the average tumor volume of 102 mm3 versus (vs.) 1481 mm3
on the 21st day (Figure 2A). On the 23rd day mice were euthanized for immunophenotyping and the
weight of the tumors (Figure 2B), the number of metastatic nodules (macrometastasis) on the lungs
(Figure 2C), and the weight of the spleens were measured (Figure 2D).
The average weight of the tumors was reduced by almost 90% due to cisplatin treatment,
namely 426.4 ± 110.1 mg (mean ± SEM) in the cisplatin treated 4T1 tumorous mice vs. 3087 ± 356 mg
in the untreated 4T1 tumor bearing mice (Figure 2B). The development of metastatic nodules on the
surface of the lungs were also inhibited by cisplatin, the average number of lung macrometastasis were
as follows: 0.42 ± 0.23 in cisplatin treated vs. 3.25 ± 0.524 in untreated 4T1 tumorous mice (Figure 2C).
Splenomegaly is one sign of myeloid cell expansion due to cancer related inflammation in tumor
bearing hosts [26]. Cisplatin treatment suppressed the enlargement of the spleen as spleen weights
were 143.04 ± 19.25 mg, 843.59 ± 38.69 mg, 123.91 ± 26.08 mg, in the naive, 4T1 tumor bearing and
cisplatin treated 4T1 tumor bearing mice, respectively (Figure 2D).
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Figure 2. Cisplatin treatment reduced 4T1 tumor growth, the number of lung metastatic nodules and
the weight of the spleen. The 4T1 cells (1.2 × 105) were transplanted by the injection into the mammary
fat pad of BALB/c mice (n = 12). Tumor growth was monitored daily (A). On the 23rd day mice were
euthanized and the weight of the tumors (B), the number of metastatic nodules on the lungs (C), and the
weight of the spleens were measured (D). Individual values and arithmetic mean values of the samples
± standard error of the mean (SEM) are plotted, statistical significance was set to *** p < 0.001.
2.3. Cisplatin Reduced the Activity of Fibroblast Activator Protein (FAP)
The increased activity of the prolyl endopeptidase FAP enzyme is a hallmark of the tumor stroma,
because of the accumulation and activation of cancer associated fibroblasts (CAFs). The FAP protease
activity either membrane bound on CAFs or solubilized, is proportional with the malignancy [27].
The activity of FAP enzyme was investigated, because it has been reported that the accumulation of
CAFs in the tumor stroma and their expression of FAP contributes to the chemoresistance to cisplatin in
carcinomas [28,29]. We have synthetized a peptide substrate (Fmoc-Gly-Pro-Cysteic acid-Ile-Gly-NH2,
Figure S2) in order to measure FAP activity in the plasma of naive, 4T1 tumor bearing and cisplatin
treated 4T1 tumorous mice (Figure 3).
72
Int. J. Mol. Sci. 2020, 21, 170
Figure 3. The proteolytic activity of the fibroblast activator protein (FAP) increased by the formation
of breast cancer, and was significantly decreased by cisplatin treatment. Area under the curve (AUC)
values from high pressure liquid chromatography (HPLC) analysis of the peptide digestion product 2
(Figure S2) were plotted. The results are shown as arithmetic mean values of the samples ± standard
error of the mean (SEM), statistical significance was set to *** p < 0.001, * p < 0.05.
FAP enzyme activity quantification was based on a direct measurement of a digested peptide
product with high pressure liquid chromatography (HPLC) (Figure S2). Fmoc-GP-Cox- was synthesized
(Avidin Ltd.) and used as a substrate, where “Cox” denotes for oxydized cysteine, namely, cysteic acid.
We used oxidized cysteine amino acid at position 3 in the peptide substrate of FAP, instead of unmodified
cysteine. In a preliminary experiment, we confirmed that the peptide with the oxidized cysteine
residue was the same or better substrate of FAP. Moreover, our improved peptide substrate is more
water soluble and after FAP digestion the dipeptide product (Fmoc-GP) could be better separated from
the intact substrate during HPLC analysis, then the unmodified version, enabling us more accurate
and sensitive quantification. We could detect FAP activity in the plasma of naive, 4T1 tumor bearing
and cisplatin treated 4T1 tumorous animals with the following average AUC (± SEM) values from
HPLC analysis: 518.5 ± 55.5 × 103, 1240.2 ± 77.9 × 103, 914.9 ± 71.7 × 103, respectively (Figure 3).
2.4. Single Cell Mass Cytometry (SCMC) Revealed the Immunophenotype of Breast Cancer Bearing Mice
2.4.1. Cisplatin Restored the Splenic Immunophenotype of 4T1 Tumor Bearing Mice
In order to investigate the immunophenotype of 4T1 breast cancer single cell mass cytometry
was performed with 24 antibodies in one single tube (see Table 1 in Section 4.5). We intended to
monitor the draining lymph nodes, bone marrow, spleen, and blood of the naive, 4T1 tumor bearing,
and cisplatin treated 4T1 tumorous animals. However, the orthotopic injection of 4T1 cells into the
mammary fat pad resulted in the outgrowth of the tumor mass in co-junction with the draining cervical
and axillary lymph nodes making them undetectable. Bone marrow staining showed homogenous
immature cells (little CD11+ Gr1+ elevation in tumor bearing hosts) excluding these samples from
further analysis. Our attention turned toward the spleen since it has been published in the seminal
paper of Bronte et al. that tolerance to tumor antigens develops in the spleen [30]. During the SCMC
analysis of the spleen CD45+ living singlets were gated and on these leukocytes the unsupervised and
multidimensional visualization of stochastic neighbor embedding (viSNE) analysis was performed
delineating the separate clouds of different main immune subsets (Figure 4) [31].
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Table 1. The list of the antibodies used for mass cytometry.
Target Clone Metal Tag
























Both the CD4+ and CD8+ T-cells were almost completely absent and the percentage of CD19+
B-cells decreased from 50% to 10% of CD45+ living singlets in the spleen of the 4T1 tumor bearing
mice (Figure 4D,E). The percentage of the myeloid CD11b+ cells increased from 10% to 80% at the
expense of lymphoid subsets due to breast cancer development (Figure 4D,E). Cisplatin treatment of
4T1 tumorous mice normalized the splenic immunophenotype similar to naive mice with 25% CD4+,
10% CD8+ T-cells, 40% CD19+ B-cells, and 20% CD11b+ cells (Figure 4F).
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Figure 4. Single cell mass cytometric immunophenotyping showed the accumulation of CD11b+
myeloid cells in 4T1 tumor bearing animals at the expense of lymphoid subsets which was reverted
by cisplatin treatment. The visualization of stochastic neighbor embedding (viSNE) analysis was run
on the (A) naive, (B) 4T1 tumor bearing, and (C) cisplatin treated 4T1 tumorous animals within the
CD45+ living singlets. Quantitative analysis of the main lymphoid subsets: CD4+ T-cells = lilac,
CD8+ T-cells = blue, CD19+ B-cells = orange and the myeloid CD11b+ = green, CD11c + = red subsets
were performed in the spleen of (D) naive, (E) 4T1 tumor bearing, and (F) cisplatin treated 4T1 tumorous
mice within the CD45+ living singlets. Representative viSNE plots and column bars are shown from the
pooled samples of 6 mice per group. Data are shown as arithmetic means on the column bars ± SEM.
Pairwise comparison of the emergence of CD11b+ population in (E) vs. (D) and its decrease by cisplatin
treatment (F) vs. (E) has statistical significance at p < 0.001.
The expression intensity of certain proteins within the viSNE plots of main subsets showed
dramatic changes (Figure 5). The expression pattern of Gr-1+ (Ly6C/Ly6G), CD44+, and IL-17A+ cells
within the cloud of CD11b+myeloid cells were uniquely high in the spleen of 4T1 breast cancer bearing
mice (Figure 5) in accordance with the splenomegaly shown in Figure 2D. On the contrary, the B220 and
CD62L markers within the cloud of CD19+ B-cells, and the CD62L within the cloud of CD4+ and CD8+
T-cells also were highly reduced in the spleen of 4T1 tumorous mice (Figure 5). Cisplatin treatment
reverted the immunophenotype of both splenic CD11b+myeloid (Gr-1+, CD44+ and IL-17A+) cells
and lymphoid (B220+/CD19+, CD62L+/CD19+, CD62L+/CD4+, CD62L+/CD8+ T-cells) cells similar to
naive mice (Figure 5).
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Figure 5. The viSNE plots illustrate the expression intensity of Gr-1, CD44, IL-17A, B220, CD62L
markers within the clouds of main subsets defined in Figure 4 in the splenic samples of naive, 4T1 tumor
bearing, and cisplatin treated 4T1 tumorous mice. The coloration is proportional to the expression
intensity (blue = low, red = high). The list of the antibodies can be found in Table 1 in Section 4.5.
Representative viSNE plots are shown from the pooled samples of 6 mice per group. The markers of
the panel which were not detected or did not show differential expression are not shown.
Quantitation of the populations with characteristic protein expression was performed by manual
gating within the CD45+ living singlets of splenocytes (Figure S3). The trajectories on the radar plots
delineate the characteristic marker profile of splenocytes of naive, 4T1 tumor bearing, and cisplatin
treated tumorous mice (Figure 6).
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Figure 6. The trajectories on the radar plots delineate the characteristic marker profile of splenocytes
in naive, 4T1 tumor bearing, and cisplatin treated tumorous mice. The accumulation of splenic (A)
CD11b+/Gr-1+MDSCs, (B) CD44+, and in a smaller extent (C) IL-17A+MDSCs is a characteristic of
4T1 breast cancer. Cisplatin restores the percentage of (D) B220+ and (E) CD62L+ B-cells, (F) CD62L+
CD4+ and (G) CD8+ T-cells. The percentage of the given populations is demonstrated on the radar
plots within the CD45+ living singlets determined by manual gating in Cytobank. The gating hierarchy
is explained in the text and in Figure S3. The markers of the panel which were not detected or did not
show differential expression are not shown. Representative radar plots are shown from the pooled
samples of 6 mice per group as described in Section 4.5.
MDSCs were defined as CD45+/CD3-/CD11+/Gr1+ cells and further evaluated for CD44 and
IL-17A staining. These MDSCs, CD44+MDSCs and IL-17A+MDSCs represented exclusively 60%,
60% and 6% of CD45+ living singlets in the spleen of 4T1 tumorous mice, respectively. The B-cell
marker B220 (except regulatory B-cells, germinal center B-cells, some plasma cells, and certain memory
B-cells [32–34]) on CD45+/CD3-/CD19+ B-cells was 40% in the naive, 30% in the cisplatin treated,
while only 6% in the untreated 4T1 tumorous mice. The homing receptor L-selectin, CD62L was almost
absent (0.2%) on the splenic B-cells of 4T1 tumorous mice but it was restored upon cisplatin treatment
to 5.5% (naive mice 12.5%). The CD45+/CD3+/TCRβ+/CD4+ and CD45+/CD3+/TCRβ+/CD8+ T-cells
expressed CD62L 15% vs. 20% and 6% vs. 10% in the splenocytes of naive and cisplatin treated 4T1
bearing mice, respectively. Sunburst charts represent the immunocomposition of main subsets of
the spleens detected by single cell mass cytometry in Figure S4A and FlowSOM (Flow data using
Self-Organizing Map, [35]) analysis demonstrates the identified clusters, minimum spanning trees
(MSTs) of splenic subsets in Figure S5.
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2.4.2. Cisplatin Could not Completely Restore the Peripheral Immunophenotye of 4T1 Tumor Bearing
mice but Increased IFN-γ Production of Myeloid Cells
Immunophenotype of the blood in breast cancer can reflect the state of the peripheral
tolerance associated with cancer-related inflammation or the activation of anti-tumor effector cellular
responses [36]. The viSNE plots of the main subsets in blood samples show the absence of peripheral
CD4+, CD8+ T-, and B-cells and the emergence of CD11b+ cells as a sign of advanced cancer compared
to naive blood (Figure 7A,B). Cisplatin treatment at least partially normalized the immunocomposition
of the blood of 4T1 tumorous mice (Figure 7C).
Figure 7. Immunophenotyping of blood showed dramatic expansion of CD11b+ cells in advanced
cancer. The viSNE analysis was run on the (A) naive, (B) 4T1 tumor bearing, and (C) cisplatin treated 4T1
tumorous animals within the CD45+ living singlets. Quantitative analysis of the main lymphoid subsets:
CD4+ T-cells = lilac, CD8+ T-cells = blue, CD19+ B-cells = orange and the myeloid CD11b+ = green,
CD11c + = red subsets was performed in the blood of (D) naive, (E) 4T1 tumor bearing, and (F) cisplatin
treated 4T1 tumorous mice within the CD45+ living singlets. Representative viSNE plots and column
bars are shown from the pooled samples of 6 mice per group. Data are shown as arithmetic means on
the column bars ± SEM. Pairwise comparison of the emergence of CD11b+ population in (E) vs. (D)
has significance at p < 0.001.
The percentage of CD11b+ cells of 4T1 tumor bearing mice due to advanced cancer-related
myeloid expansion represented around 97% (Figure 7E) in contrast to naive mice with 35% CD11b+
cells (Figure 7D) of CD45+ living singlets in the blood. The treatment of 4T1 breast cancerous mice
with cisplatin could not suppress the emergence of CD11b+ cells significantly with an average of
85% CD11b+ cells (Figure 7F). Myeloid expansion led almost to the absence of circulating T- and
B-lymphocytes in advanced cancer (Figure 7E). Cisplatin treatment at least partially restored the
percentage of these CD4+, CD8+ T- and CD19+ B-lymphocytes with an average 8.1% vs. 10.5%,
2.6% vs. 5.1%, 2.7% vs. 24.8% in naive mice, respectively (Figure 7D,F).
The differential expression intensity of the Gr-1, CD44, IFN-γ markers on blood-derived leukocytes
was plotted on the viSNE graphs (Figure 8). Interestingly, the highest expression protein pattern of
Gr-1+/CD44+ (Gr-1+ bright/CD44+ bright) within the CD11b+ subset was associated with early cancer
disease in the blood of cisplatin treated 4T1 tumorous mice. The Gr-1+ dim/CD44+ dim immature
myeloid cells have been reported to suppress T-cells and IFN-γ production [37,38], the dim expression
intensity of these markers was characteristic to 4T1 tumor bearing mice (Figure 8). In line with
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this, the smaller population of IFN-γ producing myeloid cells appeared within the CD11 subtype by
cisplatin treatment which was completely absent in the advanced cancer (Figure 8).
Figure 8. The viSNE plots illustrate the expression intensity of Gr-1, CD44, and IFN-γ markers
within the clouds of main subsets defined in Figure 7 in the blood samples of naive, 4T1 tumor
bearing, and cisplatin treated 4T1 tumorous mice. The coloration is proportional with the expression
intensity (blue = low, red = high). The list of the antibodies can be found in Table 1 in the Section 4.5.
Representative viSNE plots are shown from the pooled samples of 6 mice per group. The markers of
the panel which were not detected or did not showed different expression are not shown.
Quantitation of the populations with characteristic protein expression was performed by manual
gating within the CD45+ living singlets of blood-derived leukocytes. The trajectories on the radar
plots delineate the characteristic marker profile of peripheral leukocytes of naive, 4T1 tumor bearing,
and cisplatin treated tumorous mice (Figure 9).
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Figure 9. The trajectories on the radar plots delineate the characteristic marker profile of blood-derived
leukocytes in naive, 4T1 tumor bearing, and cisplatin treated tumorous mice. The accumulation of
peripheral (A) CD11b+/Gr-1+MDSCs and (B) CD44+MDSCs is a characteristic of 4T1 breast cancer.
(C) Due to cisplatin treatment IFN-γ+MDSCs were developed at the periphery. The percentage of the
given populations is demonstrated on the radar plots within the CD45+ living singlets determined by
manual gating in Cytobank. The gating hierarchy is explained in the text. The markers of the panel
which were not detected or did not show differential expression are not shown. Representative radar
plots are shown from the pooled samples of 6 mice per group as described in Section 4.5.
MDSCs were defined as CD45+/CD3-/CD11+/Gr1+ cells (Figure 9A) and further evaluated for
the expression of CD44 (Figure 9B) and IFN-γ (Figure 9C). The total MDSCs, CD44+ MDSCs and
IFN-γ +MDSCs represented 92%, 93%, and only 0.15% of CD45+ living singlets in the spleen of 4T1
advanced tumorous mice, respectively. Administration of cisplatin resulted in the decrease of the
percentage of both MDSCs, CD44+MDSCs to 63% (naive blood 32%). Interestingly, IFN-γ which is
indispensable for antitumor immune response [39], was increased by cisplatin in 15% of MDSCs (naive
3%). Sunburst charts represent the immunocomposition of main subsets of the blood detected by
single cell mass cytometry in Figure S4B and FlowSOM (Flow data using Self-Organizing Map, [35])
analysis demonstrates the identified clusters, minimum spanning trees (MSTs) of peripheral subsets in
Figure S5.
3. Discussion
Solid tumors manifest when cancer cells escape from immunosurveillance. During cancer
development, malignant cells develop strategies to induce peripheral tolerance and in parallel
inflammatory cells change their phenotype to nurse the tumor and suppress anti-tumor effector
functions [36,40]. Since metastatic breast cancer is the most frequent and deadliest type of cancer
among young adult women [4,5], we focused on the 4T1 murine breast carcinoma model to study the
efficacy of anti-cancer drug candidates. Among chemotherapeutic compounds, cisplatin, a well-known
DNA crosslinker, a first line option in human carcinomas was investigated (as a reference drug) in
the 4T1 murine metastatic breast carcinoma model. This type of breast carcinoma can be a relevant
80
Int. J. Mol. Sci. 2020, 21, 170
animal model for the human disease because (i) it is orthotopically transplanted into the mammary
fat pad, (ii) it grows in immunocompetent mice (BALB/c) and (iii) gives metastasis spontaneously.
Here, we studied the immunophenotype of the spleen and blood of mice with advanced cancer and
with cisplatin treated cancer compared to naive mice.
We monitored the dose-response curve of cisplatin to 4T1 cells in real-time because previous
studies described results with endpoint assays [41–43]. The half maximal inhibitory concentration
(IC50) values showed time dependence: 36.74 μM at 24 h, 7.608 μM at 48 h, 6.962 μM at 72 h, 4.128 μM at
96 h, and 3.995 μM at 120 h (Figure 1 and Figure S1). In order to investigate the alteration of the tumor
stroma or the immunophenotype changes during cancer development the 4T1 cells were orthotopically
injected into BALB/c mice. Cisplatin reduced the tumor growth, the number of lung metastatic nodules,
and splenomegaly (Figure 2). In addition to malignant cells, the alteration of the stroma of solid tumors,
namely the activation of cancer-associated fibroblasts has been described as critical determinant of
cancer development and survival, and was also confirmed as therapeutic target [2]. It was shown
that the expression of FAP prolyl endopeptidase, even on the cell surface or solubilized in the plasma,
correlates with the malignancy and cisplatin resistance of carcinomas [29,44–46]. Therefore, we have
developed an assay to measure the activity of FAP cleaving the Fmoc-Gly-Pro-Cysteic acid-Ile-Gly-NH2
peptide substrate (Figure S2). We could show that cisplatin treatment significantly reduced the FAP
activity of the plasma of 4T1 tumor bearing mice (Figure 3).
It has been widely known that the alternative polarization of the immune system, the accumulation
of immature myeloid cells (MDSCs) with potent immunosuppression contribute to the cancer
development [12,47]. The splenic immunophenotye of mice with advanced cancer showed the
emergence of the hyaluronic acid receptor CD44+ and in a smaller extent IL-17A+ MDSCs,
the loss of B220+ and CD62L+ B-cells, the loss of CD62L+ CD4+ and CD8+T-cells (Figures 5–7).
Myeloid expression of IL-17A in the spleen has been published as a sign of advanced cancer [26].
Cisplatin treatment could restore the splenic immunophenotype downregulating CD44+, IL-17A+
MDSCs presumably because of the smaller tumor burden, on the other hand MDSCs are also sensitive
to low dose chemotherapy due to their high proliferative potential [30]. The blood showed the
expression of Gr-1+dim, more immature MDSCs in advanced cancer (Figure 8), which has been
reported to suppress T-cell proliferation and IFN-γ production [37]. The expression intensity of
CD44 on circulating MDSCs was also dim suggesting more immature phenotype (Figure 8), however,
the percentage of CD44+MDSCs (irrespective of the CD44 marker intensity) was higher in the
blood of mice with advanced cancer (Figure 9). Cisplatin partially reduced the accumulation of
CD44+/CD11+/Gr1+myeloid cells in the circulation, but changed their phenotype via induction of
INF-γ production (Figure 9). It has been reported that IFN-γ producing immature myeloid cells could
exert a potent immune response against sever invasive bacterial infections [48]. Computational tools,
unsupervised algorithms were used to summarize our results, such as sunburst population analysis in
Figure S4 and the FlowSOM analysis in Figure S5.
The immunomodulatory effect of cisplatin by increasing tumor immunogenicity has been recently
published in ovarian cancer [22]. The general overview of chemotherapeutics, especially cisplatin
mediated immunomodulation has been reviewed elsewhere [49,50].
To the best of our knowledge our study is the first using single cell mass cytometry to show the
immunomodulatory effect of cisplatin in the 4T1 murine model of metastatic triple negative breast
cancer via downregulation of immature myeloid cells and upregulation of CD62L+ B- and T-cells and
IFN-γ+ peripheral myeloid cells.
4. Materials and Methods
4.1. Real-Time Cell Electronic Sensing (RT-CES) Cytotoxicity Assay
The 4T1 cells were purchased from the ATCC (American Type Culture Collection, Manassas, VA,
USA) and maintained as described previously [10]. Briefly, 4T1 were maintained in Roswell Park
81
Int. J. Mol. Sci. 2020, 21, 170
Memorial Institute 1640 medium (RPMI-1640) with 10% FCS. The pH of the cell culture media was
controlled to be between 7.2–7.4 prior use. The medium was supplemented with 2 mM GlutaMAX,
and 100 U/mL penicillin, 100 μg/mL streptomycin (Life Technologies, Carlsbad, CA, USA) before use.
Cells were passed every three days and placed in a humidified incubator at 37 ◦C 5% CO2 (Sanyo, Osaka,
Japan). The xCelligence real-time cell electronic sensing (RT-CES) cytotoxicity assay (Acea Biosciences,
San Diego, CA, USA) was performed as previously described with some modifications [25,51].
Briefly, 96-well E-plate (Acea Biosciences) was coated with gelatin solution (0.2% in phosphate buffered
saline, PBS) for 20 min at 37 ◦C, then gelatin was washed twice with PBS solution. Growth media
(50 μL) was then gently dispensed into each well of the 96-well E-plate for background readings by the
RT-CES system prior to addition of 50 μL of the cell suspension containing 2 × 104 4T1 cells. Plates
were kept at room temperature in a tissue culture hood for 30 min prior to insertion into the RT-CES
device in the incubator to allow cells to settle. Cell growth was monitored for 48 h by measurements
of electrical impedance every 15 min. Continuous recording of impedance in cells was reflected by
cell index value. 48 h later cells were treated with an increasing concentration (134 nM–100 μM)
of cisplatin (Selleckchem, Houston, TX, USA), treatments are demonstrated between 3.704–100 μM.
Treated and control wells were dynamically monitored over 120 h by measurements of electrical
impedance every 15 min. The raw plate reads for each titration point were normalized relative to
the cell index status right before treatment. Each treatment was repeated in 3 wells per plate during
the experiments. The half maximal inhibitory concentration (IC50) was calculated with relation to
untreated control cells (1 corresponds to 100% viability on the y axis), and blank wells containing
media without cells. IC50 values (50% inhibiting concentration) were calculated by GraphPad Prism®
(version 5.01, La Jolla, CA, USA).
4.2. The 4T1 in Vivo Breast Carcinoma Model
The animal experiments were performed in accordance with animal experimentation and
ethics guidelines of the EU (2010/63/EU). Experimental protocols were approved by the responsible
governmental agency (National Food Chain Safety Office) in possession of an ethical clearance
XXIX./128/2013.
Female Charles River-derivative BALB/c mice (8–10 week old) were purchased from Kobay Ltd.,
(Ankara, Turkey) and were injected orthotopically with 4T1 breast carcinoma cells (1.2 × 105 cells)
as described previously [9]. The animals had free access to food and water. Six mice were included
into each experimental group. Treatment by cisplatin (Ebewe Pharma, Unterach am Attersee, Austria)
was started after 10 days of inoculation and followed in every 5th day in 5 mg/kg dose administered
intraperitoneally twice on the day of the treatment. The experiments were repeated independently
two times under the same conditions, the pooled results have been presented in the paper (n = 12).
Tumors were evaluated macroscopically by the following parameters: 1) incidence of palpable tumors
was determined by the daily monitoring of animals in each experimental group; 2) tumor size was
measured with a precision caliper and calculated according to the formula: d2 × D × 0.5, where d and
D are the minor and major diameters, respectively; 3) after euthanizing the animals, weights of the
excised primary tumors, spleens, and lungs were measured. Spleen and blood were processed freshly
in order to isolate leukocytes. Mice showing signs of suffering (lost 15% of body weight and/or loss of
the righting reflex and/or enable to eat, drink) due to (ethical) legislation were sacrificed.
4.3. Synthesis of Fmoc-Gly-Pro-Cysteic Acid-Ile-Gly-NH2 Peptide
In order to obtain the target peptide, Fmoc-Gly-Pro-Cysteic acid-Ile-Gly-NH2,
first Fmoc-Gly-Pro-Cys-Ile-Gly-NH2 peptide was synthesized (Fmoc, 9-fluorenylmethoxycarbonyl,
Avidin Ltd., Szeged, Hungary). Reagents, otherwise not stated, were purchased from Sigma-Aldrich
(St. Louis, MI, USA). Fmoc-strategy synthesis was carried out manually in a solid-phase vessel on
Rink Amide ChemMatrix resin, the protected Fmoc-amino acids (3 equiv.) were coupled using
DCC (dicyclohexylcarbodiimide 3 equiv.) and HOBt (1-hydroxybenzotriazole, 3 equiv.) in DMF
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(N,N-dimethylformamide) for 2 h at room temperature. The deprotection of the Fmoc-group
was achieved with the treatment of the resin with 5% piperazine/DMF (1 × 5 min, 1 × 20 min).
Washings between coupling and deprotection were performed with DMF (3 × 1 min), MeOH
(methanol) (1 × 1 min) and DMF (3 × 1 min). The completion of the coupling was monitored
using the Kaiser test. Following the final coupling, the resin was washed with DMF (3 × 1 min)
and MeOH (3 × 1 min), and dried under a stream of air. The dry resin was treated with TFA/H2O
(trifluoroacetic acid/H2O, 95:5) for 3 h at room temperature. The cleavage mixture was lyophilized, and
the pellet was redissolved in MeOH/AcN (methanol/acetonitrile, 1:1) for Liquid chromatography-mass
spectrometry (LC-MS) analysis (Agilent, Santa Clara, CA, USA). The LC-MS analysis found that
Fmoc-Gly-Pro-Cys-Ile-Gly-NH2 was obtained in 90% purity (linear gradient from 0% to 100% AcN
over 30 min, tR: 21.77 min). LC-MS observed [M + H]+ 667.2, required [M + H]+ 667.8. The obtained
Fmoc-Gly-Pro-Cys-Ile-Gly-NH2 was transformed into Fmoc-Gly-Pro-Cysteic acid-Ile-Gly-NH2 peptide
with no further purification. It was dissolved in acetone, cooled to 1 ◦C in a mixture of ice and
water. First 30% aqueous H2O2 was added, then Na2WO4.2H2O in catalytic amount. After 3 h,
we did not detect the starting material (Fmoc-Gly-Pro-Cys-Ile-Gly-NH2), it completely transformed
into the desired Fmoc-Gly-Pro-Cysteic acid-Ile-Gly-NH2 peptide. The LC-MS analysis found that
Fmoc-Gly-Pro-Cysteic acid-Ile-Gly-NH2 was obtained in 75% purity (linear gradient from 0% to 100%
AcN over 30 min, tR: 16.90 min). LC-MS observed [M + H]+ 715.2, required [M + H]+ 715.8. To purify
the crude peptide, it was dissolved in AcN/MeOH/H2O, then filtered, using a 0.45 μm nylon filter.
Gradient elution was used, 70–100% AcN in 60 min at a 3 mL min-1 flow rate with detection at 220 nm.
Pure fractions were collected and lyophilized to give a fluffy white material.
4.4. FAP Activity Assay
Blood from control and tumor bearing (untreated and cisplatin treated) BALB/c mice was
drawn (200 μL) into EDTA containing tubes (separately from 3 animals from each group).
Reagents, otherwise not stated, were purchased from Sigma-Aldrich. Blood samples were centrifuged
at 12,000 RPM for 10 min. Supernatant (plasma) was removed and transferred to fresh tubes and were
immediately used. Digestion reactions were set up by combining 36 μL plasma and 9 μL solution
of cysteine acid containing peptide solution (5 mg/mL) for a final peptide concentration of 1 mg/mL.
Reactions were incubated at 37 ◦C for 60 min. After incubation, 75 μL of acetonitrile containing 0.2%
trifluoro-acetic (TFA) acid was added and samples were centrifuged at 12,000 RPM for 5 min. 80 μL
of supernatant was removed and transferred to fresh tubes and were stored at −20 ◦C until analysis.
Area under the curve (AUC) values of the peptide digestion product 2 were plotted.
4.5. Mass Cytometry
Single cell mass cytometry (CyTOF, Fluidigm, San Francisco, CA, USA)) was performed as
described previously with some modifications [52]. Briefly, naive, 4T1 breast tumor bearing and
cisplatin treated 4T1 tumor bearing mice were euthanized on the 23rd day after 4T1 injection. Spleen and
blood were processed freshly. Withdrawal of the blood was carried by cardiac puncture using 50 μL
EDTA (30 mg/mL) per syringe (Beckton Dickinson, Franklin Lakes, NY, USA). Spleen was smashed on
100 μm cell strainer (VWR, Radnoe, PA, USA), washed with PBS and centrifuged at 1400 rpm 5 min.
Blood was centrifuged at 2000 rpm for 10 min, plasma was harvested and stored at −80 ◦C. Both the
pellet of spleen and blood were resuspended. Red blood cell lysis was carried out by the incubation
of cells with 5 mL ACK (0.155 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA, pH 7.3, Sigma-Aldrich)
solution for 5 min. Samples were loaded on cell strainer (70 μm in pore size,) and washed by 20 mL
PBS. Cells were counted using Bürker chamber and trypan blue viability dye. Three million cells
were pooled from six mice per group for mass cytometry (Helios, Fluidigm, San Francisco, CA, USA).
The in vivo experiment and CyTOF were repeated twice. Cells viability was determined by cisplatin
(5 μM 195Pt, Fluidigm) staining for 3 min on ice in 300 μL PBS. Sample was diluted by 1500 μL Maxpar
Cell Staining Buffer (MCSB, Fluidigm) and centrifuged at 350 g for 5 min. Cells were suspended in
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50 μL MCSB and the antibody mix (Table 1) was added in 50 μL (each antibody diluted finally 1:100).
Two commercially available antibody panel was combined, the Maxpar® Mouse Sp/LN Phenotyping
Panel kit (Fluidigm, cat. numbers 201306) and Maxpar® Mouse Intracellular I Cytokine Panel kit
(Fluidigm, cat. number 201310).
Samples after 60 min incubation at 4 ◦C, antibodies were washed by 2 mL MCSB and centrifuged
at 300 g 5 min, two times. The pellet was suspended in the residual volume. Cells were fixed in 1.6%
formaldehyde (freshly diluted from 16% Pierce formaldehyde with PBS, Thermo Fisher Scientific,
Waltham, MA, USA) and incubated for 10 min at room temperature. Cells were centrifuged at 800 g for
5 min. Cell ID DNA intercalator (125 μM, 191/193 Iridium, Fluidigm) was added in 1000× dilution in
Maxpar Fix and Perm for overnight at 4 ◦C. Cells for the acquisition were centrifuged at 800g for 5 min
then were washed by 2 mL MCSB and centrifuged at 800 g for 5 min. Cells were suspended in 1 mL
PBS (for WB injector) and counted in Bürker-chamber during centrifugation. For the acquisition the
concentration of cells was set to 0.5 × 106/mL in cell acquisition solution (CAS, Fluidigm) containing
10% EQ Calibration Beads. Cells were filtered through 30 μm Celltrics gravity filter (Sysmex, Görlitz,
Germany) and acquired freshly. Mass cytometry data were analyzed in Cytobank (Beckman Coulter,
Brea, CA, USA). Single living cells were determined. The viSNE analysis was carried-out (iterations
= 1000, perplexity = 30, theta = 0.5) on 5 × 104 for the spleen and 2 × 104 for blood of CD45+ living
singlets. Reduction of dimensionality was performed by FlowSOM also, by an algorithm creating
self-organizing maps during automated clustering in Cytobank [35].
4.6. Statistical Analysis
Results are shown as arithmetic mean ± standard error of the mean (SEM); statistical comparisons
were performed by two-tailed Student’s t-test as pairwise comparisons as described in the figure
legends. In all statistical comparisons, probability “p” was set as the level of significance (set at
* p < 0.05, ** p < 0.01, ***, p < 0.001). Data were processed and analyzed using Microsoft Excel (Microsoft
Office 2016, Redmond, WA, USA), and visualized using GraphPad Prism or Cytobank.
5. Conclusions
Our findings showed that cisplatin treatment reduced tumor growth, number of lung metastasis
and the splenomegaly of 4T1 tumor bearing mice. Cisplatin inhibited the tumor stroma formation,
the activation of carcinoma-associated fibroblasts by the diminished proteolytic activity of fibroblast
activating protein. Single cell mass cytometry revealed that cisplatin could exert a potent
immunomodulatory effect via inhibiting the accumulation of splenic MDSCs in a murine model
of metastatic triple negative breast cancer. Emergence of certain myeloid subsets in the spleen,
such as CD44+MDSCs and IL-17A+MDSC were associated with advanced cancer, while within the
lymphoid subsets, the absence the B220+ B-cells, CD62L+ B-cells, CD62L+CD4+ T-cells, and CD62L+
CD8+ T-cells was shown in the untreated tumor bearing mice. However, cisplatin treatment could
restore the splenic immunophenotype similar to naive mice. Peripheral MDSCs in the circulation
were not completely eliminated by cisplatin but myeloid-derived IFN-γ production was increased.
Thus, our study highlights the use of low-dose chemotherapy, such as cisplatin in combination with
immunotherapies to treat triple negative breast cancer.
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Abstract: Considering the specific clinical management of neuroendocrine (NE) neoplasms (NENs),
immunohistochemistry (IHC) is required to confirm their diagnosis. Nowadays, synaptophysin (SYP),
chromogranin A (CHGA), and CD56 are the most frequently used NE immunohistochemical markers;
however, their sensitivity and specificity are less than optimal. Syntaxin 1 (STX1) is a member of
a membrane-integrated protein family involved in neuromediator release, and its expression has
been reported to be restricted to neuronal and NE tissues. In this study, we evaluated STX1 as
an immunohistochemical marker of NE differentiation. STX1, SYP, CHGA, and CD56 expression
was analyzed in a diverse series of NE tumors (NETs), NE carcinomas (NECs), and non-NE tumors.
All but one (64/65; 98%) NETs and all (54/54; 100%) NECs revealed STX1 positivity in at least 50% of
the tumor cells. STX1 showed the highest sensitivity both in NETs (99%) and NECs (100%) compared
to CHGA (98% and 91%), SYP (96% and 89%), and CD56 (70% and 93%), respectively. A wide variety
of non-NE tumors were tested and found to be uniformly negative, yielding a perfect specificity.
We established that STX1 is a robust NE marker with an outstanding sensitivity and specificity.
Its expression is independent of the site and grade of the NENs.
Keywords: neuroendocrine neoplasia; neuroendocrine tumor; neuroendocrine carcinoma;
immunohistochemistry; syntaxin 1
1. Introduction
Neuroendocrine (NE) cells comprise a cellular network integrating the nervous and endocrine
systems. They are found in virtually all organs, and the most common are in the gastrointestinal and
lower respiratory tracts. The NE cells secrete biogenic amines and peptide hormones regulating a wide
variety of functions into the bloodstream. Tumorous growths of NE cells are collectively referred
to as NE neoplasms (NENs). The bioactive substances secreted by neoplastic NE cells can lead to
distinct clinical syndromes. Although the NENs may follow an indolent clinical course, a significant
number of patients are diagnosed with advanced disease. Although there are many organ-specific
differences in tumor biology and prognostic factors among NENs of different localizations, according
to the recommendations of the International Agency for Research on Cancer (IARC) and World Health
Organization (WHO) expert consensus proposal, the terminology of NENs should be uniformized
in the future. Therefore, the currently substantially differing organ-specific classification schemes of
NENs will be potentially revised and harmonized within the next edition of each WHO Blue Book [1,2].
This proposal separates well-differentiated and poorly differentiated NENs. The well-differentiated
NENs are also referred to as NE tumors (NETs), while poorly differentiated highly malignant NENs
are also designated as NE carcinomas (NECs) ([2,3] (pp. 210–214), [4] (pp. 18–19)). The histopathologic
Int. J. Mol. Sci. 2020, 21, 1213; doi:10.3390/ijms21041213 www.mdpi.com/journal/ijms89
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diagnosis of NENs is based on the typical cytomorphological and architectural features of these
tumors; nevertheless, in atypical and especially poorly differentiated cases, immunophenotyping is
inevitable [5–7]. Rare tumors with two distinct NE and non-NE cell populations, in which either
component represents at least 30%, are defined as a mixed neuroendocrine-non-neuroendocrine
neoplasm (MiNEN) [4] (pp. 16–20). These cases may be difficult to recognize, particularly when
they are poorly differentiated, and their accurate classification also requires immunohistochemistry
(IHC) evaluation.
NE cells share common antigens characteristic of NE differentiation, which can be utilized as
immunophenotypic markers. Some of these are rather obsolete, such as the neuron-specific enolase (NSE)
and protein gene product 9.5 (PGP9.5), which are very sensitive, but seriously lack specificity [6,8]; others,
such as synaptophysin (SYP), chromogranin-A (CHGA), CD56, and insulinoma-associated protein 1
(INSM1), are more reliable, but still show disadvantages when used as individual markers [8–15].
Syntaxin 1 (STX1) is a member of a membrane-integrated nervous system-specific protein
superfamily involved in the neuromediator release from synaptic vesicles [16–18]. STX1 plays a crucial
role in ion channel regulation and synaptic exocytosis [16–18]. Two STX1 isoforms, HPC-1/syntaxin
1A and syntaxin 1B, are thought to have similar functions in the exocytosis of synaptic vesicles and
show a very high homology [19,20]. Additionally, it has been reported that STX1 is associated with
chromaffin granules in the adrenal medulla [21] and expressed in alpha, beta, and delta cells of
pancreatic islets [22,23]. Using a Web-based in silico biomarker analysis, syntaxin 1A protein expression
has been found to be restricted to NE cells [24]; however, this finding was not further evaluated.
Since STX1 represents a promising NE marker and has not yet been comprehensively tested in
diagnostic pathology, we performed a retro- and prospective IHC study on a diverse series of benign
and malignant tumors, in order to establish its utility in the immunophenotyping of NENs.
2. Results
Virtually all normal NE cells and hyperplastic NE lesions showed strong membranous and weak
to moderate cytoplasmic STX1 staining (Figure 1). Thyroid follicular cells, adrenocortical tissue,
and non-NE cells, including gastrointestinal mucosa, exocrine pancreas, liver, kidney, lymphoid
tissue, and skin, showed no STX1 positivity. Neuronal tissue in the brain and peripheral nerves,
including hypertrophic myenteric plexus in appendicitis specimens, revealed consistent STX1 staining.
The results obtained with STX1 in NE and neuroepithelial neoplastic samples are summarized in
Table 1.
Table 1. STX1, chromogranin A (CHGA), synaptophysin (SYP), and CD56 immunoreactivity of NE
neoplasms (NENs) and neuroectodermal/neuroepithelial neoplasms.
Gastrointestinal NETs STX1 CHGA SYP CD56
Gastric enterochromaffin-like (ECL) cell NET 5/5 100.0% 4/4 100.0% 3/3 100.0% 0/1 0.0%
Duodenal non-functioning NET 2/2 100.0% 2/2 100.0% 2/2 100.0% na na
Ampullary NET 1/2 50.0% 2/2 100.0% 1/2 50.0% 1/2 50.0%
Small intestinal enterochromaffin (EC) cell
NET 12/12 100.0% 12/12 100.0% 12/12 100.0% 8/12 66.7%
Appendix NET 9/9 100.0% 8/8 100.0% 7/7 100.0% 9/9 100.0%
Rectal EC cell NET 2/2 100.0% 2/2 100.0% 1/1 100.0% 0/2 0.0%
Rectal L cell NET 5/5 100.0% 2/5 33.3% 4/4 100.0% 5/5 100.0%
Metastatic NET. gastrointestinal origin 4/4 100.0% 4/4 100.0% 1/2 50.0% 0/2 0.0%
Pancreatic NETs
Pancreatic functioning NET * 3/3 100.0% 2/2 100.0% 2/2 100.0% 1/1 100.0%
Pancreatic non-functioning NET 16/16 100.0% 13/14 92.9% 12/13 92.3% 10/11 90.9%
Pulmonary carcinoids
Pulmonary carcinoid. typical 3/3 100.0% 3/3 100.0% 2/2 100.0% 2/2 100.0%
Pulmonary carcinoid. atypical 2/2 100.0% na na na na na na
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Table 1. Cont.
Gastrointestinal NETs STX1 CHGA SYP CD56
Gastroenteropancreatic NECs
Stomach small cell NEC 2/2 100.0% 1/1 100.0% 1/1 100.0% 1/1 100.0%
Duodenal large cell NEC 1/1 100.0% 1/1 100.0% 1/1 100.0% na na
Pancreatic large cell NEC 2/2 100.0% 1/1 100.0% 1/1 100.0% 2/2 100.0%
Ampullary small cell NEC 2/2 100.0% 1/1 100.0% na na 2/2 100.0%
Pulmonary NECs
Pulmonary small cell NEC 19/19 100.0% 9/10 90.0% 2/2 100.0% 16/16 100.0%
Pulmonary large cell NEC 4/4 100.0% 1/1 100.0% na 2/2 100.0%
Etc NECs
Merkel cell carcinoma 5/5 100.0% 1/1 100.0% 1/1 100.0% 2/2 100.0%
Medullary thyroid carcinoma 10/10 100.0% 5/5 100.0% 2/2 100.0% 3/3 100.0%
Metastatic small cell NEC with unknown
primary 3/3 100.0% na na na na 2/2 100.0%
Metastatic large cell NEC with unknown
primary 3/3 100.0% 3/3 100.0% na na 1/3 33.3%
Small cell NEC of the prostate 1/1 100.0% 1/1 100.0% 1/1 100.0% 1/1 100.0%
Small cell NEC of the uterine cervix 1/1 100.0% na na na na na na
Small cell NEC of the breast 1/1 100.0% na na na na na na
Tumors with mixed NE and non-NE
components **
MiNEN ** 2/2 100.0% 0/1 0 2/2 100.0% 0/2 0.0%
Mixed tumor with minor NE component ** 4/4 100.0% na na 2/2 100.0% 0/2 0.0%
Etc NENs
Pituitary adenoma 19/19 100.0% 4/4 100.0% 1/1 100.0% na na
Pheochromocytoma/paraganglioma 16/18 88.9% 15/16 93.8% 9/10 90.0% 2/2 100.0%
Neuroectodermal/neuroepithelial neoplasia
Medulloblastoma 8/9 88.9% na na 8/9 88.9% 2/2 100.0%
Neuroblastoma 8/8 100.0% 5/5 100.0% 5/5 100.0% 2/2 100.0%
Ganglioneuroma 2/2 100.0% na na na na na na
Ewing sarcoma/PNET 2/2 100.0% na na na na na na
*: 2 insulinomas, 1 gastrinoma. **: the component showing an NE morphology was positive, and the non-NE
component was negative for STX1.
 
Figure 1. Syntaxin 1 (STX1) immunoreactivity in non-neoplastic tissues. (A) Nodular neuroendocrine
(NE) cell hyperplasia in autoimmune metaplastic atrophic gastritis, 10x; (B) NE cells in normal colonic
mucosa, 20x; (C) Langerhans islets in normal pancreatic tissue, 10x; (D) NE cells in normal bronchial
mucosa, 40x.
91
Int. J. Mol. Sci. 2020, 21, 1213
All but one (99/100, 99%) cases of NENs, including metastatic NETs, proved to be STX1-positive
(Figure 2). Regarding specific subsets of gastrointestinal NETs, vesicular monoamine transporter 1
(VMAT1)-positive EC cell NETs; VMAT1-negative, autoimmune gastritis-associated NETs consistent
with ECL cell NETs; and even rectal glucagon-like peptide 1 (GLP1)-positive L cell NETs, were
consistently positive (Figure 3). At least 50% of the tumor cells were labeled with a moderate to strong
intensity, but in 92% of cases, the positivity rate was more than 85%. The STX1 staining intensity
showed no correlation with the mitotic activity, Ki-67 labeling index, or tumor grade. The single
STX1-negative case represented a grade 2 CHGA-positive NET of the major duodenal papilla. All small
and large cell NECs were consistently STX1-positive, mostly with intense diffuse staining, regardless of
the anatomical site (Figure 4). Furthermore, special types of NECs, such as Merkel cell and medullary
thyroid carcinomas, similarly showed uniform strong diffuse immunoreactivity for STX1 (Figure 5).
The staining pattern was usually both membranous and cytoplasmic. The ratio of these two
patterns varied considerably, from predominantly cytoplasmic to complete diffuse membranous.
Membrane staining was typically complete in NETs, although in some cases with an acinar architecture,
a basolateral membranous staining pattern was revealed. In some NECs, predominantly aberrant
incomplete membrane staining was noticed. In comparison to common NE IHC markers, STX1 showed
the highest sensitivity both in NETs (99%) and NECs (100%), which was followed by CHGA (98%
and 91%), SYP (96% and 89%), and CD56 (70% and 93%), respectively (Table 2). The four applied
markers detected a significantly different proportion of positive cases regarding gastrointestinal NETs
(p < 0.000001), gastrointestinal NECs (p = 0.01), and NECs in general (p = 0.007). In terms of pancreatic
NETs, no statistically significant level of such an association was seen.
 
Figure 2. CD56, CHGA, SYP, and STX1 immunoreactivity in a pancreatic non-functioning NE tumor
(NET) grade 2. (A) CD56, 20x; (B) CHGA, 20x; (C) SYP, 20x; (D) STX1, 20x.
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Figure 3. STX1 (A,C) vesicular monoamine transporter 1 (VMAT1), (B) and glucagon-like peptide 1
(GLP1) (D) immunoreactivity in a small intestinal enterochromaffin (EC) cell NET grade 2 (A,B) and
a rectal L cell NET grade 1 (C,D) 20x.
 
Figure 4. CD56, CHGA, SYP, and STX1 immunoreactivity in a pancreatic large cell NE carcinoma
(NEC). (A) CD56, 20x; (B) CHGA, 20x; (C) SYP, 20x; (D) STX1, 20x.
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Figure 5. STX1 immunoreactivity in various types of NECs. (A–C) Hematoxylin-eosin stainings; (D–F)
STX1 immunohistochemistry (IHC) reactions; (A,D) small cell NEC of the lung, 20x; (B,E) medullary
thyroid carcinoma, 20x; (C,F) Merkel cell carcinoma of the skin, 10x.






In six tumors with mixed NE and non-NE components, including those with only minor NE
components and those qualifying as MiNENs, the STX1 expression topographically always colocalized
with the morphological features of NE differentiation (Table 1), while the exocrine component showed
no STX1 positivity.
STX1 expression was generally absent in conventional carcinomas. In a subset (16/215, 7%) of
conventional (non-NE) neoplasia, a discrete (<10%) and scattered intratumoral STX1-positive cell
population was noticeable without a definite NE morphology. The expression of at least one further
(CD56, SYP, or CHGA) NE marker was also detected in all these cases. The majority (10/13, 77%) of the
hypercellular variant (type B) of mucinous breast carcinoma cases and one case of ductal carcinoma
demonstrated STX1 positivity, usually in more than 60% of the tumor cells (Table 3).
All 20 (100%) pituitary adenoma cases and 14/16 (88%) of pheochromocytoma cases showed STX1
positivity (Table 1, Figure 6). The latter tumor group included 12 cases with diffuse staining and two
cases with 30% tumor cell positivity. The two STX1-negative medullary chromaffin cell-derived tumors
represented one benign and one malignant pheochromocytoma case. In three pheochromocytomas,
faint and focal STX1 positivity was also exhibited by the sustentacular cells. Endocrine neoplasias,
including adrenocortical adenoma and adrenocortical carcinoma, parathyroid adenoma, papillary
thyroid carcinoma, and follicular thyroid adenoma cases, were consistently STX1-negative (Table 3).
All but one neuroectodermal/neuroepithelial tumor samples revealed strong diffuse STX1 positivity
in neuroblasts and ganglion cells (Table 1), whereas less than 10% of tumor cells were positive in
one medulloblastoma case. Where it was present, the neuropil component also showed a moderate
expression. The Schwann cell component of the ganglioneuromas, and all peripheral nerve sheet
tumor cases, proved to be STX1-negative (Table 3). Scattered STX1-positive tumor cells were found in
2/2 Ewing family tumor cases studied.
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Table 3. STX1 immunoreactivity in conventional (non-NE) tumors.
Tumor Type
STX1 (Positive/Total
No. of Cases; %)
No. of Cases with Scarcely
Scattered STX1 Positive Cells
Colorectal adenocarcinoma 0/8 0.0% 5
Gastric adenocarcinoma 0/12 0.0% 9
Hepatobiliary and pancreatic carcinoma 0/11 0.0% 1
Lung squamous cell carcinoma 0/5 0.0%
Lung adenocarcinoma 0/8 0.0%
Head and neck carcinoma 0/7 0.0%
Basal cell carcinoma of the skin 0/2 0.0%
Cervical and ovarian carcinoma 0/8 0.0% 1
Prostatic adenocarcinoma 0/7 0.0%
Melanocytic tumor 0/9 0.0%
Soft tissue tumor 0/13 0.0%
Lymphoma and myeloid neoplasm 0/31 0.0%
Genital germ cell tumor 0/9 0.0%
Gonadal sex-cord stromal tumor 0/5 0.0%
Solid pseudopapillary neoplasm (pancreas) 0/1 0.0%
Adrenocortical adenoma 0/11 0.0%
Adrenocortical carcinoma 0/12 0.0%
Parathyroid adenoma 0/19 0.0%
Papillary thyroid carcinoma 0/5 0.0%
Thyroid follicular adenoma 0/1 0.0%
Carcinomas of the breast
No special type 1/18 5.6% 1
Invasive lobular carcinoma 0/2 0.0%
Mucinous carcinoma, hypocellular type 0/6 0.0%
Mucinous carcinoma, hypercellular type 7/10 70.0%
Metaplastic carcinoma 0/1 0.0%
 
Figure 6. STX1 (A,B) and S100 (C) immunoreactivity in pheochromocytomas, for which the arrows
indicate sustentacular cells (B) The latter cells were visualized with an S100 IHC reaction. (A): 20x,
(B,C): 40x.
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3. Discussion
There are several IHC NE markers used in diagnostic pathology. To use these markers responsibly,
one should be aware of their advantages and limitations [12–15]. Currently, CD56, CHGA, and SYP
represent the most widely used NE markers. CD56 is highly sensitive to NE cells [4]; however, it is also
detectable in a heterogeneous group of non-NE neoplasms, including nephroblastoma, neuroblastoma,
myeloid, lymphoid, and plasma cell tumors, as well as in hepatocellular, renal cell, ovarian, endometrial,
and thyroid carcinomas [25,26]. Therefore, it is unreliable if used as a single marker. CHGA constitutes
a secretory granule protein of the NE, adenohypophyseal, and parathyroid cells [27,28]. As an IHC
NE marker, CHGA shows a good sensitivity; nevertheless, some NE cells, such as Merkel cells and
hindgut-derived NE cells [29], may demonstrate significantly weaker staining or can lack CHGA
immunoreactivity. Furthermore, the strong cytoplasmic expression seen in most NE cells may be weak
or absent in NECs, due to the low density of mature secretory granules [30,31]. SYP is an integral
membrane calcium-binding glycoprotein of synaptic vesicles. It is a sensitive marker usually expressed
in the cytoplasmic microvesicles of neuronal tumors, NENs, and neuroectoderm-derived small blue cell
tumors, as well as in many endocrine tissues, such as normal and neoplastic pituitary and parathyroid
glands and adrenocortical tissue [32–34].
In this study, we performed a comprehensive IHC analysis in an extensive series of benign and
malignant tumors to evaluate STX1 as an IHC NE marker. Using a well-characterized monoclonal
mouse antibody, we found that STX1 represents an impressive robust NE marker, with a sensitivity
of 99% in NETs and 100% in NECs, outperforming other common NE markers, such as SYP (96%
and 89%), CHGA (93% and 91%), and CD56 (70% and 93%), which was proven to be statistically
significant regarding gastrointestinal NETs and NECs. Normal NE cells in different organs, as well
as pulmonary, gastrointestinal, and pancreatic NETs and NECs, were likewise positive. Therefore,
the STX1 expression of NENs seems to be unrelated to the anatomical site. In contrast to the frequently
negative CHGA staining in rectal and appendiceal L-cell NETs [9–11], STX1 was consistently positive in
all such cases studied. Pheochromocytomas and paragangliomas were also almost consistently positive.
STX1 was uniformly expressed in all NECs, regardless of the morphological or clinicopathological
subtype, including small and large cell NECs, as well as in Merkel cell carcinomas and medullary
thyroid carcinomas. In contrast to the sometimes faint or dot-like cytoplasmic expression of SYP
and CHGA, the STX1 revealed crisp membranous and strong cytoplasmic staining in the majority of
cases studied, which makes the evaluation straightforward. Concerning the specificity of STX1, many
endocrine tumors known to express either CHGA or SYP, such as parathyroid and adrenocortical
neoplasms [35], were consistently negative for STX1. As further evidence of the excellent specificity of
STX1, a broad spectrum of non-NE tumors, including various types of carcinomas, were consistently
negative. In MiNENs and carcinomas with focal NE components, the STX1 immunostaining was
restricted to the NE areas, as was confirmed by other NE markers. A caveat is that in 7% of conventional
(non-NE) neoplasia, a discrete (<10%) and scarcely scattered STX1-positive cell population was present
without morphological features of NE differentiation. In our opinion, by correlating the IHC stains
to the histomorphology, these infrequent positive cells should not cause any diagnostic problem,
and such reactions should be interpreted as negative. Although STX1 was also expressed in neural
tumors, considering the rather distinct presentation of these neoplasms, the differentiation appears to
be straightforward.
INSM1 is a recently described IHC NE marker [36], demonstrating nuclear localization. It has
been studied in the NENs of many anatomical regions, including the lung, head and neck, central
nervous system, prostate, skin, and pancreas, but, according to the reported series, the INSM1 reveals
a lower sensitivity [13,36–41] than STX1 in our series. Although a direct comparison of the two markers
is warranted in future studies, based on the literature data and results of the present study, STX1
outperforms INSM1 in terms of its specificity and sensitivity.
In keeping with the frequent NE differentiation of hypercellular (type B) mucinous breast
carcinomas, a small cohort of these tumors were also stained positive for STX1, while breast cancer
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types infrequently expressing NE markers, such as hypocellular (type A) mucinous, conventional
invasive ductal, and lobular carcinomas, were negative. Due to the limited number of breast tumors
included in this study, additional investigations of breast cancer are warranted.
4. Materials and Methods
4.1. Samples Studied
All samples were assigned by the Department of Pathology, University of Szeged, and the
Laboratory of Tumor Pathology and Molecular Diagnostics, Szeged, Hungary, and represented
formalin-fixed paraffin-embedded (FFPE) tissues.
To study STX1 in non-neoplastic tissues, normal thyroid (8 samples), parathyroid (11 samples),
skin (2 samples), pancreas (5 samples), adrenal gland (9 samples), and brain tissue (5 samples), as well as
appendectomy specimens from acute appendicitis (5 cases), were evaluated. Hyperplastic NE lesions,
such as linear and nodular NE cell hyperplasia in autoimmune metaplastic atrophic gastritis (10 cases)
morphologically consistent with ECL cell hyperplasia [42] and one case of pancreatic nesidioblastosis,
were also included. In tumor samples, peritumoral non-neoplastic NE cells, including gastric antral
and oxyntic mucosal, as well as intestinal NE cells, pancreatic Langerhans islets, bronchial NE cells,
and cutaneous Merkel cells, were also assessed for STX1 expression, where they were present.
To evaluate the specificity and sensitivity of STX1 in neoplastic conditions, altogether, 398 cases of
various non-NE and NE neoplasms were studied (Table 1) in either whole tissue sections or tissue
microarrays (TMAs). Cases with potential diagnostic pitfalls, for example, frequently CHGA-negative
L cell NETs (three rectal and one appendiceal), were also included. In 6/215 cases of predominantly
non-neuroendocrine carcinomas, a component showing morphological features of neuroendocrine
differentiation was also present. In four (one colonic and one diffuse gastric adenocarcinoma, one
poorly differentiated squamous cell, and one adenocarcinoma of the lung) cases, the neuroendocrine
component represented 10%–30% of the tumor, while in two (one non-mucinous breast and one poorly
differentiated gastric adenocarcinoma) cases, the NE component exceeded the MiNEN defining 30% [5]
(pp. 18–19). TMA blocks were constructed with the manual TMA builder instrument (Histopathology
Ltd., Pécs, Hungary), as previously published [43]. Each tumor case in TMA blocks was represented
with at least two cores (central and peripheral regions) of 2 mm. To compare the proportion of positive
cases by the applied markers, Fisher’s exact test was performed.
All NENs were diagnosed and graded according to the WHO Blue Book [1], corresponding to
their anatomical location.
The study was performed in agreement with the guidelines of the Declaration of Helsinki for
human medical research and was ethically approved by the Clinical Research Coordination Office of
the University of Szeged (4430/2018) 7 January 2019.
4.2. Immunohistochemistry and Evaluation of Staining Patterns
The IHC reactions were uniformly performed in FFPE sections. Briefly, 2–5 μm-thick paraffin
sections were routinely de-waxed, blocked for endogenic peroxidase activities in ethanol containing
1.5% (v/v) H2O2, and heat-treated in 10 mM Sodium citrate (0.05 % Tween-20, pH 10.0) antigen retrieval
buffer using a household electric pressure cooker. After protein blocking in 50 mM Tris-buffered saline
(TBS, pH 7.4) containing 5% (w/v) low-fat milk powder, the sections were incubated with the primary
antibodies at room temperature for 70 min. Detection was performed using the Novolink polymer
kit (Leica Biosystems/Novocastra, Newcastle Upon Tyne, United Kingdom), and nuclear staining
was carried out with Mayer’s hematoxylin. The IHC stains were executed by a four-channel TECAN
Freedom Evo liquid handling platform (TECAN, Mannedorf, Switzerland).
For STX1, we utilized a well-characterized mouse monoclonal antibody HPC-1 (sc-12736; 1:200;
Santa Cruz Biotechnology, Dallas, TX, USA), which detects both STX1 A and B isoforms. A tumor
sample was considered to be STX1-positive if more than 50% of the neoplastic cells showed either
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membranous or cytoplasmic staining. The staining intensity was categorized as weak, moderate,
or strong. Samples were independently assessed by three of the authors (S.T-N., B.K., and L.K.).
In a case with discordant results, a consensus was reached by a second-look evaluation made jointly.
In NENs investigated using the TMA technique, immunostainings for the most common NE
markers, such as SYP (27G12; 1:100; Leica Biosystems), CHGA (5H7; Leica Biosystems/Novocastra,
Newcastle Upon Tyne, United Kingdom), and CD56 (MRQ-42; 1:500; Cell Marque, Rocklin, CA,
USA), were also performed to compare the results with STX1 expression. In cases where STX1
immunostainings were performed on whole tissue sections, the SYP, CHGA, and CD56 expression
was not tested systematically; however, the SYP, CHGA, and CD56 immunostainings performed
for the original pathology report were re-evaluated, if available. Cytoplasmic staining for SYP
and CHGA or membranous staining for CD56 were considered positive. To identify the various
subtypes of gastrointestinal NETs, IHC reactions were performed against VMAT1 (RMT77; 1:100; Leica
Biosystems/Novocastra, Newcastle Upon Tyne, United Kingdom) as a marker of EC cells and GLP1
(sc-57166; HYB 147-06; 1:100; Santa Cruz Biotechnology, Dallas, TX, USA) as a marker of L-cells. The
sustentacular cell population in paragangliomas and pheochromocytomas was identified with S100.
5. Conclusions
In conclusion, we showed that STX1 outperforms common NE IHC markers in terms of its
specificity and sensitivity and appears to be the most advantageous immunophenotypic marker of
NE cells and NENs. STX1 demonstrated a near-perfect specificity and an outstanding sensitivity,
even in NECs. We recommend that STX1 be added to the IHC panel of NE differentiation in routine
diagnostic histopathology. The consistent STX1 expression in all NETs, regardless of the anatomical
site or subtype, makes it a reliable marker, even in the hands of routine pathologists who are less
experienced with NENs and unaware of the specific expression patterns and possible pitfalls of classic
NE markers.
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IARC International Agency for Research on Cancer
WHO World Health Organization
MiNEN Mixed neuroendocrine-non neuroendocrine neoplasm
NSE Neuron-specific enolase
PGP9.5 Protein gene product 9.5
INSM1 Insulinoma-associated protein 1
HPC-1 Syntaxin 1
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Abstract: Gene expression studies of molar pregnancy have been limited to a small number of
candidate loci. We analyzed high-dimensional RNA and protein data to characterize molecular
features of complete hydatidiform moles (CHMs) and corresponding pathologic pathways.
CHMs and first trimester placentas were collected, histopathologically examined, then flash-frozen or
paraffin-embedded. Frozen CHMs and control placentas were subjected to RNA-Seq, with resulting
data and published placental RNA-Seq data subjected to bioinformatics analyses. Paraffin-embedded
tissues from CHMs and control placentas were used for tissue microarray (TMA) construction,
immunohistochemistry, and immunoscoring for galectin-14. Of the 14,022 protein-coding genes
expressed in all samples, 3,729 were differentially expressed (DE) in CHMs, of which 72% were
up-regulated. DE genes were enriched in placenta-specific genes (OR = 1.88, p = 0.0001), of which
79% were down-regulated, imprinted genes (OR = 2.38, p = 1.54 × 10−6), and immune genes
(OR = 1.82, p = 7.34 × 10−18), of which 73% were up-regulated. DNA methylation-related enzymes
and histone demethylases were dysregulated. “Cytokine–cytokine receptor interaction” was the
most impacted of 38 dysregulated pathways, among which 17 were immune-related pathways.
TMA-based immunoscoring validated the lower expression of galectin-14 in CHM. In conclusion,
placental functions were down-regulated, imprinted gene expression was altered, and immune
pathways were activated, indicating complex dysregulation of placental developmental and immune
processes in CHMs.
Keywords: choriocarcinoma; hydatidiform mole; galectin; gestational trophoblastic disease;
placental-specific gene; systems biology; trophoblast differentiation
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1. Introduction
Gestational trophoblastic disease (GTD) is characterized by abnormal trophoblastic proliferation
and includes hydatidiform mole (complete and partial) and gestational trophoblastic neoplasia (invasive
mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor) [1,2].
Diagnosis relies on clinical presentation and histologic assessment, and treatment is aimed at uterine
evacuation with chemotherapy typically reserved for gestational trophoblastic neoplasia (GTN) [2,3].
Post-molar human chorionic gonadotropin (hCG) monitoring is an essential part of management for
evaluating the development of GTN, which follows complete hydatidiform moles (CHMs) in ~15–20%
of cases [4]. Although GTN is considered among the most curable of all solid tumors with cure
rates over 90%, unrecognized and misdiagnosed GTD can result in unnecessarily increased maternal
morbidity and mortality [3].
The reported incidence of GTD varies by geographic location, race or ethnicity, maternal age,
and histopathologic subtype. Hydatidiform mole reportedly complicates up to two per 1000 pregnancies
in Southeast Asia and Japan, nearly twice that proportion reported in North America, Australia,
New Zealand, and Europe [5]. This geographic variation has been partially attributed to racial and
ethnic differences, as the prevalence of GTD is elevated in American Indians, Asians, and Hispanics
across the world [6,7]. Asian and American Indian women have also been shown to have more
aggressive disease, with increased risk of developing GTN compared to other ethnic groups [8,9].
Extremes of maternal age are also correlated with higher rates of CHMs, with an increased incidence
among women over 40 years of age and under 20 years of age [10]. Beyond maternal age and ethnicity,
prior GTD is the strongest risk factor for GTD, with an incidence of 1.3% [11].
These described risk factors (race/ethnicity and prior GTD) are in accord with an underlying genetic
etiology of GTD [1,2,12]. The pathophysiology of hydatidiform moles involves overrepresentation of
the paternal genome. The biparental diandric triploid karyotype of partial moles accords with dispermic
fertilization, while androgenetic diploid karyotype of most CHMs is consistent with monospermic or
dispermic fertilization. Recently, some women with recurrent androgenetic CHMs were shown to have
bi-allelic deleterious mutations in MEI1 (meiotic double-stranded break formation protein 1), TOP6BL
(type 2 DNA topoisomerase 6 subunit B-like), and REC114 (meiotic recombination protein REC114),
leading to meiotic double-strand break formation and extrusion of all maternal chromosomes [13].
Absence of maternal imprinting of gene expression in hydatidiform moles has also been observed in the
rare biparental hydatidiform moles due to NLRP7 (NLR family pyrin domain containing 7) or KHDC3L
(KH domain containing 3 like) mutations, suggesting a common endpoint of pathogenesis [12,14,15].
However, for the more common sporadic CHMs, little is known regarding mechanisms responsible for
either pathogenesis or progression to GTN.
The few targeted gene expression studies on molar tissue and a recent meta-analysis of these
studies showed that the main genes differentially expressed (DE) in molar tissues may be those
involved in villous trophoblast differentiation [16]. However, these findings were based on a limited
set of molecules, and these studies mostly targeted placenta- or trophoblast-specific transcripts that
were known to be differentially expressed during trophoblast differentiation. A more comprehensive
approach to identifying genes and pathways involved in the development of molar disease would be a
genome-wide gene expression analysis using either microarrays or RNA-Seq, followed by protein-level
validation of DE transcripts.
We sought to implement such a high-dimensional and systems biology approach, similar to
that used in our recent study on the pathophysiological processes in preeclampsia [17], to gain more
in-depth insight into CHM pathogenesis at RNA and protein levels. This high-dimensional, agnostic
study is the first to evaluate gene expression levels in CHMs using RNA-Seq followed by protein
level validation of selected DE transcripts by immunostaining of tissue microarrays (TMA) and
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immunoscoring. The aim of our study is to identify genes with expression levels that differ in molar
tissue from CHMs in comparison to placental chorionic tissue from uncomplicated pregnancies at
similar stages of gestation. More complete understanding of the molecular pathways perturbed in
CHMs may inform future efforts to improve procedures for early diagnosis and prognostication.
2. Results
2.1. The Transcriptome of First Trimester Placentas and CHMs
To evaluate absolute gene expression levels, mean expression values were calculated for both
groups from RNA-Seq count data by normalizing for housekeeping genes. The highest expression in
first trimester placentas was mostly detected for genes with placenta-specific or predominant placental
expression [17–19]. Indeed, the 20 most highly-expressed genes (Table 1) included genes previously
shown to have predominant placental (n = 2) or placenta-specific (n = 12) expression and unique
placental functions in humans. These encode hormones (CGA, chorionic gonadotrophin subunit
alpha, CSH1 and CSH2, chorionic somatomammotropin hormone 1 and 2), an estrogen synthesizing
enzyme (CYP19A1, cytochrome P450 family 19 subfamily A member 1), proteases (ADAM12, ADAM
metallopeptidase domain 12; KISS1, kisspeptin-1; PAPPA and PAPPA2, pregnancy-associated plasma
protein A and A2; TFPI2, tissue factor pathway inhibitor 2), and immune proteins (PSG3 and PSG4,
placenta-specific glycoprotein 3 and 4).
Table 1. Genes encoding the 20 transcripts most highly expressed in first trimester placentas.
Gene Symbol Entrez ID Base Mean lfcSE Log2 FC pFDR p-Value Control Mean
CGA 1081 164,079.45 0.63 0.07 0.93 0.91 155,778.30
FN1 2335 141,988.22 0.56 0.32 0.64 0.57 135,448.78
TFPI2 7980 125,046.51 0.58 −1.16 0.08 0.05 127,071.15
CSH1 1442 87,798.80 0.67 −4.58 0.00 0.00 93,037.03
EEF1A1 1915 84,023.14 0.15 −1.20 0.00 0.00 87,193.18
PEG10 23089 77,282.40 0.24 −1.74 0.00 0.00 82,299.13
CSH2 1443 61,726.09 0.81 −4.23 0.00 0.00 65,433.13
COL3A1 1281 60,159.32 0.29 −1.30 0.00 0.00 63,035.40
KISS1 3814 65,121.70 0.65 0.13 0.88 0.84 61,457.48
ADAM12 8038 44,435.52 0.35 −0.06 0.90 0.86 43,427.10
CYP19A1 1588 40,376.35 0.53 −1.27 0.03 0.02 41,478.58
SPP1 6696 37,734.38 0.41 −4.02 0.00 0.00 40,796.23
TGM2 7052 39,725.43 0.36 −0.36 0.39 0.31 39,553.03
PSG3 5671 38,487.88 0.51 −1.05 0.07 0.04 39,153.23
PAPPA 5069 35,537.55 0.59 −1.35 0.04 0.02 36,733.78
PSG4 5672 33,870.64 0.59 −3.17 0.00 0.00 36,069.85
COL4A1 1282 36,995.51 0.37 0.33 0.46 0.37 35,055.03
PAPPA2 60676 34,031.77 0.48 0.31 0.60 0.52 32,044.98
FBN2 2201 30,126.49 0.26 −1.57 0.00 0.00 31,930.00
ACTB 60 31,472.69 0.22 0.39 0.11 0.07 29,870.08
Placenta-specific genes are shown in bold blue. False discovery rate, pFDR; fold change, FC; log fold change
standard error, lfcSE.
In CHMs, the overall median gene expression levels were ~13% higher than in normal placentas
(control placentas: 337.7 vs. CHMs: 382.8). However, placenta-specific transcript levels were 23% lower
in CHMs than in normal placentas (placentas: 3,729.6 vs. CHMs: 3,044.3), reflected in a lower number
of placenta-specific genes (n = 8) among the 20 most highly-expressed transcripts (Table 2). In turn,
the 20 most abundant transcripts in CHMs encode proteins with immune, hormone, and oxygen
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transport functions (FSTL3, follistatin-like 3; HBA2, hemoglobin-alpha 2; HBB, hemoglobin-beta; IGF2,
insulin-like growth factor 2; LEP, leptin; PAEP, progestogen-associated endometrial protein).
Table 2. Genes encoding the 20 transcripts most highly expressed in complete hydatidiform moles.
Gene Symbol Entrez ID Base Mean lfcSE Log2 FC pFDR p-Value Control Mean CHM Mean
HBB * 3043 33,412.13 0.49 7.74 0.00 0.00 1,608.00 373,335.00
CGA 1081 164,079.45 0.63 0.07 0.93 0.91 155,778.30 189,408.50
FN1 2335 141,988.22 0.56 0.32 0.64 0.57 135,448.78 184,274.75
PAEP * 5047 7,444.75 0.96 7.11 0.00 0.00 545.88 95,119.25
KISS1 3814 65,121.70 0.65 0.13 0.88 0.84 61,457.48 78,481.00
GDF15 * 9518 24,551.03 0.58 1.70 0.01 0.00 19,462.58 73,765.25
TFPI2 7980 125,046.51 0.58 −1.16 0.08 0.05 127,071.15 66,657.75
IGF2 * 3481 26,174.25 0.22 1.20 0.00 0.00 23,075.75 60,786.25
HBA2 * 3040 5,986.27 0.56 4.95 0.00 0.00 1,590.28 52,014.25
COL4A1 1282 36,995.51 0.37 0.33 0.46 0.37 35,055.03 49,353.25
ADAM12 8038 44,435.52 0.35 −0.06 0.90 0.86 43,427.10 47,781.00
LEP * 3952 6,372.49 0.65 3.52 0.00 0.00 3,092.85 45,604.50
ACTB 60 31,472.69 0.22 0.39 0.11 0.07 29,870.08 45,004.50
PAPPA2 60676 34,031.77 0.48 0.31 0.60 0.52 32,044.98 44,734.75
EEF1A1 * 1915 84,023.14 0.15 −1.20 0.00 0.00 87,193.18 43,702.00
AHNAK 79026 25,150.93 0.24 0.66 0.01 0.01 23,452.63 43,214.25
CGB5 93659 18,949.99 0.70 1.13 0.16 0.11 16,161.30 40,758.75
FLT1 2321 19,476.41 0.32 0.96 0.01 0.00 17,411.10 38,701.00
FSTL3 * 10272 7,919.03 0.63 2.57 0.00 0.00 5,172.10 36,659.00
CGB3 * 1082 13,840.61 0.66 1.49 0.04 0.02 11,254.20 35,670.25
Placenta-specific genes are shown in bold blue. Differentially expressed genes are shown with asterisks. Complete
hydatidiform mole, CHM; false discovery rate, pFDR; fold change, FC; log fold change standard error, lfcSE.
2.2. Differential Gene Expression in CHMs
Among transcripts of 14,022 protein-coding genes analyzed with RNA-Seq, a total of 3,729 (27%)
were found to be DE in CHMs in comparison to normal first trimester placental tissues. Of these,
2,667 (72%) were up-regulated while 1,062 (28%) were down-regulated in CHM tissues (Supplementary
Table S1, Figure 1). Of note, there were seven genes with placenta-specific expression among the top 20
transcripts most down-regulated but not up-regulated in CHMs (Table 3).
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Figure 1. Differential gene expression in complete hydatidiform moles. All 14,022 expressed
protein-coding genes are represented in terms of their measured differences in transcript abundance
(x-axis) and the significance of the difference (y-axis) on a volcano plot. The significance is represented
as negative log (base 10) of the adjusted p-value so that more significant differences in expression are
plotted higher on the y-axis. Dotted lines represent the thresholds used to select the differentially
expressed (DE) genes: <−1 and >1 for the magnitude of differential expression and pFDR <0.05 for
statistical significance. According to these criteria, of the 3,729 DE transcripts, 2,667 were up-regulated
(depicted with red), while 1062 were down-regulated (depicted with blue) in molar tissues.
Enrichment analysis revealed significant enrichment (OR = 1.88, p = 0.0001) of placenta-specific
genes (Supplementary Table S2, Figure 2A) among DE genes. Of interest, 50 out of
63 (79%) placenta-specific DE genes, found to be expressed mainly by the trophoblast,
were down-regulated. Among functions of products of these genes were growth hormones (CSHL1,
chorionic somatomammotropin hormone-like 1; CSH1, CSH2), immune response (LGALS14, lectin,
galactoside-binding, soluble, 14; PSG4), cell attachment (EGFL6, EGF-like domain multiple 6; SMAGP,
small cell adhesion glycoprotein; SVEP1, Sushi, Von Willebrand factor type A, EGF and pentraxin
domain containing protein 1), coagulation and blood pressure regulation (AGTR1, angiotensin II
receptor type 1; F13A1, coagulation factor XIII A chain), and cell differentiation and developmental
processes (PAGE4, PAGE family member 4; PLAC1, placenta specific 1; RASA1, RAS P21 protein
activator 1).
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Table 3. Genes encoding the 20-20 transcripts with highest and lowest expression in complete
hydatidiform moles.
Gene Symbol Entrez ID Base Mean Log2 FC lfcSE p-Value pFDR
HBB 3043 33,412.13 7.74 0.49 4.64 × 10−57 4.06 × 10−54
PAEP 5047 7,444.75 7.11 0.96 1.70 × 10−13 2.45 × 10−12
CP 1356 307.65 7.01 0.69 1.38 × 10−24 8.39 × 10−23
C2CD4B 388125 59.15 6.66 0.54 6.42 × 10−35 1.25 × 10−32
IRX3 79191 99.72 6.32 0.53 1.90 × 10−32 2.77 × 10−30
BEST1 7439 801.46 6.23 0.76 2.40 × 10−16 5.15 × 10−15
DSEL 92126 88.53 6.12 0.25 4.36 × 10−128 3.05 × 10−124
B4GALNT3 283358 83.11 5.85 0.51 2.80 × 10−30 3.32 × 10−28
PGR 5241 62.02 5.85 0.49 3.04 × 10−33 4.90 × 10−31
ZNF623 9831 59.42 5.77 0.18 1.30 × 10−214 1.82 × 10−210
KIAA1324 57535 79.48 5.58 0.46 1.77 × 10−33 3.03 × 10−31
IGFBP7 3490 658.18 5.52 0.46 3.03 × 10−33 4.90 × 10−31
RORC 6097 36.06 5.47 0.43 3.04 × 10−36 6.86 × 10−34
DEFB1 1672 47.01 5.44 0.58 5.59 × 10−21 2.16 × 10−19
PKHD1 5314 74.85 5.36 0.71 5.31 × 10−14 8.23 × 10−13
ADCY1 107 53.12 5.33 0.37 6.31 × 10−48 2.95 × 10−45
MAPT 4137 23.64 5.30 0.48 4.39 × 10−28 4.15 × 10−26
PRUNE2 158471 140.93 5.29 0.49 9.85 × 10−27 7.89 × 10−25
GALNT15 117248 23.91 5.18 0.47 8.01 × 10−28 7.28 × 10−26
WDR38 401551 74.42 5.12 1.02 5.62 × 10−07 2.74 × 10−06
HAPLN1 1404 3,248.02 −3.66 0.31 1.18 × 10−32 1.80 × 10−30
CD36 948 2,906.67 −3.71 0.39 6.13 × 10−22 2.71 × 10−20
WNT2 7472 1,855.95 −3.72 0.33 8.29 × 10−29 8.30 × 10−27
EGFL6 25975 4,141.42 −3.75 0.29 1.50 × 10−37 3.69 × 10−35
BMP5 653 1,150.58 −3.86 0.37 3.40 × 10−25 2.29 × 10−23
F13A1 2162 7,493.03 −3.98 0.41 1.75 × 10−22 8.18 × 10−21
SPP1 6696 37,734.38 −4.02 0.41 6.04 × 10−23 2.97 × 10−21
HBG2 3048 4,458.52 −4.05 0.38 4.57 × 10−26 3.35 × 10−24
MFSD14A 64645 776.11 −4.19 0.26 5.42 × 10−59 5.96 × 10−56
CSH2 1443 61,726.09 −4.23 0.81 1.94 × 10−07 1.03 × 10−06
AGTR1 185 664.42 −4.27 0.38 2.85 × 10−29 3.03 × 10−27
COX4I2 84701 131.49 −4.28 0.47 1.36 × 10−19 4.47 × 10−18
SVEP1 79987 15,505.08 −4.33 0.46 5.20 × 10−21 2.01 × 10−19
LYVE1 10894 2,663.78 −4.56 0.34 6.68 × 10−42 2.23 × 10−39
CSH1 1442 87,798.80 −4.58 0.67 5.61 × 10−12 6.40 × 10−11
AREG 374 710.42 −4.64 0.45 4.88 × 10−25 3.19 × 10−23
SPESP1 246777 321.55 −5.11 0.40 1.75 × 10−36 4.01 × 10−34
RPS10 6204 742.05 −5.28 0.44 3.32 × 10−33 5.29 × 10−31
CSHL1 1444 2,846.50 −5.43 0.41 2.25 × 10−40 6.85 × 10−38
ZC3H11A 9877 2,887.90 −5.95 0.32 4.7 × 10−76 8.29 × 10−73
Placenta-specific genes are depicted with bold blue. False discovery rate, pFDR; fold change, FC; log fold change
standard error, lfcSE.
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Since majority of these placenta-specific genes are most highly expressed in the trophoblast,
we wished to learn whether their differential expression may reflect alterations in developmental or
functional processes of the trophoblast. Therefore, we examined whether genes involved in villous
trophoblast differentiation [19] (Figure 2A) are enriched among molar DE genes. However, we found
only minimal enrichment (OR = 1.15, p = 0.006).
Figure 2. Venn diagrams of gene enrichment in complete hydatidiform moles. (A) Overlap between
genes differentially expressed (DE) in complete hydatidiform moles (CHMs; MoleDE), and genes
previously shown to have specific expression in the placenta (PPE) or during villous trophoblast
differentiation (TBDE). (B) Overlap between genes DE in CHMs and previously described imprinted
genes (Imprinted). (C) Overlap between genes DE in CHMs and genes previously shown to be involved
in immune-related processes (Immune).
We also analyzed 25 genes that are involved in epigenetic programming (four DNA
methyltransferases, three methylcytosine dioxygenases, a cytidine deaminase, and 17 histone
demethylases) and found two DNA methylation-related enzymes (DNMT3A, DNA methyltransferase
3 alpha; TET3, Tet methylcytosine dioxygenase 3) and four histone demethylases (KDM4C, lysine
demethylase 4C; KDM4D; KDM4E; KDM6B) to be dysregulated in CHMs. DNMT3A, which was
down-regulated, is required for genome-wide de novo DNA methylation and parental imprinting [20].
TET3, which was up-regulated, plays a key role in epigenetic reprogramming of the zygotic paternal
DNA [21]. All four histone (lysine) demethylases [22] were up-regulated. In addition, there was an
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enrichment of genes impacted by parental imprinting (Supplementary Table S3, Figure 2B) among DE
genes (OR = 2.38, p = 1.54 × 10−6).
Of note, the DE gene list contained 379 genes involved in immune-related functions (Supplementary
Table S4, Figure 2C), of which 278 (73%) were overexpressed in CHMs. Genes contributing to this
enrichment (OR = 1.82, p = 7.34 × 10−18) included those encoding several cytokines, chemokines and
their receptors (IL1A, interleukin 1 alpha; IL6, IL7, IL8/CXCL8, IL10, IL15, TGFB1, transforming growth
factor beta 1; CXCR2, C-X-C chemokine receptor type 2; CXCR4, IL2RB, IL2RG, IL7R, IL15RA, TGFBR1),
integrins (e.g., ITGA5, integrin subunit alpha 5; ITGAE, ITGAL, ITGAX, ITGB7, integrin subunit beta 7),
and galectins (LGALS4, LGALS13, LGALS14).
2.3. Dysregulated Biological Processes and Pathways in CHMs
Use of iPathwayGuide to investigate biological processes and pathways dysregulated in CHMs
revealed that among 665 gene ontology (GO) biological processes, the most impacted were “cell
adhesion”, “biological adhesion”, “multicellular organismal process”, and “signaling” (Supplementary
Table S5). Applying Elim pruning that iteratively removes genes mapped to a significant GO term
from more general higher level GO terms, identified “calcium ion binding”, “growth factor activity”,
“extracellular matrix structural constituent”, and “G protein-coupled receptor activity” to be the most
impacted among 150 dysregulated biological processes (Table 4, Supplementary Table S6).
Table 4. Twenty most impacted Gene Ontology biological processes in complete hydatidiform moles.
GO ID GO Name Count DE Count All p Elim Pruning
GO:0005509 calcium ion binding 178 426 1.60 × 10−13
GO:0008083 growth factor activity 50 84 5.50 × 10−11
GO:0005201 extracellular matrix structural constituent 74 130 3.00 × 10−08
GO:0004930 G protein-coupled receptor activity 90 188 9.00 × 10−07
GO:0008201 heparin binding 47 99 2.40 × 10−06
GO:0005125 cytokine activity 36 70 3.60 × 10−06
GO:0030020 extracellular matrix structural constituent conferringtensile strength 22 35 4.00 × 10−06
GO:0004888 transmembrane signaling receptor activity 192 421 4.80 × 10−06
GO:0042605 peptide antigen binding 13 17 1.70 × 10−05
GO:0039706 co-receptor binding 8 8 1.90 × 10−05
GO:0005178 integrin binding 42 91 2.00 × 10−05
GO:0005044 scavenger receptor activity 24 43 2.60 × 10−05
GO:0038023 signaling receptor activity 259 568 3.10 × 10−05
GO:0005249 voltage-gated potassium channel activity 23 27 3.70 × 10−05
GO:0004252 serine-type endopeptidase activity 30 60 4.60 × 10−05
GO:0005179 hormone activity 19 34 1.80 × 10−04
GO:0008331 high voltage-gated calcium channel activity 6 6 2.90 × 10−04
GO:0020037 heme binding 29 63 3.90 × 10−04
GO:0030506 ankyrin binding 10 14 4.40 × 10−04
GO:0003996 acyl-CoA ligase activity 7 8 4.40 × 10−04
Differentially expressed, DE; Gene Ontology, GO.
We found the most impacted GO molecular functions to be “signaling receptor activity”, “molecular
transducer activity”, and “gated channel activity” among 105 dysregulated molecular functions
(Supplementary Table S7). Applying Elim pruning, “regulation of signaling receptor activity”, “cell
adhesion”, “chemical synaptic transmission”, and “extracellular matrix organization” were identified
as the most impacted among 628 dysregulated molecular functions (Table 5, Supplementary Table S8).
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Table 5. Twenty most impacted Gene Ontology molecular functions in complete hydatidiform moles.
GO ID GO Name Count DE Count All p Elim Pruning
GO:0010469 regulation of signaling receptor activity 143 285 3.90 × 10−14
GO:0007155 cell adhesion 407 1,014 2.00 × 10−13
GO:0007268 chemical synaptic transmission 165 397 3.60 × 10−07
GO:0030198 extracellular matrix organization 122 271 3.80 × 10−07
GO:0030449 regulation of complement activation 22 33 1.20 × 10−06
GO:0006958 complement activation, classical pathway 16 22 6.40 × 10−06
GO:0034765 regulation of ion transmembrane transport 130 295 1.50 × 10−05
GO:0045669 positive regulation of osteoblast differentiation 29 54 1.50 × 10−05
GO:0007156 homophilic cell adhesion via plasma membraneadhesion molecules 36 76 5.40 × 10−05
GO:0007186 G protein-coupled receptor signaling pathway 196 516 6.00 × 10−05
GO:0007166 cell surface receptor signaling pathway 686 2,116 8.60 × 10−05
GO:0007601 visual perception 51 123 1.50 × 10−04
GO:0006957 complement activation, alternative pathway 8 9 1.50 × 10−04
GO:0006805 xenobiotic metabolic process 32 68 1.60 × 10−04
GO:0002576 platelet degranulation 44 103 1.80 × 10−04
GO:0042102 positive regulation of T cell proliferation 32 60 2.20 × 10−04
GO:0035115 embryonic forelimb morphogenesis 17 29 2.20 × 10−04
GO:0030501 positive regulation of bone mineralization 19 34 2.20 × 10−04
GO:0048662 negative regulation of smooth muscle cellproliferation 23 39 2.30 × 10−04
GO:0035116 embryonic hindlimb morphogenesis 14 22 2.20 × 10−04
Differentially expressed, DE; Gene Ontology, GO.
The most impacted Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways included
“cytokine–cytokine receptor interaction”, “cell adhesion molecules”, “protein digestion and absorption”,
and “neuroactive ligand–receptor interaction”, all important for placental functions (Table 6,
Supplementary Table S9, Figure 3). An unanticipated finding was the most extensive dysregulation of
“cytokine–cytokine receptor interaction” pathway (Figure 4) and “cell adhesion” pathway, both required
for immune cell influx and activation. In addition, representation of 17 immune-related pathways
among 38 dysregulated pathways (Table 6, Supplementary Table S9) reflects a strong immune
component of molar pathogenesis.
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Table 6. Top 20 most impacted pathways in complete hydatidiform moles.
Pathway Name p-value pFDR
Cytokine-cytokine receptor interaction 1.38 × 10−07 2.31 × 10−05
Cell adhesion molecules (CAMs) 1.43 × 10−07 2.31 × 10−05
Protein digestion and absorption 6.20 × 10−07 6.68 × 10−05
Neuroactive ligand-receptor interaction 1.32 × 10−06 1.07 × 10−04
Complement and coagulation cascades 6.91 × 10−06 4.46 × 10−04
Hypertrophic cardiomyopathy (HCM) 1.05 × 10−05 4.87 × 10−04
Extracellular matrix (ECM)-receptor interaction 1.06 × 10−05 4.87 × 10−04
Autoimmune thyroid disease 2.91 × 10−05 1.17 × 10−03
Allograft rejection 7.36 × 10−05 2.39 × 10−03
Graft-versus-host disease 8.01 × 10−05 2.39 × 10−03
Antigen processing and presentation 8.15 × 10−05 2.39 × 10−03
Intestinal immune network for IgA production 9.94 × 10−05 2.68 × 10−03
Staphylococcus aureus infection 1.18 × 10−04 2.94 × 10−03
Metabolism of xenobiotics by cytochrome P450 1.64 × 10−04 3.63 × 10−03
Hematopoietic cell lineage 1.73 × 10−04 3.63 × 10−03
Immune-related pathways are shown in bold blue. False discovery rate, pFDR.
Figure 3. Pathways perturbation vs. over-representation in complete hydatidiform moles. Pathways are
plotted according to two types of evidence computed by iPathwayGuide: over-representation on the
x-axis (pORA) and the total pathway accumulation on the y-axis (pAcc). For both measures p-values
are displayed on the negative log (base 10) scale. Extracellular matrix, ECM; human papilloma virus,
HPV; Janus kinase, JAK; signal transducer and activator of transcription, STAT.
112
Int. J. Mol. Sci. 2019, 20, 4999
Figure 4. Cytokine–cytokine receptor interaction perturbation in complete hydatidiform moles. Top:
The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway diagram (KEGG: 04060) is overlaid
with the computed perturbation of each gene. Estimates of perturbation account for both for the genes′
measured fold change and for the accumulated perturbation propagated from any upstream genes
(accumulation). The highest negative perturbation is shown in dark blue, and the highest positive
perturbation in dark red. The legend describes values on the gradient. Bottom: Gene perturbation
bar plot. All genes in the cytokine–cytokine receptor interaction pathway (KEGG: 04060) are ranked
according to absolute perturbation values, negative values depicted in blue and positive values in
red. The box and whisker plot on the left summarizes the distribution of all gene perturbations
in this pathway, the box representing the first quartile, median and third quartile, while circles
represent outliers.
2.4. Validation of RNA-Seq Results at the Protein Level
First, we immunostained TMA slides for cyclin-dependent kinase inhibitor p57 (p57) expression
to confirm the histopathology diagnosis of CHM at the molecular level. Out of 26 samples with
the histopathology diagnosis of CHM, we detected cytotrophoblastic p57 staining in three samples,
while 23 (88%) samples were devoid of p57 expression (Supplementary Figure S1), confirming
the histopathological diagnosis of CHM in 23 samples. For validation of RNA-level findings, we
conducted immunostaining of galectin-14 (gal-14), which is encoded by LGALS14, one of the genes
most down-regulated in CHMs according to our RNA-Seq study. Average gal-14 immunoscores were
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43% lower in CHMs than in gestational age-matched controls (1.47 ± 0.08 and 2.60 ± 0.06, respectively,
p < 0.001). Additionally, the percentage of low-intensity staining (1+) was higher in molar than in
control tissues (58% and 3%, respectively), while the percentage of high-intensity staining (3+) was
lower in molar than in control tissues (6% and 61%, respectively), resulting in a significant difference in
the distribution of gal-14 immunoscores (p < 0.001), consistent with RNA-Seq results for this locus
(Figure 5).
Figure 5. Differential expression of galectin-14 in syncytiotrophoblast in complete hydatidiform
moles and first trimester control placentas. Five-μm-thick first trimester placental sections from
normal pregnancy (A) or from CHMs (B) were stained for galectin-14 (gal-14). Chorionic villi
exhibited intense syncytiotrophoblast cytoplasmic staining (arrows), while the villus stroma and
cytotrophoblasts were negative (arrowheads) in normal placentas, and the syncytiotrophoblast layer
had weak staining in CHMs. Representative images, hematoxylin counterstain, 200×magnifications.
(C) Gal-14 immunoscores (mean ± SEM) and proportion of staining intensities in control placentas
(n = 29) and CHMs (n = 23) are displayed on the left and right graphs, respectively. An unpaired t-test
was used to compare mean immunoscores between control and CHM groups. Fisher’s exact test was
used to test the difference in frequency of gal-14 immunostaining between the two groups. *** p < 0.001.
Cytotrophoblast, CTB; syncytiotrophoblast, STB; villous stroma, VS.
3. Discussion
3.1. Principal Findings of This Study
High-dimensional transcriptomic analysis identified numerous distinctions between CHM and
normal placenta, from which noteworthy patterns can be discerned. (1) the most highly expressed
genes in first trimester normal placentas are those previously shown to have placenta-specific or
predominantly placental expression; (2) in CHMs, overall gene expression levels are higher, while
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expression of placenta-specific transcripts are lower than in first trimester normal placentas; (3) the
pathogenesis of CHMs involves the dysregulation of 27% of protein-coding genes expressed in both
normal placentas and CHMs; (4) most DE genes (72%) in CHMs are up-regulated; (5) placental functions
appear to be down-regulated in CHMs, since placenta-specific genes are enriched in DE genes, and most
are down-regulated; (6) epigenetic reprogramming of the zygotic DNA and parental imprinting is
dysregulated in CHMs; and (7) immune pathways are activated in CHMs as immune-related genes are
enriched in DE genes and 17 immune-related pathways are impacted, mostly up-regulated, among 38
dysregulated pathways.
3.2. Placental Gene Expression and Functions are Down-Regulated in CHMs
In accord with previous studies [17,23], here we found genes with placenta-specific or predominant
placental expression among the most highly expressed genes—12 out of 20—in first trimester normal
placentas. These genes are involved in unique placental functions, including hormones, hormone
synthesizing machinery, proteases, and immune proteins, which are pivotal for placental development,
growth, signaling, and maternal–fetal immune tolerance. In CHMs, however, in spite of the overall
median gene expression level being ~13% higher than in normal first trimester placentas, the overall
median placenta-specific transcript level was 23% lower. This is also substantiated by the lower number
of placenta-specific genes among the 20 most highly expressed transcripts in CHMs.
When investigating differential gene expression, we found 27% of the expressed protein-coding
genes dysregulated in CHMs, of which 72% were up-regulated, underlining the generally higher
gene expression levels in CHMs. Placenta-specific genes were enriched among DE genes, and there
were much more down-regulated (79%) than up-regulated placenta-specific DE genes. In fact, the 20
most down-regulated genes included seven placenta-specific genes, while the 20 most up-regulated
genes were devoid of these. Based on the functions of down-regulated placenta-specific genes, we can
infer that placental growth and development, cell attachment, signaling, and immune defense are the
most highly impacted processes in CHM. This was also supported by the classical pathway analysis,
which revealed among the most impacted GO biological processes “cell adhesion”, “signaling”,
“hormone activity”, “growth factor activity”, and “extracellular matrix structural constituent”, while
the most impacted KEGG pathways included “cell adhesion molecules”, “neuroactive ligand–receptor
interaction”, and “ECM–receptor interaction”.
3.3. Possible Causes of the Dysregulation of Placental Gene Expression in CHMs
Targeted gene expression studies on molar tissues and a recent meta-analysis of these studies
showed that placenta-specific genes involved in villous trophoblast differentiation are also differentially
expressed in molar tissues, and concluded that molar pathogenesis is, indeed, rooted in problems
with trophoblast differentiation [16]. However, these studies were focusing on just a limited set of
placenta-specific transcripts known to be differentially expressed during trophoblast differentiation,
thus did not give a comprehensive insight into this important question. We recently discovered
that abnormal villous trophoblast differentiation is at the root of the pathogenesis of early-onset
preeclampsia, also reflected by profound placental dysregulation of placenta-specific genes [17,19].
Here we applied a similar non-targeted approach to investigate this issue. First, we intersected the
list of DE genes in CHMs with the list of DE genes during villous trophoblast differentiation from
our parallel study [19] and found only minimal enrichment for trophoblast differentiation genes
in dysregulated genes in CHMs, much less than for placenta-specific genes. This suggests that
trophoblast differentiation is moderately affected in CHMs, while the expression of placenta-specific
genes is more extensively impacted. Among the affected placenta-specific genes we validated the
down-regulation of LGALS14 at the protein level. Since histopathological evidence shows the generally
two-layered structure of villous trophoblasts in CHMs as in normal first trimester placentas, in spite of
the histological and molecular evidence of locally more proliferative and or immortalized trophoblasts
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in CHMs [24–31], the histopathology of CHMs also underlines the generally moderate problem with
villous trophoblast differentiation in CHMs.
A more compelling explanation would be that there is a problem with placental gene regulation
due to the changes in DNA methylation and imprinting [32–34] since CHMs only contain paternal
but not maternal genomes [35–37]. To test this hypothesis, we intersected the list of DE genes with
the list of imprinted genes obtained from the GeneImprint database, and we found a significant
enrichment of imprinted genes, underlining the link between CHM pathogenesis and affected paternal
imprinting. In addition, we detected the down-regulation of the de novo DNA methyltransferase
DNMT3A in CHMs, similar to the down-regulation of DNMT3A in absent fetal development, which is
also the characteristics of Dnmt3a or Dnmt3b knockout mice [38]. Moreover, TET3, which is enriched
specifically in the male pronucleus and responsible for paternal-genome conversion of 5mC into
5hmC [21], was two-fold up-regulated in CHMs. This is in good accordance with the paternal origin of
all chromosomes in CHMs. Furthermore, four histone demethylases, which are active in the regulation
of chromatin remodeling and gene expression and in influencing cellular differentiation, development,
tumorigenesis, and inflammatory diseases [22,39], were found to be up-regulated in CHMs. These
findings suggest that the epigenetic reprogramming of the zygotic DNA and parental imprinting are
dysregulated in CHMs.
3.4. Immune Functions are Widely Dysregulated in CHMs
The pathogenesis of familial, biparental hydatidiform moles is caused by the inactivating mutations
of NLRP7 and KHDC3L [40–42], genes involved in imprinting and inflammation. Inactivating mutations
in NLRP7 inhibit cytokine (IL-1, interleukin-1; TNF, tumor necrosis factor) secretion by interfering with
their trafficking, resulting in an in utero environment tolerogenic for the growth of these complete
paternal allografts [41]. In this context, it is important that we found a wide dysregulation of
immune pathways at the maternal–fetal interface in CHMs, which may also be at the heart of disease
pathogenesis. To understand how this would be possible, we need to look first at immune processes
in normal pregnancies. In healthy pregnant women, maternal–fetal immune tolerance mechanisms
are complex and dynamic since embryo implantation in the first trimester is a pro-inflammatory
process at the maternal–fetal interface, while the second trimester brings an anti-inflammatory
milieu for the growing fetus in the womb, and the initiation of parturition at the end of pregnancy
is characterized by a transition back towards a pro-inflammatory state [43–46]. These dynamic
alterations in immune states are driven by the changing placental expression of molecules that regulate
maternal immune responses [47–58]. Importantly, the dysregulated expression of immunoregulatory
molecules at the maternal–fetal interface and the consequent disturbances in maternal–fetal immune
regulation are strongly linked with alterations in the invasiveness of the trophoblast [59,60] and the
development of severe pregnancy complications, such as miscarriages [61–65], preterm labor [66–72],
or preeclampsia [73–79].
Herein, we detected the enrichment of genes involved in immune-related functions among DE
genes in CHMs, and there were much more up-regulated than down-regulated immune-related genes.
Of note, we noticed that IL1A and IL33 were down-regulated while FOXP3 (forkhead box P3), IL7, IL10,
LIF (leukemia inhibitory factor), and TGFB1 were up-regulated, which could theoretically induce a
tolerogenic environment, similarly to familial hydatidiform moles. Indeed, previous studies described
the infiltration of regulatory T cells, CD3+ T cells, and NK cells in CHMs at the implantation site [80–82].
This is in line with the finding herein on the up-regulation of chemokines and the activation of
“cytokine–cytokine receptor interaction” and “cell adhesion molecules” pathways as well as biological
processes such as “cell adhesion”, “biological adhesion”, and “signaling” needed for immune cell
influx and immune responses.
On the other hand, we also detected the down-regulation of LGALS13, LGALS14, the up-regulation
of various HLA-I (A, B, C, E, F, G) and HLA-II (DMA, DMB, DPB1, DRA) genes, complement pathway
genes (e.g., C1S, C3, C5, CR1) and interleukins (e.g., IL6, IL8/CXCL8, IL15, IL16, IL17D), and the overall
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involvement of 17 immune-related pathways among 38 dysregulated pathways. Of note, eight out of
10 (e.g., CD14, CD36, FCGRT, neonatal Fc receptor; LYVE1, lymphatic vessel endothelial hyaluronan
receptor 1) Hofbauer cell marker genes [83] were down-regulated in CHMs in our study in line with the
relative lack of Hofbauer cells in CHM villi [84,85]. These findings suggest an enhanced maternal, over
fetal, antigen-presenting and pro-inflammatory environment at the implantation site, which is also
supported by the activation of the “antigen processing and presentation”, “phagosome”, “complement
and coagulation cascades”, “allograft rejection”, and “graft-versus-host disease” pathways. This is in
line with the fact that CHMs express only paternal antigens and thus represent complete allografts
that could stimulate a vigorous alloimmune response from the maternal host [85], including local
synthesis of complement C3 and complement activation [86]. Not only paternal alloantigens but
also increased necrosis and apoptosis, due to the higher trophoblastic cell proliferation and turnover
rate in CHMs [87,88], may trigger the production of several pro-inflammatory cytokines [89] and the
activation of the complement system [89,90].
Based on all of these findings, we suggest that there is a complex immune dysregulation at
the implantation site in CHMs, which include the parallel induction of anti- and pro-inflammatory
processes due to the presentation of excess paternal antigens, aponecrotic trophoblastic debris, and the
dysregulation of upstream transcription factors and other gene regulatory mechanisms. These are
probably the consequences of abnormal paternal genome dosage and imprinting, resulting in impaired
gene expression and placental development. To delineate the exact sequence of events, one would
need to collect multiple samples from the implantation site in a time-series from patients and controls,
and then to perform the extensive characterization of the localization and expression of RNA and
protein signals. However, this type of sample collection is not possible due to ethical and technical
reasons in spite of the fact that cellular and molecular characterization of such time-series materials
would now be possible using, for example, RNA-Seq after laser capture microdissection or single-cell
RNA-Seq as well as mass spectrometry-based tissue imaging. However, these techniques were not
available for our current study.
3.5. Strengths and Limitations of the Study
According to our knowledge, this is the first non-hypothesis testing study that utilized various tools
of high-dimensional biology to gain in-depth insights into the pathogenesis of CHMs. The strengths of
the study are as follows: (1) strict clinical definitions and homogenous patient groups; (2) standardized,
quick placental sample collection during surgeries and pregnancy terminations; (3) standardized
histopathological examination of molar pregnancies and placentas based on international criteria;
(4) high-quality sample processing and state-of-the-art high-dimensional methods for RNA and protein
level analysis; (5) parallel expression profiling of various proteins on large tissue sets with tissue
microarray and immunostaining followed by semi-quantitative immunoscoring and statistical analysis;
and (6) the use of leading bioinformatics tools for RNA-Seq, gene ontology, and pathway analyses.
Limitations of the study are as follows: (1) the relatively modest number of cases due to the strict
clinical and histopathological inclusion criteria used for patient enrollment. Paradoxically, this was also
one of the most important strengths of our study; (2) data for cases and controls were retrieved from
various sources in the RNA-Seq discovery study; (3) TMAs did not allow us the cellular compositional
analysis of the investigated tissues due to the small core diameter size; and (4) it is possible that the
differences in gene expression levels may originate from differential gene expression of particular cell
types, differential cellular composition of CHMs and normal placentas, or the surgical/methodological
differences in tissue sampling during elective terminations or CHM surgeries.
3.6. Concluding Remarks
In conclusion, our data shows that placental functions are down-regulated, expression of imprinted
genes is altered, and immune pathways are activated in CHMs. Taken together, the results indicate
that complex dysregulation of placental developmental and immune processes are pivotal for the
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pathogenesis of CHMs, providing new biological insight likely to inform molecular translational
research addressing multiple stages of the natural history of CHM, such as assays for improved
detection and refined diagnosis in early pregnancy [91], risk stratification with respect to malignant
potential [92], and differential diagnosis of unexplained pregnancy loss [93].
4. Materials and Methods
4.1. Human Subjects, Clinical Samples, and Definitions
4.1.1. Subjects in the RNA-Seq Discovery Study
All research participants completed a process of informed consent per the University of Southern
California (USC) Health Sciences Institutional Review Board (protocols HS-09-00468 [12 November
2009) and HS-11-00095 (15 June 2011)]. Eligible subjects were identified upon presentation to Los
Angeles County (LAC) and USC Medical Center. CHMs were identified clinically by a combination of
ultrasonographic features (“snowstorm” or “cluster of grapes” appearance) with elevated blood hCG
levels. Molar tissues were obtained between 8 2/7 and 14 0/7 weeks of gestational age by therapeutic
surgical dilation and curettage. Confirmation of CHM diagnosis was determined by the histopathologic
examination of surgical material. One subject who had CHM on the basis of clinical features was
subsequently reclassified as having choriocarcinoma after pathological examination and was excluded
from the study. Another subject with CHM was excluded due to pooling of several samples from
various curettages into one sample, leaving the analyzed number of CHMs at four. Gestational
age-matched control chorionic villous tissues were obtained at the Reproductive Options Clinic at LAC
+ USC Medical Center from surgical elective pregnancy terminations. To increase control group size,
we also obtained RNA-Seq data of first trimester control chorionic villous tissues from a published
study [23] (Table 7).
Table 7. Demographic characteristics of patients in the RNA-Seq discovery study.
Patients Providing GTD Tissue Samples
(n = 4)




































Gestational age at tissue collection (days) 79.2 (58–98) 84.2 (77–124)
Gestational trophoblastic disease, GTD.
4.1.2. Subjects in the Tissue Microarray Validation Study
GTD tissue samples had been collected during usual care of women who underwent treatment
for GTD at the Department of Obstetrics and Gynecology, Keck School of Medicine, USC (Los Angeles,
CA, USA). After approvals (protocols HS-14-00808 and HS-15-00720 for IRB approval, Lab agreement:
16-03-03) were obtained from the USC IRB, the institutional pathology database at the LAC Medical
Center, Keck Medical Center of USC, and Norris Comprehensive Cancer Center was utilized to identify
GTD cases by searching for the keywords “gestational trophoblastic disease”, “molar pregnancy”,
“hydatidiform mole”, “complete mole”, and “invasive mole” between 1 January 2000 and 11 September
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2017. Inclusion criteria included GTD cases from whom archived histopathology specimens were
available. GTD cases without salient clinical information were excluded.
For eligible GTD cases, data describing clinical and demographic features, tumor characteristics
and markers, treatment course, and survival outcomes were abstracted from the medical record.
Clinical and demographic features included patient age at diagnosis of GTD, ethnicity, pregnancy
history including interval months from the last menstrual period of index pregnancy, body mass
index, and medico-surgical history. Tumor characteristics and markers included the World Health
Organization (WHO) score, histology subtype, tumor size, pretreatment beta-hCG, metastatic sites,
and number. Treatment course included surgical intervention (dilation and curettage, or hysterectomy)
and chemotherapy (type, cycle number, and response). Survival outcomes included progression-free
survival (PFS) and overall survival. Progression-free survival was determined as the time interval
between treatment initiation for GTD and the date of first recurrence or last follow-up date if there was
no recurrence. Overall survival was determined as the time interval between treatment initiation for
GTD and the date of death related to GTD or last follow-up date if the patient was alive.
Of 311 cases that were initially identified, 44 CHM cases were chosen for TMA based on tissue
availability (Tables 8 and 9). We placed no restriction on the age of gestation and found pregnancies to
be dated according to ultrasound scans between 5 and 15 weeks. Patients with multiple pregnancies
were excluded, and specimens and data were de-identified for use in research according to procedures
approved by the Institutional Review Boards of USC. From the 44 GTD tissues identified between 4 2/7
and 36 1/7 weeks of gestational age, the TMA project included 26 samples obtained from therapeutic
surgical dilation and curettage within the first trimester (13 6/7 weeks) and having good tissue quality.
The 26 samples were obtained from 23 patients. One patient provided two specimens at the same
sampling time, while another patient provided three specimens at different time points.
Table 8. Demographic characteristics of patients in the TMA validation study.
Patients Providing GTD Tissue Samples
(n = 23 *)
























Complete mole 26 (100%) 0 (0%)
p57 immunostaining confirmation of CHM 23 (88%)
Gestational age at the procedure (days) b 64.4 ± 18.2 62.3 ± 11.8
* A total of 26 samples altogether; one case with two specimens at the same time; another case with three specimens
at different time points. a Data are presented as number (percentage). b Data are presented as mean ± SD. c Data are
presented as median (IQR). Cyclin-dependent kinase inhibitor p57; human chorionic gonadotropin, hCG; gestational
trophoblastic disease, GTD; tissue microarray, TMA.
Control samples of first trimester placental tissue (n = 29) matched by gestational age to GTD
samples were collected prospectively at the Maternity Private Clinic (Budapest, Hungary) and deposited
into the Perinatal Biobank of the Research Centre for Natural Sciences, Hungarian Academy of Sciences
(Budapest, Hungary). Informed consent for use of the material in research was obtained from women
prior to sample collection, and specimens and data were stored anonymously. The research was
approved by the Health Science Board of Hungary (TUKEB 4834-0/2011-1018EKU), and all use of tissue
and data in this research conformed to the principles set out in the World Medical Association (WMA)
Declaration of Helsinki. Placentas were collected from pregnancies voluntarily terminated by surgical
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dilation and curettage between 5 and 14 weeks of gestation according to ultrasound scans, excluding
multiple pregnancies (Table 8).
Table 9. Criteria for categorizing gestational trophoblastic disease cases and number of samples in
each category included in the tissue microarray study.
Grouping Definition Sample No. *
1 D&C then cured 15
2a D&C then persistent GTD, cured by first-line single agent 1
2b D&C then persistent GTD, cured by upfront hysterectomy 4
2c D&C then persistent GTD, cured by upfront hysterectomy and adjuvant chemotherapy 0
3a D&C then persistent GTD, received first-line single agent but failed 3
3b D&C then persistent GTD, received first-line multi-agent and cured 0
3c D&C then persistent GTD, received first-line multi-agent and failed 0
3d D&C then persistent GTD, received upfront hysterectomy but recurred 0
4 Recurrent GTD 3
* A total of 26 samples altogether; one case with two specimens at the same time; another case with three specimens
at different time points. Dilatation and curettage, D&C; gestational trophoblastic disease, GTD.
4.2. Experimental Procedures
4.2.1. Sample Collection and Preparation for RNA-Seq
Tissue samples were rinsed with sterile saline and examined under a lightbox for content
confirmation and selection of molar tissue or chorionic villi. Samples were then stored in RNAlater
RNA stabilization reagent (approximately 10 μL reagent per 1mg of tissue, Qiagen, Germantown, MD,
USA) at 37 ◦C for a maximum of 24 h until collected for dissection. Samples were then dissected into
~1 g tissue aliquots and stored at −80 ◦C. Stored samples were then thawed at room temperature and
homogenized with electric homogenizer. Total RNA was isolated using the protocol provided with the
Qiagen RNeasy Mini Kit. RNA quantity was measured by a Nanodrop ND-8000 analyzer (Thermo
Scientific, Waltham, MA, USA). Samples were then stored at −80 ◦C until used.
4.2.2. RNA Sequencing
Library preparation and paired-end sequencing were performed by the USC Epigenome Core
Laboratory. Double-stranded cDNA fragments were synthesized from mRNA, ligated with adapters,
and size-selected for library construction according to Illumina protocol [94]. RNA sequencing was
carried out on Illumina Genome Analyzer (Illumina, San Diego, CA, USA).
4.2.3. Histopathological Examinations
All slides cut from formalin-fixed, paraffin-embedded (FFPE) molar tissue blocks were retrieved
from our USC + LAC histology archives. The slides were reviewed for confirmation of the diagnosis
and regions were identified for TMA construction. The blocks from the matching slides were retrieved
and submitted for TMA construction.
Samples of tissue from first trimester placentas had been fixed in 10% neutral-buffered formalin
and then embedded in paraffin. Five μm sections were cut from tissue blocks, stained with hematoxylin
and eosin (H&E), and examined using light microscopy. A perinatal pathologist blinded to patients’
clinical information, except for the gestational age, examined the histopathology of placental samples
using standard perinatal pathological protocol and previously-published diagnostic criteria [95–97],
and identified regions of each tissue block from which to sample cores.
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4.2.4. Tissue Microarray Construction
A material transfer agreement between the Hungarian Academy of Sciences and USC (No:
1996/2017) enabled the construction of TMAs containing tissues collected at USC and at Maternity
Private Clinic and deposited into the Perinatal Biobank. Four TMAs were constructed, each containing
three cylindrical cores two mm in diameter from each sample of first trimester FFPE placental (n = 29)
or GTD (n = 26) tissue. Cores from the same sample were transferred into recipient paraffin blocks
adjacent to each other using an automated tissue arrayer (TMA Master II, 3DHISTECH, Budapest,
Hungary). Each paraffin block contained three cores from all tissues, with liver included as negative
control and third trimester placenta as positive control material.
4.2.5. Immunohistochemistry and Immunoscoring
To validate the histological diagnosis of CHM, we conducted immunostaining for p57, which is
expressed from a paternally imprinted gene and is a recognized diagnostic marker in CHM [12,98,99].
To validate RNA level findings at the protein level for one down-regulated gene, five-μm-thick sections
were cut from each TMA onto adhesive glass slides (SuperFrost Ultra Plus, TS Labor, Budapest,
Hungary), and immunostained for p57 and galectin-14 using antibodies and conditions listed in
Table 10. Briefly, sections were dewaxed using xylene and rehydrated in graded alcohol series.





































For p57 immunostaining, endogen peroxidases were blocked using 10% H2O2 in methanol
for 20 min, then antigen retrieval was performed in Tris-EDTA pH 9.0 buffer for 20 min at 96 ◦C.
For galectin-14 immunostaining, endogen peroxidases were blocked using 1% H2O2 in methanol for
20 min, then antigen retrieval was performed in Tris-EDTA pH 9.0 buffer for 32 min at 100 ◦C. In all
staining procedure, after 10 min Novolink protein blocking (Leica-Novocastra, Wetzlar, Germany),
the sections were incubated at room temperature with antibodies and then with reagents of the
Novolink Polymer Detection System (Leica-Novocastra). Between incubation steps, the sections
were washed trice for 5 min in Tris-buffered saline (pH 7.4). Finally, sections were counterstained
with hematoxylin, and these were mounted (DPX Mountant; Sigma-Aldrich, St. Louis, MO, USA)
after dehydration.
Immunostained TMA images were semi-quantitatively scored by two examiners blinded to
the clinical information with an immunoreactive score modified from one previously used in our
studies [18,65,74,100–102]. Trophoblastic immunostaining intensity was graded as 0 = negative,
1 =weak, 2 = intermediate, and 3 = strong. For each specimen, all villi and trophoblastic tissues in a
random field of each of the cores were evaluated by both examiners using Panoramic Viewer 1.15.4
(3DHISTECH Ltd., Budapest, Hungary).
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4.3. Data Analysis
4.3.1. Analysis of mRNA Expression (RNA-Seq Data)
For data produced from five samples, FASTQ files were generated by Illumina’s pipeline and
read quality was assessed by FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).
Subsequently, reads were submitted to alignment with HISAT2 (v2.1.0) [103]. The mapping was
made using default parameters with reference human genome GRCh38 (downloaded from Illumina
iGenomes). Aligned BAM files were indexed and sorted with Samtools (v0.1.18) [104] for downstream
analysis. Genomic features and read count matrices were obtained using featureCounts (v1.5.2) [105]
based on annotation file hg38 (RefSeq track of UCSC Table Browser).
RNA-Seq count data for additional late first trimester control placentas (22 XY and 17 XX) were
downloaded from GEO (AccNo: GSE109082) [23]. Differential gene expression analysis was performed
using the R package DESeq2 [106,107].
Because data included differing amounts of non-coding RNA leading to high numbers of DE genes
presumed to be spurious, we restricted the differential gene expression analysis to 19,690 protein-coding
genes based on the ENSEMBL “biotype” annotation. We further excluded genes with zero read count
in any sample, resulting in a final analytic set of data on 14,022 genes. As a set of DE transcripts, we
selected those with a fold change of ≥2 between CHM and control, while holding the false discovery
rate (pFDR) to <0.05.
To estimate absolute levels of expression, we normalized RNA-Seq count data by the geometrical
mean of measured counts of four housekeeping genes (TBP, TATA-box binding protein; CYC1,
cytochrome C1; UBC, ubiquitin C; TOP1, topoisomerase (DNA) I), and calculated the mean expression
both in CHM and control groups of samples.
4.3.2. Pathway Analysis
To identify significantly impacted pathways, biological processes, and molecular functions,
we compared expression between CHM and control groups using Advaita Bio’s iPathwayGuide
(https://www.advaitabio.com/ipathwayguide). This software analysis tool implements the “impact
analysis” approach that takes into consideration the direction and type of all signals on a pathway and
the position, role and type of every gene, as described in [108].
4.3.3. Enrichment Analyses
We used Fisher’s exact test to test enrichment of the DE transcript set with genes previously
demonstrated to have expression patterns of particular relevance: (1) genes with placenta-specific
expression (n = 164, Supplementary Table S2) [17]; (2) genes involved in villous trophoblast
differentiation (n = 1,937; GEO: GSE130339, the list was provided by authors of an unpublished
work [19]); (3) genes imprinted in humans (n = 209; imprinted gene databases, www.geneimprint.com,
Supplementary Table S3 and 4 genes related to immune processes (n = 1,449; www.innatedb.com;
the final list is the manual curation and combination of Immport, Immunogenetic Related Information
Source, and Immunome Database Gene Lists, Supplementary Table S4).
4.3.4. Analysis of TMA Data
For each core, immunostain was scored by each of two examiners using a scale of 0 to 3,
0 representing none and 3 strong immunostaining. Quantitative immunoscores were determined
as follows. For each core, immunoscores from examiners were first averaged to represent that core,
and resulting values for each of the three cores representing one sample were averaged to represent that
sample. Mean immunoscores between control and CHM groups were compared using the unpaired
t-test. The Fisher’s exact test was performed to test the distribution of gal-14 immunoscores between
the control and CHM groups. Results were considered statistically significant at * p < 0.05, ** p < 0.01,
and *** p < 0.001.
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4.3.5. Data Availability
USC RNA-Seq data was deposited to the Gene Expression Omnibus (GEO) database according to
the MIAME guidelines (accession number: GSE138250).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/20/
4999/s1.
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Abstract: Altered expression and function of the Toll-like receptor (TLR) homologue CD180 molecule
in B cells have been associated with autoimmune disorders. In this study, we report decreased
expression of CD180 at protein and mRNA levels in peripheral blood B cells of diffuse cutaneous
systemic sclerosis (dcSSc) patients. To analyze the effect of CD180 stimulation, together with
CpG (TLR9 ligand) treatment, on the phenotype defined by CD19/CD27/IgD/CD24/CD38 staining,
and function (CD69 and CD180 expression, cytokine and antibody secretion) of B cell subpopulations,
we used tonsillar B cells. After stimulation, we found reduced expression of CD180 protein and
mRNA in total B cells, and CD180 protein in B cell subpopulations. The frequency of CD180+ cells
was the highest in the CD19+CD27+IgD+ non-switched (NS) B cell subset, and they showed the
strongest activation after anti-CD180 stimulation. Furthermore, B cell activation via CD180 induced
IL-6 and natural autoantibody secretion. Treatment with the combination of anti-CD180 antibody
and CpG resulted in increased IL-6 and IL-10 secretion and natural autoantibody production of B
cells. Our results support the role of CD180 in the induction of natural autoantibody production,
possibly by NS B cells, and suggest an imbalance between the pathologic and natural autoantibody
production in SSc patients.
Keywords: B cells; non-switched B cells; systemic sclerosis; dcSSc; TLR; CD180; RP105; CpG; IL-6;
IL-10; natural autoantibodies; IgM; citrate synthase; DNA topoisomerase I
1. Introduction
The production of scleroderma-specific autoantibodies and secretion of pro-inflammatory and
pro-fibrotic cytokines by B cells is a well-described result that reflects immune dysregulation affecting
B cells in systemic sclerosis (SSc) [1–4]. However, a large number of autoantibodies directed against
well-conserved functional structures of the cell (e.g., nucleosome, DNA, nuclear and mitochondrial
proteins, and receptors), the so-called natural autoantibodies that serve a protective function, can also be
detected in healthy subjects and are dysregulated in patients with systemic autoimmune diseases [4,5].
Autoantibody production is a widely investigated function of B cells in SSc, but less attention
has been devoted to their activation by innate immune receptors, including Toll-like receptors (TLRs),
that are involved in recognizing pathogen- and damage-associated molecular patterns. CD180, or RP105
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(radioprotective 105 kDa), is a TLR-like membrane protein that lacks an intracellular Toll-IL-1R (TIR)
signaling domain [6]. CD180 was originally defined as a B cell surface molecule mediating polyclonal
B cell activation, proliferation, and immunoglobulin production [7,8]. It was later described as
a TLR homologue also expressed by monocytes and dendritic cells (antigen presenting cells), and the
expression of CD180 correlated with TLR4 expression. CD180 and its helper molecule, MD-1, interact
directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligands; thus, it serves
as a negative regulator of TLR4 responses of antigen-presenting cells [6,9].
Differential expression and functions of CD180 on B cells have been associated with
immune-mediated pathologies, including infection, chronic inflammation, and autoimmune
disorders [6]. The severity of the disease in systemic lupus erythematosus (SLE) patients correlated with
the amount of CD180-negative B cells in the peripheral blood [10,11]. CD180-negative peripheral blood
B cells were also increased in patients with Sjögren’s syndrome; furthermore, these cells extensively
infiltrated the salivary glands [12].
As the natural ligand of CD180 remains unknown, effects of crosslinking CD180 with monoclonal
anti-CD180 antibody has been investigated. Anti-CD180 antibody activates over 85% of human
and mouse B cells in vitro and induces robust immunoglobulin production [8]. The stimulation
with anti-CD180 antibody synergizes with TLR9 ligands [8,13]. When CpG and anti-CD180 were
used simultaneously, the proliferation of peripheral blood B cells was enhanced, and IgG and IgM
production increased [13]. Simultaneous treatment with anti-CD180 antibody and LPS or CpG resulted
in increased cytokine production of murine B cells [14].
In this study, we investigated the expression of CD180 at protein and mRNA levels in peripheral
blood B cells of early diffuse cutaneous SSc (dcSSc) patients, and compared to healthy control (HC)
B cells. We found that CD180 expression of dcSSc B cells was significantly lower than in HC B cells.
To further investigate the role of CD180 in B cell activation, we used tonsillar B lymphocytes as a model.
To investigate the CD180-mediated activation of B cell subsets, we used anti-CD180 antibody to ligate
the receptor, and combined with treatment with CpG, a TLR9 ligand. Expression of CD180 in B cell
subsets, and molecules of B cell activation, cytokine, and autoantibody production were analyzed.
The frequency of CD180+ cells was the highest in non-switched memory (NS) B cells, which showed the
strongest activation (CD69+) upon anti-CD180 stimulation. This activation was not influenced by the
addition of CpG. Stimulation with anti-CD180 antibody alone, and in combination with CpG resulted
in downregulation of CD180 protein and mRNA expression in total B cells, and decreased CD180
protein expression in B cell subsets. Activation via CD180 induced the elevation of IL-6 production and
the anti-DNA topoisomerase I (anti-topo I) IgM natural autoantibody secretion, which were enhanced
by the addition of CpG. Furthermore, treatment with the combination of anti-CD180 antibody and CpG
resulted in increased IL-10 secretion and anti-citrate synthase IgM natural autoantibody production of
B cells. Our results support the role of CD180 in the induction of natural autoantibody production,
possibly by NS B cells, which are diminished in SSc patients, resulting in an imbalance between the
pathologic and natural autoantibody production.
2. Results
2.1. CD180 Expression Is Decreased in dcSSc B Cells
Since it was described in other autoimmune diseases that differential expression of CD180 (RP105)
might have a pathological role in B cell activation and autoantibody production [10–12,15], first we
determined the CD180 expression of monocytes, T cells, and B cells. We compared the level (mean
fluorescence intensity, MFI) of CD180 in PBMC samples of early, untreated dcSSc patients and HCs
with flow cytometry. We found that the MFI of CD180 labeling was the highest in B cells, followed
by monocytes, and T cells showed the lowest expression. The expression of CD180 in monocytes
and T cells was similar in patients and HCs, while its level was significantly lower in B cells of dcSSc
patients than in HC B cells (Figure 1A,B). Next, we examined the mRNA expression of the CD180
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gene in purified B cells of early, untreated dcSSc patients and compared to HCs. We found highly
downregulated expression of CD180 mRNA in dcSSc patients (Figure 1C).
Figure 1. Analysis of CD180 expression in diffuse cutaneous systemic sclerosis (dcSSc) B cells.
(A) Representative flow cytometry plots of peripheral blood leukocytes (a), B and T cells (b), and CD19+ B
cells stained with CD27 and IgD defining the following four subsets: CD27+IgD+ non-switched memory
(NS) B cells, CD27+IgD− switched memory (S) B cells, CD27−IgD+ naive B cells, and CD27−IgD−
double negative (DN) B cells (c). (B) Flow cytometric analysis of CD180 expression in peripheral
blood B cells, T cells, and monocytes of early untreated dcSSc patients compared to healthy controls
(HCs). (C) CD180 mRNA expression in B cells of early untreated dcSSc patients compared to HCs.
Gene expression was normalized to HCs and the horizontal line (value 1) represents the expression of
control samples. Changes in gene expression are shown as relative quantification (RQ) values. Data are
shown as mean ± standard error of the mean (SEM), n = 4 HC and n = 4 dcSSc, * p < 0.05.
2.2. TLR Ligation Results in Reduced CD180 mRNA and Protein Expression of B Cells
The CD180-negative B cells were described as highly activated cells in SLE [11], and stimulation
via CD180 is known to activate B cells [6]. Furthermore, TLR ligands were reported to downregulate the
mRNA expression of CD180 molecule [16], thus we hypothesized that the decreased CD180 expression
of dcSSc B cells could be a result of activation through TLRs. To investigate whether TLR stimulation
leads to diminished expression of CD180 molecules in B cells, we stimulated tonsillar B cells with
anti-CD180 antibody. We measured the expression of CD180 at protein and mRNA levels, and found
that following anti-CD180 ligation, the MFI and mRNA levels of CD180 significantly decreased
(Figure 2A,B). To study the influence of other TLR ligands on the activation via CD180, we co-treated
the B cells with CpG, and found that the expression of CD180 was similar to anti-CD180-stimulated
cells both at protein (Figure 2A) and mRNA (Figure 2B) levels. Treatment with CpG alone did not
result in changes of CD180 MFI (Figure 2A) or CD180 mRNA (Figure 2B) levels in B cells.
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Figure 2. Effect of Toll-like receptor (TLR) stimulation on CD180 protein and mRNA expression.
(A) CD180 expression of unstimulated (control), CpG, anti-CD180 antibody-stimulated, and anti-CD180
+ CpG-treated (24 h) tonsillar B cells (mean fluorescence intensity, MFI). (B) CD180 mRNA expression
in tonsillar B cells following CpG, anti-CD180, and anti-CD180 + CpG stimulation (24 h). Changes in
gene expression are shown as RQ values, normalized to unstimulated controls. The horizontal line
(value 1) represents the CD180 mRNA of unstimulated control samples. Data are shown as mean ±
SEM, n = 4, * p < 0.05.
2.3. The Frequency of CD180+ Cells Is the Highest in the Non-Switched Memory B Cell Subset
To assess phenotypical and functional alterations of B cells upon anti-CD180 stimulation, first we
investigated the expression of CD180 in B cell subsets, defined by CD27 and IgD labeling (Figure 1A).
Using tonsillar B cells, we analyzed the following subpopulations: CD27+IgD+ non-switched memory
(NS) B cells, CD27+IgD− switched memory (S) B cells, CD27−IgD+ naive B cells (N), and CD27−IgD−
double negative (DN) B cells. We found that the percentage of CD180+ cells was significantly higher
in NS B cells compared to all other subsets, namely, naive, S, and DN B cells (Figure 3A,B). Next,
we measured the changes in the percentage of CD180+ B cells in the NS, S, naive, and DN B cell
subpopulations upon anti-CD180 stimulation, and found that the frequency of CD180+ cells was
significantly decreased in all four B cell subsets (Figure 3B). Addition of CpG to the anti-CD180
antibody-treated B cells did not result in further changes in the ratio of CD180+ B cell subpopulations
(Figure 3B). Treatment with CpG alone did not reduce the percentage of CD180+ cells in the investigated
B cell subsets (Figure 3B). The overall pattern of the changes in CD180 MFI in the investigated B cell
subsets was similar to that found in the frequency of CD180+ cells, but the CD180 MFI in unstimulated
B cells was the highest in naive B cells (Figure 3C). We also investigated the expression of CD180 in
regulatory B cells (Bregs). There is still no consensus on the phenotype of Bregs, multiple subsets
with many similarities in phenotype and effector functions have been described [17]. In humans,
both CD19+CD24highCD38high [18] and CD19+CD24highCD27+ [19] Bregs have been defined. Based on
these findings, we analyzed the CD180 expression of Breg subsets with these phenotypes using
flow cytometry. We found that the percentage of CD180+ cells and the MFI of CD180 labeling was
significantly decreased after anti-CD180 antibody treatment, and also after combined treatment with
anti-CD180 antibody and CpG (Figure 3D,E).
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Figure 3. Effect of TLR stimulation on CD180 expression in B cell subpopulations. Flow cytometric
analysis of the distribution of CD180+ B cells and CD180 MFI in CD27+IgD+ non-switched memory
(NS), CD27+IgD− switched memory (S), CD27−IgD+ naive, and CD27−IgD− double negative (DN) B
cell subsets (A–C), and in CD24highCD38high and CD24highCD27+ Breg subsets (D,E). Representative
dot plots show the changes of CD180 positivity in control and treated NS B cells (A). Changes of
CD180+ cell ratios (B) and CD180 MFI (C) in different B cell subsets defined by CD27 and IgD staining
after CpG, anti-CD180 antibody stimulation or anti-CD180 + CpG treatment. Changes of CD180+ cell
ratios (D) and CD180 MFI (E) in Breg subsets defined by CD24, CD27, and CD38 staining after CpG,
anti-CD180 antibody stimulation or anti-CD180 + CpG treatment. Data are presented as means ± SEM,
n = 4, * p < 0.05.
2.4. Anti-CD180 Stimulation Resulted in Activation of B Cell Subsets
We also examined the activation of the B cell subsets defined by CD27 and IgD labeling after 24 h
of anti-CD180, CpG, and anti-CD180 + CpG stimulation by detecting CD69, an early activation marker.
Upon anti-CD180 stimulation, the frequency of CD69+ cells was increased in all investigated subsets
compared to CpG stimulation, showing the highest ratio in NS B cells (Figure 4A,B). This result is
consistent with our observation that NS B cells show the highest ratio of CD180+ cells. CpG, when used
together with anti-CD180 antibody stimulation, did not alter the percentage of CD69+ cells in NS,
S, or DN B cells compared to anti-CD180 stimulation alone. However, a significant decrease in the
frequency of CD69+ naive B cells was observed, compared to anti-CD180 ligation alone (Figure 4B).
The overall pattern of the changes in CD69 MFI was similar to that found in the frequency of CD69+
cells, and after anti-CD180 antibody stimulation, the CD69 MFI was the highest in NS B cells. Yet,
CD69 MFI was not significantly different between CpG- and anti-CD180 + CpG-stimulated DN B cells,
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while combined anti-CD180 and CpG treatment compared to anti-CD180 antibody stimulation alone
significantly reduced the MFI of CD69 in DN B cells (Figure 4C).
Figure 4. Expression of CD69 activation marker on B cell subpopulations. Representative dot plots
show the changes of CD69 positivity in control and treated NS B cells (A). The percentage of CD69+ (B)
B cells and CD69 MFI (C) in CD27+IgD+ non-switched memory (NS), CD27+IgD− switched memory
(S), CD27−IgD+ naive, and CD27−IgD− double negative (DN) B cell subsets defined by CD27 and
IgD in anti-CD180 antibody, CpG-stimulated, and in anti-CD180 and CpG co-treated tonsillar B cells.
Data are presented as means ± SEM, n = 4, * p < 0.05.
2.5. TLR Stimulation Differentially Affects IL-6 and IL-10 Production of B Cells
Recently, it was described that prominent IL-6 production by activated B cells promotes
spontaneous germinal center formation and plasma cell differentiation, further supporting the role of
this cytokine in the pathogenesis of systemic autoimmune diseases [20]. To test whether anti-CD180
stimulation influences B cell–derived IL-6 production, or induces the production of Breg cytokine
IL-10, we measured the concentration of these cytokines in the supernatant of separated B cells after
24 h of stimulation. Anti-CD180 stimulation alone significantly increased the concentration of IL-6
in the supernatant of tonsillar B cells compared to both unstimulated and CpG-stimulated cells,
while it had no significant effect on the production of IL-10. CpG on its own significantly elevated
the concentration of IL-6 in the supernatant, but did not increase the production of IL-10. However,
supplementing anti-CD180 antibody with CpG significantly augmented the production of both IL-6
and IL-10 compared to unstimulated, CpG-, and anti-CD180-stimulated B cells (Figure 5A,B).
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Figure 5. TLR induced cytokine production of total B cells. Detection of IL-6 (A) and IL-10 cytokines
(B) in the supernatant of tonsillar B cells stimulated with CpG, anti-CD180 antibody, or anti-CD180 +
CpG, or left unstimulated (control), as measured by ELISA. Data are presented as means ± SEM, n = 4,
* p < 0.05.
2.6. CD180 Stimulation Induces Natural Autoantibody Production
Since CD180 stimulation resulted in the most pronounced activation of NS memory B cells,
resembling the B1 B cell population, which includes cells responsible for natural IgM autoantibody
production [21], we investigated the effect of CD180 ligation on the production of natural autoantibodies
by tonsillar B cells. In our previous studies, we detected anti-citrate synthase (CS) IgM antibodies in
HCs and patients with autoimmune diseases [22,23]. Here we measured the anti-CS IgM autoantibody
in the supernatant of anti-CD180-stimulated and control tonsillar B cells after 7 days of culture, but did
not find any differences between the control and anti-CD180-stimulated samples. Treatment with
CpG alone resulted in a significant increase in the level of anti-CS IgM in the supernatant. Combined
treatment with anti-CD180 antibody and CpG significantly increased the production of anti-CS IgM
autoantibody compared to unstimulated, CpG-, and anti-CD180-stimulated B cells (Figure 6A).
Previously, we reported that different epitopes of topoisomerase I (Scl-70) induce not only
pathologic autoantibodies in dcSSc patients, but the antigen has epitopes (including F4) that induce
natural autoantibody production in healthy individuals as well [24]. Therefore, we also measured the
level of anti-topoisomerase I F4 fragment (anti-topo I) antibody in the supernatant of CD180-stimulated
B cells. Anti-CD180 itself significantly raised the level of anti-topo I IgM antibodies in the supernatant
of tonsillar B cells similarly to CpG, and the level was further elevated with addition of CpG
(Figure 6B). Further, we measured the production of pathologic autoantibodies in the supernatant
of anti-CD180- and anti-CD180 + CpG-stimulated tonsillar B cells. Antinuclear antibodies (ANA),
anti-dsDNA, and anti-nucleosome antibodies were not detectable in the supernatant of B cells under
the investigated conditions.
Figure 6. Induction of natural autoantibody production by TLR stimulation. Anti-citrate synthase IgM
and (A) anti-DNA topoisomerase I IgM (B) production of B cells stimulated with CpG, anti-CD180
antibody, or anti-CD180 + CpG, or left unstimulated (control). Data are presented as means ± SEM,
n = 3, * p < 0.05.
3. Discussion
In SSc, data on the role of innate immune molecules in the dysregulated B cell functions are
scarce. The TLR homologue CD180 molecule activates the majority of B cells, resulting in phenotypic
and functional alterations [8,14,25]. CD180-negative B cells, macrophages, and dendritic cells were
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shown to be elevated in SLE and in lupus-prone mice [15,26]. Here, we demonstrated that the
expression of CD180 is decreased in early dcSSc peripheral blood B cells compared to HCs, while the
percentage of CD180-negative monocytes was unaltered, emphasizing the potential role of CD180 in B
cell dysfunction in SSc. CD180-negative B cells in SLE were described as highly activated cells [15],
and CD180 can be internalized after ligation by anti-CD180 antibody [14]; thus, B cell activation via
CD180 might be a possible explanation for the decreased expression of CD180 in SSc B cells.
We were the first to investigate the distribution of CD180 molecules in tonsillar B cell
subpopulations defined by CD27 and IgD labeling, and found that the frequency of CD180+ cells
was the highest among NS cells. The percentage of CD180+ cells was significantly decreased in all
subsets upon anti-CD180 stimulation, suggesting that ligation of CD180 triggered its internalization.
Interestingly, we also found that anti-CD180 stimulation downregulated the mRNA expression of
CD180, strengthening the possibility of autoregulation of CD180 expression by B cells. Signaling via
TLRs can interfere with CD180 signals, since ligands of TLR7 and TLR9 have already been shown to
downregulate CD180 expression in human peripheral blood B cells [16]. Nevertheless, according to
our results, co-treatment with anti-CD180 and CpG reduced the expression of CD180 to a similar level
as anti-CD180 did on its own, while CpG treatment alone had no significant effect on the expression
of CD180. All investigated B cell subsets were activated by anti-CD180 and anti-CD180 and CpG
co-treatment, as indicated by CD69 expression.
Anti-CD180 antibody is known to activate marginal zone (MZ) B cells and induces overexpression
of CD69 in mice [14]. NS B cells in human peripheral blood represent MZ-derived B cells [21],
and according to our results, ratio of CD69+ cells was the highest among NS B cells upon anti-CD180
stimulation. Moreover, the combination of anti-CD180 stimulation with CpG showed no additional
effect on the activation of NS B cells.
We have already described that the percentage of NS B cells is lower in SSc than in HC [27].
NS B cells resemble B1 B cells with innate-like features [21], suggesting that they produce natural
autoantibodies. Natural IgM autoantibodies are polyreactive and serve as scavengers of damaged
molecules and cells, and therefore have been implicated in the control of inflammation and autoimmune
diseases [28]. The therapeutic effects of intravenous immunoglobulins (IVIg) could partly be due
to the appropriate pool of natural autoantibodies [29], and IVIg seems to be beneficial in SSc [30];
therefore, we also examined the effect of anti-CD180 and anti-CD180 and CpG co-treatment on the
production of natural and pathologic autoantibodies of tonsillar B cells. Pathologic autoantibodies
were undetectable in the supernatant of cells, while anti-CD180 and CpG co-treatment significantly
enhanced the production of both anti-CS and anti-topoisomerase I IgM antibodies, suggesting the
synergistic beneficial effect of anti-CD180 antibody and TLR9 ligand on natural antibody production
of B cells. Interestingly, anti-CD180 stimulation increased the level of anti-topoisomerase I IgM,
while it had no influence on anti-CS IgM production. However, CpG stimulation increased the level of
anti-topoisomerase I IgM and anti-CS IgM as well. CS molecule is not the target of a disease-specific
pathologic antibody, while natural anti-topoisomerase I autoantibodies recognize distinct epitopes of
topoisomerase I, which is the target antigen of an SSc-specific pathologic autoantibody (anti-Scl-70) [24].
The onset of autoimmune diseases may correlate with a switch from production of self-reactive
low-affinity IgM to high-affinity IgG isotype autoantibodies by B cells. B cell activation via CD180 may
have a role in regulating the level of natural IgM antibodies directed against the target antigens of
pathologic antibodies.
The serum concentration of IL-6 is elevated both in SSc [31] and SLE patients [32]; furthermore,
IL-6 production by B cells drives autoimmune germinal center formation in a mouse model of SLE,
promoting the disease [20]. We found that ani-CD180 stimulation enhanced the IL-6 production by
tonsillar B cells, which was further augmented by the addition of CpG. IL-6 was shown to have
a pronounced effect on plasma cell survival [33], and if combined with IL-2 or IL-10, IL-6 enhanced
the generation of early plasma cells [34]. Moreover, in SLE patients, endogenous IL-6 produced by B
cells bound to IL-6R of B cells and drove them into terminal differentiation [35]. Consequently, B cell
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activation via CD180 alone or together with the TLR9 ligand may help plasma cell differentiation and
antibody production. Bregs are decreased and functionally impaired in SSc patients [36], thus we
also investigated the effect of anti-CD180 treatment on the IL-10 production of B cells. We found
that CpG alone did not induce the production of IL-10, which is in agreement with the findings of
Gantner et al. [37]. The concentration of IL-10 was increased only when anti-CD180 antibody was
combined with CpG, suggesting their synergisitc effect on Bregs. However, CD180 expression was
significantly decreased in CD19+CD24highCD38high and CD19+CD24highCD27+ Breg subsets after
anti-CD180 antibody treatment, and also after combined treatment with anti-CD180 antibody and
CpG, suggesting that anti-CD180 antibody stimulation alone may influence Breg functions other than
the production of IL-10.
Our findings suggest that the TLR homologue CD180 molecule may be involved in B cell
dysfunction in early dcSSc. We also described the effects of anti-CD180 activation on natural
autoantibody and cytokine production of tonsillar B cells and conclude that our data raise the
possibility that anti-CD180 stimulation might shift the type of antibodies produced by B cells towards
the natural autoantibodies.
4. Materials and Methods
4.1. Patients
Diffuse cutaneous systemic sclerosis patients (dcSSc) enrolled for the gene expression and flow
cytometric studies all fulfilled the 2013 ACR/EULAR SSc classification criteria. Disease duration was
1.75 ± 0.96 years, age at enrollment was 39 ± 22.73 years. None of the patients were on current or
previous immunosuppressive therapy. The controls were age- and sex-matched healthy individuals
(HC). All participants gave their informed consent to the study following approval by the Hungarian
National Ethics Committee (ETT TUKEB 47861-6/2018/EKU) and Regional Clinical Research Ethics
Committee (7724-PTE 2019).
4.2. Mononuclear Cell Isolation, B Cell Separation
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque Plus (GE Healthcare,
Chicago, IL, USA) density gradient centrifugation of peripheral blood samples (SSc n = 4, HC n = 4).
Negative selection of B cells was performed using the MACS B cell isolation kit II (Miltenyi Biotech,
Bergisch Gladbach, Germany), according to the manufacturer’s protocol. B cell purity was >95%.
Tonsil tissue was collected from asymptomatic children who underwent routine tonsillectomy at
the Department of Pediatrics, University of Pécs. After surgical removal, the tonsils were transported
immediately to the laboratory and they were prepared the same day.
Tonsils were manually homogenized, and the cell suspension was filtered through a 70 μm sterile
cell strainer, followed by isolation of mononuclear cells and separation of B cells, as described above.
4.3. Cell Stimulation
For RNA isolation, B cell subset analysis and cytokine measurements, 3 × 105 B cells were
stimulated with LEAF Purified anti-human CD180 (RP105) antibody (Clone: MHR73-11) (BioLegend,
San Diego, CA, USA) at 1 μg/mL (hereafter referred to as anti-CD180) or anti-CD180 in combination
with 1 μg/mL CpG (Hu/Ms CpG-B DNA, ODN2006, Hycult Biotech, Wayne, NJ, USA) or with CpG
alone or were left unstimulated for 24 h at 37 ◦C. To assess natural and pathologic antibody production,
4 × 105 B cells were stimulated with anti-CD180, or CpG or anti-CD180 in combination with CpG,
or left unstimulated for 7 days at 37 ◦C.
4.4. RNA Isolation, cDNA Synthesis, and qPCR
Total RNA was extracted from isolated B cells using the NucleoSpin RNA XS kit (Macherey-Nagel
Inc, Bethlehem, PA, USA). Following cDNA generation (High Capacity cDNA Reverse Transcription Kit,
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Thermo Fisher Scientific, Waltham, MA, USA), the CD180 mRNA expression was analyzed individually
in dcSSc patients (n = 4) and HCs (n = 4) using Applied Biosystems TaqMan Gene Expression Assays
(Thermo Fisher Scientific, Waltham, MA, USA). To determine the CD180 mRNA expression of tonsillar
B cells (n = 4), the SensiFAST SYBR Lo-ROX Kit (Bioline, London, UK) was used. Amplifications were
performed using an Applied Biosystems 7500 RT-PCR System (Thermo Fisher Scientific, Waltham, MA,
USA). Gene expression was analyzed with 7500 Software v2.0.6 (Thermo Fisher Scientific, Waltham,
MA, USA) and normalized to GAPDH (a “housekeeping” gene) as reference. Fold changes (RQ) were
calculated according to the 2-ddCT method.
4.5. Flow Cytometric Analysis
To measure the expression of CD180 of B cells, PBMCs from dcSSc patients (n = 4) and HCs
(n = 4) were labeled with the combination of anti-human CD19-AmCyan (SJ25C1, Becton Dickinson,
Franklin Lakes, NJ, USA) and anti-human CD180-PE (G28-8, Becton Dickinson, Franklin Lakes, NJ,
USA) antibodies. Multiparametric flow cytometry was performed on tonsillar B cells (n = 4) with
antibodies specific for CD19, CD27, IgD, CD24, CD38, CD180, and CD69. Purity of B cells was
assessed using anti-human CD19-AmCyan antibody. To distinguish between memory B cell subsets
and to evaluate the expression of CD180 and the activation marker CD69, four-color analysis was
conducted using the combination of anti-human CD27-PE/Cy7 (M-T271, BioLegend, San Diego, CA,
USA), anti-human IgD-PerCP (IA6-2, BioLegend, San Diego, CA, USA), anti-CD180-PE (G28-8, Becton
Dickinson, Franklin Lakes, NJ, USA), and anti-human CD69-APC/Cy7 (FN50, BioLegend, San Diego,
CA, USA), while Breg subsets were defined by anti-human CD27-PE/Cy7, anti-human CD24-BV421
(ML5, BioLegend, San Diego, CA, USA), and anti-human CD38-APC/Cy7 (HIT2, BioLegend, San Diego,
CA, USA) antibodies following the manufacturer’s instructions. Briefly, PBMCs or separated B cells
were incubated with the appropriate antibodies for 30 min on ice, washed twice in phosphate-buffered
saline (PBS), and fixed with FACSFix (0.5% PFA in PBS). Fluorescence of the labeled cells was recorded
using a FACS Canto II flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) and analyzed with
FCS Express 6 software (De Novo Software, Pasadena, CA, USA).
4.6. IL-10 and IL-6 ELISA
Supernatant of anti-CD180, CpG, and CpG + anti-CD180 stimulated, and unstimulated B cells
were collected (n = 4) and stored at −80 ◦C until being measured. IL-10 and IL-6 production was
quantified using Human IL-10 and IL-6 DuoSet ELISA kits (Bio-Techne, Minneapolis, MN, USA)
according to the manufacturer’s protocols. The reaction was developed with TMB and measured at
450 nm using an iEMS MF microphotometer (Thermo Labsystem, Beverly, MA, USA).
4.7. Measurement of Natural and Pathologic Autoantibodies
The supernatant obtained from tonsillar B cells treated with anti-CD180, CpG, or CpG+ anti-CD180,
or left unstimulated were collected (n = 3) and stored at −80 ◦C until being measured. The levels
of anti-citrate synthase (anti-CS) IgM autoantibodies and anti-topoisomerase I (fragment F4) IgM
autoantibodies were determined with in-house ELISAs, as previously described [23,24]. The amounts
of autoantibodies against dsDNA, nucleosome, and antinuclear antibodies (ANA) in the supernatant
of tonsillar B cells were measured using commercial ELISA kits (ORGENTEC Diagnostika GmbH,
Mainz, Germany). The reaction was developed with TMB and measured at 450 nm using an iEMS MF
microphotometer (Thermo Labsystem, Beverly, MA, USA).
4.8. Statistical Analysis
Statistical evaluation was performed with SPSS v. 25.0 statistics package (IBM, Armonk, NY, USA)
using Student’s t-tests and ANOVA where p-values < 0.05 were considered significant.
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Abstract: Altered cell surface glycosylation in congenital and acquired diseases has been shown
to affect cell differentiation and cellular responses to external signals. Hence, it may have an
important role in immune regulation; however, T cell surface glycosylation has not been studied
in systemic lupus erythematosus (SLE), a prototype of autoimmune diseases. Analysis of the
glycosylation of T cells from patients suffering from SLE was performed by lectin-binding assay, flow
cytometry, and quantitative real-time PCR. The results showed that resting SLE T cells presented an
activated-like phenotype in terms of their glycosylation pattern. Additionally, activated SLE T cells
bound significantly less galectin-1 (Gal-1), an important immunoregulatory lectin, while other lectins
bound similarly to the controls. Differential lectin binding, specifically Gal-1, to SLE T cells was
explained by the increased gene expression ratio of sialyltransferases and neuraminidase 1 (NEU1),
particularly by elevated ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 (ST6GAL1)/NEU1 and
ST3 beta-galactoside alpha-2,3-sialyltransferase 6 (ST3GAL6)/NEU1 ratios. These findings indicated
an increased terminal sialylation. Indeed, neuraminidase treatment of cells resulted in the increase
of Gal-1 binding. Altered T cell surface glycosylation may predispose the cells to resistance to the
immunoregulatory effects of Gal-1, and may thus contribute to the pathomechanism of SLE.
Keywords: systemic lupus erythematosus; T cells; glycosylation; sialylation; lectin binding;
glycosylation enzymes; galectin 1
1. Introduction
Numerous congenital and acquired diseases show altered cell surface glycosylation, including
several types of cancer and autoimmune syndromes [1,2]. Altered oligosaccharide structures have
been identified in tumors and have proven to be diagnostic markers of malignant phenotypes [1,3,4].
Protein glycosylation has become an integral part of research in autoimmunity, as defective glycan
structures have been described on serum immunoglobulins [5] and the different glycans at certain
residues on IgG subclasses affected the effector function of autoantibodies [6,7]. Surface glycosylation
of immune cells has also been studied, and glycoconjugates have been proven to play a role in many
fields of cellular physiology, such as migration and signal transduction [8]. T cell functions can also
be modulated by interaction between cell surface glycoproteins and endogenous lectins, including
galectins [9].
Glycoconjugates are created in the endoplasmic reticulum, the Golgi apparatus, and on the
cell surface by enzymes, including mannosidases, glycosyltransferases, sialyltransferases, and
neuraminidases (NEU) [10]. The concerted action of these enzymes produces the specific sugar
‘code’ presented on the cell surface, which then regulates further signaling and adhesion properties
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of a particular cell type. The expression of enzymes participating in glycosylation can determine the
sensitivity of the cells to numerous extracellular signals.
Galectin 1 (Gal-1) is a member of the β-galactoside binding mammalian lectin family with specific
affinity to terminal N-acetyllactosamine motifs on multi-antennary cell surface glycans [11]. One of
the major effects of Gal-1 in immunoregulation is the induction of apoptosis of the activated T cell
subpopulations Th1 and Th17, whereas Th2 and Treg cell functions are promoted by Gal-1 [12,13].
This selectivity is caused by the differences in surface glycosylation of various T cell subtypes [9].
Gal-1-triggered cell death has been extensively studied in vitro, and its mechanism has been
described [14–18]. Lactosamine sequences, required for Gal-1 binding, are synthesized by specific
glycosyltransferases, such as beta-N-acetylglucosaminyltransferases and beta-galactosyltransferases.
The expression of such enzymes controls T cell susceptibility to Gal-1-driven apoptosis [19].
We have recently demonstrated that activated T cells from patients with active systemic lupus
erythematosus (SLE) are resistant to the apoptotic effect of Gal-1 [20], and we suggested that this
finding is relevant to the immunoregulatory dysfunction observed in SLE. As a potential cause of this
resistance may be an impaired binding of Gal-1 to the T cell surface, we set out to examine cell surface
glycosylation and the expression of glycosylation enzymes in SLE T cells in comparison with healthy
control T cells. The glycosylation pattern of resting SLE T cells resembled the activated phenotype of
T cells. Activated SLE T cells bound significantly less galectin 1 (Gal-1) than the controls, while other
lectins bound similarly. To understand the distinct lectin binding, specifically Gal-1, to SLE T cells, we
found that the terminal sialylation increased in the autoimmune cells, and accordingly, neuraminidase
treatment resulted in a remarkable increase in Gal-1 binding.
2. Results
The N-glycome diversity of T cell surface glycans was analyzed by the binding of lectins derived
from plants (concanavalin-A (ConA), Lens culinaris agglutinin (LCA), wheat germ agglutinin (WGA),
Phaseolus vulgaris leukoagglutinin (PHA-L), and Sambucus nigra agglutinin (SNA)) or of a human
lectin, Gal-1, with known sugar binding specificity (Figure S1 and Table 1). Lectin binding to resting
and phytohaemagglutinin (PHA)-activated T cells obtained from SLE patients and healthy controls
was measured. Analysis of resting T cells from SLE patients and control individuals revealed that
resting SLE T cells bound significantly more ConA, LCA, and WGA than healthy T cells (Figure 1A).
ConA couples with mannoses present in early high-mannose glycans and mannoses in complex
sugars [21,22], while LCA has high affinity to fucosylated core mannoses present in bi-antennary
complex N-glycans and does not bind to tri- and tetra-antennary N-glycans [23]. WGA binds to
N-acetyl glucosamines present in hybrid-type sugar chains (early and complex sugars) or to sialic acid,
which can be terminally attached to complex multi-antennary glycans, and its affinity to the sialylated
version of tri- or tetra-antennary glycan-containing glycoproteins was shown to be higher than to the
desialylated form [24,25].
Table 1. Names, abbreviations, and binding specificities of lectins.
Lectins Abbreviation Specificity Reference
Concanavalin A ConA mannose, glucose (low affinity) [21,22]
Lens culinaris agglutinin LCA core-fucosylated bi-antennary N-glycan [22,23]
Wheat germ agglutinin WGA GlcNAc, sialic acid [24,25]
Phaseolus vulgaris leucoagglutinin PHA-L β-1,6-branched tri- and tetra-antennaryN-glycans [26]
Sambucus nigra agglutinin SNA α-2,6-linked sialic acid [27]
Galectin-1 Gal-1 LAcNAc [28]
Abbreviation: GlcNAc: N-acetylgucosamine; LacNAc: N-acetyllactoseamine.
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Figure 1. Lectin binding properties of resting and activated T cells from healthy donors and from
systemic lupus erythematosus (SLE) patients. Peripheral blood T cells were obtained from healthy
controls and SLE patients. The cells were left unstimulated (resting state, A) or were activated
with 1 μg/mL phytohaemagglutinin L (PHA L) for 72 h (activated state, B). Cells were stained with
viability dye, fixed then labeled with anti-CD3-PE-Cy5 antibody, followed by fluorescein isothiocyanate
(FITC)-conjugated lectin. The samples were evaluated with flow cytometry. Binding of FITC-conjugated
lectins is shown as mean (±SEM) of the median fluorescence intensity (MFI) values of flow cytometry
histograms of resting (A) or activated (B) CD3-positive live T cells. Lectin names are listed in Table 1.
MFI: mean fluorescence intensity, ConA: concanavalin-A, LCA: Lens culinaris agglutinin, WGA: wheat
germ agglutinin, PHA-L: Phaseolus vulgaris leukoagglutinin, SNA: Sambucus nigra agglutinin, Gal-1:
galectin 1. Statistical analysis was performed using an unpaired Student t-test. ** p < 0.01; *** p < 0.001;
n. s.: not significant. SLE: n = 18, and healthy controls: n = 19.
Comparing healthy and autoimmune-activated T cells, we found that activated SLE T cells bound
lectins in levels similar to control cells with the exception of Gal-1. SLE cells bound significantly less
Gal-1 than control cells, indicating that terminal N-acetyllactosamine side chains, the Gal-1 ligands,
were less accessible on these cells (Figure 1B). The changes in the pattern of lectin bindings did not
occur preferentially on either CD4+ or CD4- (CD8+) cells, as these were similar in the control as well
as in SLE activated T cells (Figure S2).
Glycosylation of proteins is regulated by multiple factors in the Golgi apparatus, such as
sub-Golgi localization of glycosylation enzymes, transporters, pH, endoplasmic reticulum stress, or
substrate availability (reviewed in [29]). However, a major element is the expression and function
of glycosylation enzymes [30,31]. Therefore, expression levels of the genes involved in N-linked
glycosylation (Figure S1 and Table 2) were examined by qPCR analysis of activated T cells. Gene
expression of alpha mannosidases (MAN1A1, MAN1A2, MAN2A1 and MAN2A2) in activated SLE
T cells did not differ from the controls (Figure 2A). Analysis of beta-N-acetylglucosaminyltransferases
(MGAT1–5) presented a slight but significant difference in the cases of MGAT4A and MGAT4B
(Figure 2B).
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Table 2. Symbols and full names of glycosylation enzyme genes.
Enzyme Genes Gene Symbol Full Gene Name
Mannosidases MAN1A1 Mannosidase alpha class 1A member 1
MAN1A2 Mannosidase alpha class 1A member 2
MAN2A1 Mannosidase alpha class 2A member 1
MAN2A2 Mannosidase alpha class 2A member 2
N-Acetylglucosaminyltransferase MGAT1 Mannosyl (alpha-1,3-)-glycoproteinbeta-1,2-N-acetylglucosaminyl-transferase
MGAT4A Mannosyl (alpha-1,3-)-glycoproteinbeta-1,4-N-acetylglucosaminyl-transferase isozyme A
MGAT4B Mannosyl (alpha-1,3-)-glycoproteinbeta-1,4-N-acetylglucosaminyl-transferase isozyme B
MGAT5 Mannosyl (alpha-1,6-)-glycoproteinbeta-1,6-N-Acetyl-glucosaminyltransferase
Sialyltransferases ST3GAL3 ST3 beta-galactosidealpha-2,3-sialyltransferase 3
ST3GAL4 ST3 beta-galactosidealpha-2,3-sialyltransferase 4
ST3GAL6 ST3 beta-galactosidealpha-2,3-sialyltransferase 6
ST6GAL1 ST6 beta-galactosamidealpha-2,6-sialyltranferase 1
Neuraminidases NEU1 Neuraminidase 1
Figure 2. Gene expression of mannosidases (MANs) (A) and N-acetyl glucosaminyltransferases
(MGATs) (B) in activated T cells. Total RNA was extracted from activated T cells and mRNA expression
levels were analyzed by qPCR. Results of the relative expression were normalized to the expression
levels of the RPL27 housekeeping gene (log2 transformation, ΔCt). Gene names and primer sequences
are listed in Table 2 and Table 4, respectively. Upper and lower quartiles and whiskers of boxes extend
to the minimum and maximum values, and the band inside the box is the median. Statistical analysis
was performed using an unpaired Student’s t-test, where * p < 0.05; SLE: n = 18, and healthy controls:
n = 19.
Poly-N-acetyllactosamine chains on N glycans can be capped with the attachment of α-2,6
sialic acid by ST6 beta-galactosamidealpha-2,6-sialyltranferase 1 (ST6GAL1) and α-2,3 sialic acid by
ST3GAL3, ST3GAL4, and ST3GAL6 [32],and cleaved by neuraminidases. In the control and patient
groups, ST6GAL1, ST3GAL3, ST3GAL4, and neuraminidase 1 (NEU1) gene expression levels were
similar, whereas the mRNA level of ST3GAL6 was significantly elevated in SLE T cells (Figure 3A).
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During T cell activation, the gene expression of NEU1 is strongly upregulated, while NEU3 expression
remains constant [33]; hence, only NEU1 was analyzed.
Figure 3. Gene expression of sialyltransferases (ST) and neuraminidase-1 (NEU1) in activated T cells.
Total RNA was extracted from activated T cells and mRNA expression levels were analyzed by qPCR.
(A) Results of the relative expression were normalized to the expression levels of RPL27 housekeeping
gene (log2 transformation, ΔCt). Gene names and primer sequences are listed in Table 2 and Table
4, respectively. (B) ST/NEU1 mRNA expression ratios. The sialyltransferase-neuraminidase mRNA
expression ratios of individual persons were calculated as follows: ΔCt ST/ΔCtNEU1. Upper and lower
quartiles and whiskers of boxes extend to the minimum and maximum values, and the band inside
the box is the median. Statistical analysis was performed using an unpaired Student t-test, where
** p< 0.01; *** p< 0.001. SLE: n = 18, and healthy controls: n = 19.
Concerted action of sialyltransferases and neuraminidases determine the sialylation pattern.
The large variations between the Gal-1 binding of the control and SLE T cells (Figure 1B) indicated
an alteration in the sialylation of SLE surface glycans. As this is determined by the net effect of
enzymes that sialylate (sialyltransferase) and desialylate (neuraminidase) the glycans, gene expression
ratios of the opposing acting enzymes were calculated. A significantly higher ST3GAL6/NEU1
and ST6GAL1/NEU1 mRNA ratio was observed in SLE compared to control T cells (Figure 3B),
indicating higher sialylation of SLE T cells. Other sialyltransferase/neuraminidase mRNA ratios, such
as ST3GAL3/NEU1 andST3GAL4/NEU1, remained similar in the control and SLE groups (Figure 3B).
These results indicated that reduced Gal-1 binding to SLE T cells may be a result of a more densely
sialylated glycan profile. Indeed, cleaving sialic acid from the surface of SLE activated T cells by
α2-3,6,8 Neu (specific to α2-3,6,8 linked sialic acid) resulting in the elevation of Gal-1 binding (Figure 4).
The increase of Gal-1 binding to SLE cells was similar to that of control T cells (data not shown).
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Figure 4. Effect of neuraminidase treatment on Gal-1 binding of SLE T cells. Activated SLE T cells
were treated with α2-3,6,8 neuraminidase (Gal-1 + α2-3,6,8 Neu; dotted line) or left untreated (Gal-1;
empty, continuous line), and then Gal-1 binding was investigated by cytofluorimetry, as described in
the materials and methods section. The grey shadowed histogram shows the negative control: no
Gal-1, +streptavidin—FITC. The upper image shows a representative profile of Gal-1 binding, the
lower graph shows means (±SEM) of the mean fluorescence intensity (MFI) values of activated SLE
T cells. Statistical analysis was performed using a two-tailed paired t-test. * p < 0.05, n = 3.
3. Discussion
Selected steps of mammalian N linked glycosylation and lectin binding to specific sugar side chains
are summarized in Figure S1. It must be noted that binding of the used lectins was more degenerated
than what is shown in the simplified Figure S1; however, it may help in a better apprehension of
this work.
Remarkable differences were detected in ConA, LCA, and WGA binding between resting SLE
and control T cells, since SLE T cells bound significantly higher amounts of these lectins. As LCA and
WGA recognize matured sugar side chains and ConA couples both unmatured (early) and matured
(complex) glycans, these results indicated that resting SLE T cells present a glycan structure similar
to their activated phenotype. Detection of other activation markers, such as heightened CD40L
expression [34], CD44 expression [35–37], exhibition of constant membrane raft polarization and
increased GM1 content [38], measured by others, also suggest similarity to an activated state. On the
other hand, this activated phenotype did not manifest in terms of CD25 expression on resting SLE
T cells, as CD25 levels were similar on resting and activated T cells, suggesting that the activated
phenotype is limited to several, but not all activation markers (Figure S3).
Stimulation of control T cells with PHA-L resulted in an elevation of binding of all used lectins,
except the terminal α-2,6 sialic acid binding SNA (data not shown), indicating a generally increased
complexity of glycosylation pattern upon activation. These results were in accordance with previous
findings, arguing that N-glycan abundance, branching, glycan chain elongation, and hereby complexity
enhanced [39,40], and terminal α-2,6 sialic acid residues declined [41–43] on freshly activated T cells.
However, the increase in glycan complexity after activation was hardly seen in SLE T cells, as an
increase in lectin binding upon activation was rather low or was absent in SLE, a phenomenon that
is also explained by the activated phenotype of SLE T cells, even without treatment with activating
agents. Furthermore, the decreased Gal-1 binding of SLE T cells was observed, not only in resting
state, but also persisting after activation. No difference was found between CD4+ and CD4- (CD8)
cells in terms of binding of any of the lectins (Figure S2). Some previous findings indicate that the
proportion of effector memory (C-C Motif Chemokine Receptor 7{CCR7}-CD27+) and terminally
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differentiated effector memory (CCR7-CD27-) cells increase in SLE, and may correlate with disease
activity or damage [44,45]. It would be interesting to compare the cell surface glycosylation patterns of
naive and various subtypes of memory T cells; however, it was outside the scope of our present study.
It is also to be noted that SLE memory effector T cells are crippled in response to antigen stimulation, as
they respond to stimulation with apoptosis instead of proliferation [45], which might be a consequence
of the altered glycosylation.
Variation in the binding of lectins tested was only confined to Gal-1, whose binding is determined
by the presence of asialylated terminal N-acetyl lactose residues [46]. To clarify the background
of this specific variability of Gal-1 binding, the expression of enzymes involved in creating the
glycosylation pattern was determined. Analysis of the mRNA expression of glycosylation enzymes was
chosen, since previous data indicated that glycosylation was primarily regulated at the transcriptional
level of the appropriate enzymes [31]. Expressions of glycosyltransferases, alpha mannosidases,
beta-N-acetylglucosaminetransferases, sialytransferases, and a neuraminidase, NEU1, were similar in
control and SLE T cells. These findings are in accordance with the results of lectin assays, as all lectins
tested bound similarly to the activated control and autoimmune T cells, with the exception ofGal-1.
The difference in Gal-1 binding between control and patient activated T cells might therefore result
from the distinct sialylation of the Gal-1 binding glycoconjugates. This presumption seemed to be
supported by the finding that ratios of the expression of sialyltransferases (ST3GAL6 and ST6GAL1)
and neuraminidase shifted towards the sialytransferases, indicating a more intensified sialylation of
SLE T cell glycans, including Gal-1 binding structures. Sialylation plays an important role in masking
terminal carbohydrate chains, hence regulating lectin binding and signal transduction processes.
Sialyltransferases attach, while neuraminidases remove sialic acid residues of terminal carbohydrate
groups. Consequently, the accessibility of lectin binding sites is specifically regulated by the concerted
action of sialyltransferases and neuraminidases. This point of view was supported with the finding,
that ablation of sialic acid from surface glycoconjugates of living activated SLE T cells by neuraminidase
treatment resulted in an increase in Gal-1 binding.
An important issue is how glycosylation affects autoimmune T cell activation, cell–cell interactions
and autoantibody production. The available literature data are limited, and further detailed
investigation is required. However, several studies suggest that pathological glycosylation results
in disturbed T cell receptor (TCR)-major histocompatibility complex (MHC) interactions [38], cell
adhesion [40], necrotic cell death- and glycan-specific autoantibody production [47], and deviant
antigen presentation [48,49]. How closely the pathomechanism of SLE is associated with the surface
glycosylation pattern and its abnormalities remains to be elucidated. Nevertheless, the present
findings seem to corroborate our hypothesis regarding the resistance of activated SLE T cells to the
apoptotic effects of Gal-1. As we described earlier [20], activated SLE T cells showed a reduced
response to Gal-1 due to their defective expression of intracellular Gal-1. The present work suggests
that altered glycosylation and, hence, the decreased binding of extracellular Gal-1 to SLE T cells can
be another cause of the resistance to Gal-1-mediated immunomodulation, serving a putative novel
pathogenic mechanism in SLE. It has to also be clarified whether removal of sialic acid from cell
surface glycoconjugates results in the restoration of Gal-1-induced apoptotic sensitivity. Nevertheless,
it has become clear from this work that analyzing the glycosylation process, especially the expression
ratio of sialyltransferases and the neuraminidases and the binding of Gal-1 to the cell surface, may
emerge as a novel approach to connecting disease phenotypes with functional pathways within T cells
(differential-diagnosis of diseases or patient subset analysis within particular multisystem autoimmune
diseases).
Since SLE is an autoimmune disease with multiple alterations on genetic, protein, signaling, and
glycosylation levels, it is difficult to determine the primary cause of the disorder. It is likely that all the
more-or-less relational changes result in the final manifestation of SLE. As glycosylation affects cell
migration, adhesion, and signal transduction, its changes must be an important factor contributing to
the pathomechanism of the disease. This view is supported by the finding that the binding of Gal-1
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to SLE T cells, an anti-inflammatory human lectin, decreases because of the different sialylation of
SLE T cells from that of healthy T cells, and thus it must be another reason that SLE T cells are more
resistant to Gal-1-induced apoptosis [20].
The glycosylation phenotype resembles an activated state of SLE T cells. Though the fundamental
causes behind the development of SLE are unclear, it is known that alpha-mannosidase II knock out mice
develop an SLE-like disease [50]. This enzyme removes early mannose from maturing glycoconjugates,
therefore, it is crucial to the final formation of healthy complex N-glycan structures observed in
mammals. Its deficiency leads to immature, mannose-rich glycan chains being upregulated because of
a disruption in their stepwise disassembly before the complex chain can be built in their place [51].
This effect is similar to our findings indicating a higher-than-normal distribution of mannose-rich
glycans on SLE T cells before activation. It is known that mannose-rich chains are much more common
on many strains of fungi and are easily recognized as non-self structures leading to auto-immune
reactions [50].
Altered glycosylation in SLE is not confined to T cells, as the glycan profile of IgG is a primary
predictor of the inflammatory capability of the molecule. Asialylated, agalactosylated glycan chains
are stronger activators of complement than sialylated chains, and as such, pro-inflammatory responses
are upregulated by the IgG molecule if it contains less terminal syalic acid units [5].
Altogether, the above data indicate that alteration in glycosylation in SLE is likely to be a primary
phenomenon, and it contributes to the pathomechanism of the disease.
To our knowledge, the current work provides the first evidence for altered T cell surface
glycosylation in SLE. Our major findings are that resting SLE T cells show an activated phenotype from
the glycosylation point of view and lectin binding of activated SLE T cells is similar to the controls, with
exception of the significantly lower Gal-1 binding. Furthermore, this is a consequence of a shift toward
terminal sialylation of glycan structures due to an increased ST6GAL1/NEU1 and/or ST3GAL6/NEU1
ratio. Indeed, desialylation of the surface glycans on SLE T cells results in a remarkable increase in
Gal-1 binding.
4. Materials and Methods
4.1. Ethical Statement
The study was designed in accordance with the guidelines of the Declaration of Helsinki and was
approved by the Human Investigation Review Board, University of Szeged reference, No. 2833/2011
on 21 February 2011.
4.2. Patients
Patients with SLE (n = 18) and healthy controls (n = 19) were examined, except in one experiment
where n = 3 (Figure 3). All patients met the 2012 SLICC classification criteria for SLE [52,53] and
had active disease, as reflected by relevant disease activity indices. Eligible patients had an SLE
Disease Activity-Index-2000 (SLEDAI-2K) ≥ 6 [54], did not have a co-existent inflammatory condition
(overlapping autoimmune disease or infection), and did not have diabetes mellitus. Treatment
with potent immunosuppressive drugs (mycophenolate mofetil, cyclophosphamide, rituximab) or
corticosteroid at a dose >5 mg prednisolone equivalent was also an exclusion criterion. Controls were
healthy individuals without any inflammatory disease or diabetes mellitus.
Demographics and the relevant disease activity data are presented in Table 3.
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Table 3. Demographics and disease activity parameters. Numbers before and in brackets indicate
mean and range, respectively. SLEDAI-2K: SLE Disease Activity-Index-2000, anti-dsDNA: antibody to
double-stranded DNA.
Subject Characteristics Age Female/Male Disease Activity Parameter
SLE 42 (23–54) 17/1
SLEDAI-2K 14 (6–30)
anti-dsDNA (IU/mL) 88 (2–220)
Control 54 (31–75) 17/2
4.3. Cells
Peripheral blood mononuclear cells (PBMC) were isolated from SLE patients and healthy donors
using Ficoll (GE Healthcare, Amersham, UK) gradient centrifugation. A part of the PBMCs was
stimulated with 1 μg/mL phytohaemagglutinin-L (PHA-L, Sigma-Aldrich, St. Louis, MO, USA) and
the cells were cultured for 72 h in a humidified incubator with 5% CO2 at 37 ◦C in Roswell Park
Memorial Institute (RPMI)-1640 medium (Gibco, Life Technologies, Paisley, UK) supplemented with
10% fetal bovine serum (FBS) (Gibco, Life Technologies, Paisley, UK), 2 mM L-glutamine (Gibco,
Life Technologies, Paisley, UK) and penicillin-streptomycin (Sigma-Aldrich, St. Louis, MO, USA),
henceforward referred to as activated T cells. Activated T cell cultures were > 90% pure, as controlled
with flow cytometry using anti-human CD3 antibody (BioLegend, San Diego, CA, USA) (data not
shown).
4.4. Lectin Binding Assay
Resting or activated T cells were washed twice with cold phosphate buffered saline (PBS) and
incubated at 4 ◦C for 30 min with eFluor 660 fixable viability dye (eBioscience, Thermo Fisher
Scientific, Waltham, MA, USA), then fixed with 4% paraformaldehyde for 4 min at room temperature.
After washing the samples twice in PBS supplemented with 1% FBS and 0.1% sodium-azide
(fluorescence-activated cell sorting (FACS) buffer), the cells were incubated at 4 ◦C for 20 min with
fluorescein-labeled lectins or unlabeled Gal-1 (lectins used are listed in Table 1). The fluorescein-labeled
plant lectin kit (Vector Laboratories, Burlingame, CA, USA) was used according to the manufacturer’s
instructions. Recombinant galectin-1 was produced and characterized in our laboratory, as previously
described [15]. Gal-1-binding was detected as follows: after washing with FACS buffer, biotinylated
mouse monoclonal antibody to Gal-1 (2C1/6) was added and incubated at 4 ◦C for 45 min. Samples were
washed with cold FACS buffer before adding fluorescein isothiocyanate(FITC)-labeled streptavidin
and incubating the cells at 4 ◦C for 20 min. Finally, the samples were washed twice in FACS buffer.
Samples were analyzed with a FACSCalibur system (BD Biosciences, Franklin Lakes, NJ, USA) and
data were evaluated using FlowJo V10 software (BD Biosciences, Franklin Lakes, NJ, USA). The lectin
binding was evaluated on resting T cells within PBMCs or activated T cells by gating CD3+ cells with
PE/Cy5-conjugated anti-human CD3 antibody (BioLegend, San Diego, CA, USA).
4.5. Neuraminidase Treatment
Activated T cells (2 × 106/sample) were treated with α2-3,6,8 neuraminidase (α2-3,6,8 Neu, New
England BioLabs, Ipswich, MA, USA) according to the manufacturer’s instructions or left untreated.
Briefly, the cells were washed with PBS then incubated with 200 U of α2-3,6,8Neu in a total volume
of 40 μL glycobuffer (provided by the manufacturer) for 15 min at 37 ◦C. After washing the samples
with cold PBS, Gal-1 binding, viability staining, fixation, and flow cytometry analysis were done, as
described above.
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4.6. Quantitative Real-Time PCR (qPCR)
The qPCR assays were performed according to the MIQE (Minimum Information for Publication
of Quantitative Real-Time PCR Experiments) guidelines [55]. The names of genes are listed in
Table 2. Total RNA was extracted from activated T cells (1–3 × 106 cells) using PerfectPure RNA
Cultured Cell kit (5 PRIME, Gaithersburg, MD, USA) according to the manufacturer’s instructions with
on-column DNase digestion. The amount and quality of RNA were measured using NanoDrop-1000
spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). For cDNA synthesis, 2 μg of total
RNA/reaction was reverse transcribed using RevertAid H Minus First Strand cDNA Synthesis Kit
(Thermo Fisher Scientific, Waltham, MA, USA) in the presence of 1.66 μM of oligo (dT) 18 and random
hexamer primers, 0.5 mMdNTP, 10 U RiboLock RNase Inhibitor, and 200 U RevertAid H Minus Reverse
Transcriptase for 60 min at 42 ◦C, then heated for 10 min at 70 ◦C. Quantitative PCR amplifications
were carried out with appropriate negative controls at least in duplicate. The reaction volume was
20 μL and composed of AccuPower 2 × Greenstar qPCR Master Mix (Bioneer, Alameda, CA, USA),
300–300 nM primers, and 40-fold diluted cDNA. For PCR amplifications, RotoGene3000 instrument
(Corbett Research, Sydney, Australia) was used. The qPCR program included: initial 95 ◦C for 15 min,
followed by repeated 45 cycles (95 ◦C for 15 s, 60–62 ◦C for 20 s, 72 ◦C for 20 s), and melting temperature
analysis increasing the temperature from 55 ◦C to 98 ◦C at 0. 5 ◦C/step with 8 sec stops between each
step. Quantitative real-time PCR data were analyzed using the Rotor Gene software (v6.1 build 93).
Relative mRNA levels, normalized to RPL27, were presented as log2 transformation of relative gene
expression, namely subtraction of Ct values (ΔCt = CtRPL27 − CtGOI). The mRNA expression ratios
were calculated using the following formula: ΔCt × gene −ΔCt Y gene. Primer sequences were partly
taken from [56–59], or designed using the Universal Probe Library Assay Design program (Roche
Applied Science, Basel, Switzerland). Primer sequences used in the study are shown in Table 4.
Table 4. Primer sequences used in the study for the mRNA amplification of glycosylation enzymes.
















Statistical analysis was performed using GraphPad Prism Version 7.01. In all statistical analyses,
an unpaired, two-tailed t-test was used to compare data obtained in T cells of healthy controls and
SLE patients. There was only one exception (Figure 4B), where paired two-tailed Student’s t-test was
chosen for the comparison of values from T cells of the same patient with or without neuraminidase
treatment. The significant differences were indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/18/
4455/s1.
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LCA Lens culinaris agglutinin
WGA Wheat germ agglutinin
PHA phytohaemagglutinin
PHA-L Phaseolus vulgaris leukoagglutinin
SNA Sambucus nigra agglutinin





SLEDAI-2K SLE disease activity index-2000
Anti-dsDNA Antibody to double-stranded DNA
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